UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Form 10-Q


☒ý			Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended ~~September~~June 30, ~~2021~~2022


☐¨			Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to

Commission File Number 1-7293

_________________________________________

TENET HEALTHCARE CORPORATION

(Exact name of Registrant as specified in its charter)


Nevada			95-2557091
(State of Incorporation)			(IRS Employer Identification No.)

14201 Dallas Parkway

Dallas, TX 75254

(Address of principal executive offices, including zip code)

(469) 893-2200

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading symbol

Name of each exchange on which registered

Common stock,

$0.05 par value

THC

New York Stock Exchange

6.875% Senior Notes due 2031

THC31

New York Stock Exchange

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months, and (2) has been subject to such filing requirements for the past 90 days. Yes xý No ¨

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months. Yes xý No ¨

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company (each as defined in Exchange Act Rule 12b-2).

Large accelerated filer

xý

Accelerated filer

Non-accelerated filer

Smaller reporting company

☐¨

Emerging growth company

☐¨

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the Registrant is a shell company (as defined in Exchange Act Rule 12b-2). Yes ☐¨ No x

At ~~October~~July 22, ~~2021,~~2022, there were ~~107,125,882~~107,888,705 shares of the Registrant’s common stock outstanding.

Table of Contents

TENET HEALTHCARE CORPORATION

TABLE OF CONTENTS

Table of Contents

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

TENET HEALTHCARE CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

Dollars in Millions

(Unaudited)


		September 30,		December 31,			June 30,		December 31,
		2021		2020			2022		2021
ASSETS	ASSETS					ASSETS
Current assets:	Current assets:					Current assets:
Cash and cash equivalents	Cash and cash equivalents	$	2,292	$	2,446	Cash and cash equivalents	$	1,351	$	2,364
Accounts receivable	Accounts receivable	2,742		2,690		Accounts receivable	2,840		2,770
Inventories of supplies, at cost	Inventories of supplies, at cost	376		368		Inventories of supplies, at cost	387		384
Income tax receivable						Income tax receivable	18		—

Assets held for sale		—		140
Other current assets	Other current assets	1,495		1,503		Other current assets	1,468		1,557
Total current assets	Total current assets	6,905		7,147		Total current assets	6,064		7,075
Investments and other assets	Investments and other assets	2,564		2,534		Investments and other assets	3,297		3,254
Deferred income taxes	Deferred income taxes	140		325		Deferred income taxes	60		65
Property and equipment, at cost, less accumulated depreciation and amortization ($5,872 at September 30, 2021 and $6,043 at December 31, 2020)		6,162		6,692
Property and equipment, at cost, less accumulated depreciation and amortization ($6,172 at June 30, 2022 and $5,960 at December 31, 2021)						Property and equipment, at cost, less accumulated depreciation and amortization ($6,172 at June 30, 2022 and $5,960 at December 31, 2021)	6,259		6,427
Goodwill	Goodwill	8,662		8,808		Goodwill	9,479		9,261
Other intangible assets, at cost, less accumulated amortization ($1,326 at September 30, 2021 and $1,284 at December 31, 2020)		1,480		1,600
Other intangible assets, at cost, less accumulated amortization ($1,389 at June 30, 2022 and $1,374 at December 31, 2021)						Other intangible assets, at cost, less accumulated amortization ($1,389 at June 30, 2022 and $1,374 at December 31, 2021)	1,462		1,497
Total assets	Total assets	$	25,913	$	27,106	Total assets	$	26,621	$	27,579
LIABILITIES AND EQUITY	LIABILITIES AND EQUITY					LIABILITIES AND EQUITY
Current liabilities:	Current liabilities:					Current liabilities:
Current portion of long-term debt	Current portion of long-term debt	$	125	$	145	Current portion of long-term debt	$	125	$	135
Accounts payable	Accounts payable	1,100		1,207		Accounts payable	1,083		1,300
Accrued compensation and benefits	Accrued compensation and benefits	1,071		942		Accrued compensation and benefits	811		896
Professional and general liability reserves	Professional and general liability reserves	268		243		Professional and general liability reserves	272		254
Accrued interest payable	Accrued interest payable	262		248		Accrued interest payable	221		203
Liabilities held for sale		—		70

Contract liabilities	Contract liabilities	1,218		659		Contract liabilities	474		959
Other current liabilities	Other current liabilities	1,335		1,333		Other current liabilities	1,382		1,362
Total current liabilities	Total current liabilities	5,379		4,847		Total current liabilities	4,368		5,109
Long-term debt, net of current portion	Long-term debt, net of current portion	14,009		15,574		Long-term debt, net of current portion	14,947		15,511
Professional and general liability reserves	Professional and general liability reserves	762		735		Professional and general liability reserves	789		791
Defined benefit plan obligations	Defined benefit plan obligations	444		497		Defined benefit plan obligations	407		421
Deferred income taxes	Deferred income taxes	29		29		Deferred income taxes	161		36
Contract liabilities – long-term	Contract liabilities – long-term	15		918		Contract liabilities – long-term	14		15
Other long-term liabilities	Other long-term liabilities	1,592		1,617		Other long-term liabilities	1,824		1,439
Total liabilities	Total liabilities	22,230		24,217		Total liabilities	22,510		23,322
Commitments and contingencies	Commitments and contingencies	0		0		Commitments and contingencies	0		0
Redeemable noncontrolling interests in equity of consolidated subsidiaries	Redeemable noncontrolling interests in equity of consolidated subsidiaries	2,048		1,952		Redeemable noncontrolling interests in equity of consolidated subsidiaries	1,997		2,203
Equity:	Equity:					Equity:
Shareholders’ equity:	Shareholders’ equity:					Shareholders’ equity:
Common stock, $0.05 par value; authorized 262,500,000 shares; 155,402,362 shares issued at September 30, 2021 and 154,407,524 shares issued at December 31, 2020		8		7
Common stock, $0.05 par value; authorized 262,500,000 shares; 156,160,385 shares issued at June 30, 2022 and 155,520,691 shares issued at December 31, 2021						Common stock, $0.05 par value; authorized 262,500,000 shares; 156,160,385 shares issued at June 30, 2022 and 155,520,691 shares issued at December 31, 2021	8		8
Additional paid-in capital	Additional paid-in capital	4,862		4,844		Additional paid-in capital	4,756		4,877
Accumulated other comprehensive loss	Accumulated other comprehensive loss	(274)		(281)		Accumulated other comprehensive loss	(231)		(233)
Accumulated deficit	Accumulated deficit	(1,463)		(2,128)		Accumulated deficit	(1,036)		(1,214)
Common stock in treasury, at cost, 48,333,196 shares at September 30, 2021 and 48,337,947 shares at December 31, 2020		(2,411)		(2,414)
Common stock in treasury, at cost, 48,330,239 shares at June 30, 2022 and 48,331,649 shares at December 31, 2021						Common stock in treasury, at cost, 48,330,239 shares at June 30, 2022 and 48,331,649 shares at December 31, 2021	(2,410)		(2,410)
Total shareholders’ equity	Total shareholders’ equity	722		28		Total shareholders’ equity	1,087		1,028
Noncontrolling interests	Noncontrolling interests	913		909		Noncontrolling interests	1,027		1,026
Total equity	Total equity	1,635		937		Total equity	2,114		2,054
Total liabilities and equity	Total liabilities and equity	$	25,913	$	27,106	Total liabilities and equity	$	26,621	$	27,579

See accompanying Notes to Condensed Consolidated Financial Statements.

Table of Contents

TENET HEALTHCARE CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

Dollars in Millions, Except Per-Share Amounts

(Unaudited)


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended June 30,				Six Months Ended June 30,
		2021		2020		2021		2020			2022		2021		2022		2021
Net operating revenues	Net operating revenues	$	4,894	$	4,557	$	14,629	$	12,725	Net operating revenues	$	4,638	$	4,954	$	9,383	$	9,735
Grant income	Grant income	3		(66)		53		445		Grant income	94		19		100		50
Equity in earnings of unconsolidated affiliates	Equity in earnings of unconsolidated affiliates	45		44		141		103		Equity in earnings of unconsolidated affiliates	54		54		100		96
Operating expenses:	Operating expenses:									Operating expenses:
Salaries, wages and benefits	Salaries, wages and benefits	2,209		2,142		6,690		6,193		Salaries, wages and benefits	2,126		2,280		4,308		4,481
Supplies	Supplies	827		784		2,490		2,158		Supplies	811		859		1,596		1,663
Other operating expenses, net	Other operating expenses, net	1,051		1,058		3,177		3,054		Other operating expenses, net	1,006		1,054		1,948		2,126
Depreciation and amortization	Depreciation and amortization	209		215		654		624		Depreciation and amortization	216		221		419		445
Impairment and restructuring charges, and acquisition-related costs	Impairment and restructuring charges, and acquisition-related costs	15		57		55		166		Impairment and restructuring charges, and acquisition-related costs	57		20		73		40
Litigation and investigation costs	Litigation and investigation costs	29		9		64		13		Litigation and investigation costs	18		22		38		35
Net gains on sales, consolidation and deconsolidation of facilities	Net gains on sales, consolidation and deconsolidation of facilities	(412)		(1)		(427)		(4)		Net gains on sales, consolidation and deconsolidation of facilities	(1)		(15)		—		(15)
Operating income	Operating income	1,014		271		2,120		1,069		Operating income	553		586		1,201		1,106
Interest expense	Interest expense	(227)		(263)		(702)		(761)		Interest expense	(222)		(235)		(449)		(475)
Other non-operating income, net		7		—		16		3
Other non-operating income (expense), net										Other non-operating income (expense), net	—		(1)		—		9
Loss from early extinguishment of debt	Loss from early extinguishment of debt	(20)		(312)		(74)		(316)		Loss from early extinguishment of debt	(66)		(31)		(109)		(54)
Income (loss) from continuing operations, before income taxes		774		(304)		1,360		(5)
Income tax benefit (expense)		(197)		197		(303)		227
Income (loss) from continuing operations, before discontinued operations		577		(107)		1,057		222
Income from continuing operations, before income taxes										Income from continuing operations, before income taxes	265		319		643		586
Income tax expense										Income tax expense	(86)		(61)		(185)		(106)
Income from continuing operations, before discontinued operations										Income from continuing operations, before discontinued operations	179		258		458		480
Discontinued operations:	Discontinued operations:									Discontinued operations:
Income from operations		1		1		—		—
Income (loss) from operations										Income (loss) from operations	—		(1)		1		(1)

Income from discontinued operations		1		1		—		—
Net income (loss)		578		(106)		1,057		222
Income (loss) from discontinued operations										Income (loss) from discontinued operations	—		(1)		1		(1)
Net income										Net income	179		257		459		479
Less: Net income available to noncontrolling interests	Less: Net income available to noncontrolling interests	129		90		392		237		Less: Net income available to noncontrolling interests	141		138		281		263
Net income available (loss attributable) to Tenet Healthcare Corporation common shareholders		$	449	$	(196)	$	665	$	(15)
Net income available to Tenet Healthcare Corporation common shareholders										Net income available to Tenet Healthcare Corporation common shareholders	$	38	$	119	$	178	$	216
Amounts available (attributable) to Tenet Healthcare Corporation common shareholders	Amounts available (attributable) to Tenet Healthcare Corporation common shareholders									Amounts available (attributable) to Tenet Healthcare Corporation common shareholders
Income (loss) from continuing operations, net of tax		$	448	$	(197)	$	665	$	(15)
Income from discontinued operations, net of tax		1		1		—		—
Net income available (loss attributable) to Tenet Healthcare Corporation common shareholders		$	449	$	(196)	$	665	$	(15)
Income from continuing operations, net of tax										Income from continuing operations, net of tax	$	38	$	120	$	177	$	217
Income (loss) from discontinued operations, net of tax										Income (loss) from discontinued operations, net of tax	—		(1)		1		(1)
Net income available to Tenet Healthcare Corporation common shareholders										Net income available to Tenet Healthcare Corporation common shareholders	$	38	$	119	$	178	$	216
Earnings (loss) per share available (attributable) to Tenet Healthcare Corporation common shareholders:	Earnings (loss) per share available (attributable) to Tenet Healthcare Corporation common shareholders:									Earnings (loss) per share available (attributable) to Tenet Healthcare Corporation common shareholders:
Basic	Basic									Basic
Continuing operations	Continuing operations	$	4.18	$	(1.87)	$	6.23	$	(0.14)	Continuing operations	$	0.35	$	1.12	$	1.64	$	2.04
Discontinued operations	Discontinued operations	0.01		0.01		—		—		Discontinued operations	—		(0.01)		0.01		(0.01)
		$	4.19	$	(1.86)	$	6.23	$	(0.14)		$	0.35	$	1.11	$	1.65	$	2.03
Diluted	Diluted									Diluted
Continuing operations	Continuing operations	$	4.12	$	(1.87)	$	6.13	$	(0.14)	Continuing operations	$	0.35	$	1.11	$	1.63	$	2.00
Discontinued operations	Discontinued operations	0.01		0.01		—		—		Discontinued operations	—		(0.01)		0.01		(0.01)
		$	4.13	$	(1.86)	$	6.13	$	(0.14)		$	0.35	$	1.10	$	1.64	$	1.99
Weighted average shares and dilutive securities outstanding (in thousands):	Weighted average shares and dilutive securities outstanding (in thousands):									Weighted average shares and dilutive securities outstanding (in thousands):
Basic	Basic	107,050		105,263		106,727		104,803		Basic	107,790		106,822		107,636		106,566
Diluted	Diluted	108,761		105,263		108,465		104,803		Diluted	108,750		108,569		114,054		108,317

See accompanying Notes to Condensed Consolidated Financial Statements.

Table of Contents

TENET HEALTHCARE CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE INCOME

Dollars in Millions

(Unaudited)


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended June 30,				Six Months Ended June 30,
		2021		2020		2021		2020			2022		2021		2022		2021
Net income (loss)		$	578	$	(106)	$	1,057	$	222
Net income										Net income	$	179	$	257	$	459	$	479
Other comprehensive income:	Other comprehensive income:									Other comprehensive income:
Amortization of net actuarial loss included in other non-operating income, net		2		2		8		6
Unrealized gains on debt securities held as available-for-sale		—		—		—		1
Amortization of net actuarial loss included in other non-operating income (expense), net										Amortization of net actuarial loss included in other non-operating income (expense), net	3		3		5		6
Unrealized losses on debt securities held as available-for-sale										Unrealized losses on debt securities held as available-for-sale	(1)		—		(3)		—

Foreign currency translation adjustments	Foreign currency translation adjustments	1		—		1		—		Foreign currency translation adjustments	1		—		1		—
Other comprehensive income before income taxes	Other comprehensive income before income taxes	3		2		9		7		Other comprehensive income before income taxes	3		3		3		6
Income tax benefit (expense) related to items of other comprehensive income	Income tax benefit (expense) related to items of other comprehensive income	—		2		(2)		(1)		Income tax benefit (expense) related to items of other comprehensive income	(1)		2		(1)		(2)
Total other comprehensive income, net of tax	Total other comprehensive income, net of tax	3		4		7		6		Total other comprehensive income, net of tax	2		5		2		4
Comprehensive net income (loss)		581		(102)		1,064		228
Comprehensive net income										Comprehensive net income	181		262		461		483
Less: Comprehensive income available to noncontrolling interests	Less: Comprehensive income available to noncontrolling interests	129		90		392		237		Less: Comprehensive income available to noncontrolling interests	141		138		281		263
Comprehensive income available (loss attributable) to Tenet Healthcare Corporation common shareholders		$	452	$	(192)	$	672	$	(9)
Comprehensive income available to Tenet Healthcare Corporation common shareholders										Comprehensive income available to Tenet Healthcare Corporation common shareholders	$	40	$	124	$	180	$	220

See accompanying Notes to Condensed Consolidated Financial Statements.

Table of Contents

TENET HEALTHCARE CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Dollars in Millions

(Unaudited)


		Nine Months Ended September 30,					Six Months Ended June 30,
		2021		2020			2022		2021
Net income	Net income	$	1,057	$	222	Net income	$	459	$	479
Adjustments to reconcile net income to net cash provided by operating activities:	Adjustments to reconcile net income to net cash provided by operating activities:					Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	Depreciation and amortization	654		624		Depreciation and amortization	419		445
Deferred income tax expense (benefit)		183		(246)
Deferred income tax expense						Deferred income tax expense	132		48
Stock-based compensation expense	Stock-based compensation expense	43		38		Stock-based compensation expense	34		30
Impairment and restructuring charges, and acquisition-related costs	Impairment and restructuring charges, and acquisition-related costs	55		166		Impairment and restructuring charges, and acquisition-related costs	73		40
Litigation and investigation costs	Litigation and investigation costs	64		13		Litigation and investigation costs	38		35
Net gains on sales, consolidation and deconsolidation of facilities	Net gains on sales, consolidation and deconsolidation of facilities	(427)		(4)		Net gains on sales, consolidation and deconsolidation of facilities	—		(15)
Loss from early extinguishment of debt	Loss from early extinguishment of debt	74		316		Loss from early extinguishment of debt	109		54
Equity in earnings of unconsolidated affiliates, net of distributions received	Equity in earnings of unconsolidated affiliates, net of distributions received	10		(11)		Equity in earnings of unconsolidated affiliates, net of distributions received	18		10
Amortization of debt discount and debt issuance costs	Amortization of debt discount and debt issuance costs	25		30		Amortization of debt discount and debt issuance costs	15		17

Pre-tax loss (income) from discontinued operations						Pre-tax loss (income) from discontinued operations	(1)		1
Other items, net	Other items, net	(23)		(4)		Other items, net	(59)		(22)
Changes in cash from operating assets and liabilities:	Changes in cash from operating assets and liabilities:					Changes in cash from operating assets and liabilities:
Accounts receivable	Accounts receivable	(202)		280		Accounts receivable	(74)		(101)
Inventories and other current assets	Inventories and other current assets	(111)		30		Inventories and other current assets	173		56
Income taxes	Income taxes	67		9		Income taxes	(86)		25
Accounts payable, accrued expenses, contract liabilities and other current liabilities	Accounts payable, accrued expenses, contract liabilities and other current liabilities	(149)		1,546		Accounts payable, accrued expenses, contract liabilities and other current liabilities	(764)		(232)
Other long-term liabilities	Other long-term liabilities	8		205		Other long-term liabilities	(41)		(6)
Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements	Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements	(116)		(252)		Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements	(98)		(85)
Net cash used in operating activities from discontinued operations, excluding income taxes		(1)		(1)

Net cash provided by operating activities	Net cash provided by operating activities	1,211		2,961		Net cash provided by operating activities	347		779
Cash flows from investing activities:	Cash flows from investing activities:					Cash flows from investing activities:
Purchases of property and equipment	Purchases of property and equipment	(354)		(374)		Purchases of property and equipment	(307)		(243)
Purchases of businesses or joint venture interests, net of cash acquired	Purchases of businesses or joint venture interests, net of cash acquired	(64)		(61)		Purchases of businesses or joint venture interests, net of cash acquired	(66)		(64)
Proceeds from sales of facilities and other assets	Proceeds from sales of facilities and other assets	1,235		13		Proceeds from sales of facilities and other assets	209		124

Proceeds from sales of marketable securities, long-term investments and other assets	Proceeds from sales of marketable securities, long-term investments and other assets	18		44		Proceeds from sales of marketable securities, long-term investments and other assets	9		18
Purchases of marketable securities and equity investments	Purchases of marketable securities and equity investments	(23)		(41)		Purchases of marketable securities and equity investments	(41)		(19)

Other items, net	Other items, net	(10)		13		Other items, net	(4)		(11)
Net cash provided by (used in) investing activities		802		(406)
Net cash used in investing activities						Net cash used in investing activities	(200)		(195)
Cash flows from financing activities:	Cash flows from financing activities:					Cash flows from financing activities:
Repayments of borrowings under credit facility		—		(740)
Proceeds from borrowings under credit facility		—		740
Repayments of other borrowings		(3,183)		(3,244)
Proceeds from other borrowings		1,413		3,815

Repayments of borrowings						Repayments of borrowings	(2,744)		(2,012)
Proceeds from borrowings						Proceeds from borrowings	2,013		1,409
Debt issuance costs	Debt issuance costs	(15)		(48)		Debt issuance costs	(24)		(15)
Distributions paid to noncontrolling interests	Distributions paid to noncontrolling interests	(316)		(184)		Distributions paid to noncontrolling interests	(310)		(212)
Proceeds from sale of noncontrolling interests		14		7
Proceeds from the sale of noncontrolling interests						Proceeds from the sale of noncontrolling interests	9		12
Purchases of noncontrolling interests	Purchases of noncontrolling interests	(19)		(34)		Purchases of noncontrolling interests	(29)		(5)
Proceeds from shares issued under stock-based compensation plans, net of taxes paid related to net share settlement		11		13

Medicare advances and grants received by unconsolidated affiliates, net of recoupment	Medicare advances and grants received by unconsolidated affiliates, net of recoupment	(8)		150		Medicare advances and grants received by unconsolidated affiliates, net of recoupment	—		6
Other items, net	Other items, net	(64)		8		Other items, net	(75)		(19)
Net cash provided by (used in) financing activities		(2,167)		483
Net increase (decrease) in cash and cash equivalents		(154)		3,038
Net cash used in financing activities						Net cash used in financing activities	(1,160)		(836)
Net decrease in cash and cash equivalents						Net decrease in cash and cash equivalents	(1,013)		(252)
Cash and cash equivalents at beginning of period	Cash and cash equivalents at beginning of period	2,446		262		Cash and cash equivalents at beginning of period	2,364		2,446
Cash and cash equivalents at end of period	Cash and cash equivalents at end of period	$	2,292	$	3,300	Cash and cash equivalents at end of period	$	1,351	$	2,194
Supplemental disclosures:	Supplemental disclosures:					Supplemental disclosures:
Interest paid, net of capitalized interest	Interest paid, net of capitalized interest	$	(664)	$	(757)	Interest paid, net of capitalized interest	$	(416)	$	(486)
Income tax payments, net	Income tax payments, net	$	(54)	$	(10)	Income tax payments, net	$	(140)	$	(34)

See accompanying Notes to Condensed Consolidated Financial Statements.

Table of Contents

TENET HEALTHCARE CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1. BASIS OF PRESENTATION

Description of Business and Basis of Presentation

Tenet Healthcare Corporation (together with our subsidiaries, referred to herein as “Tenet,” ~~“we,” “our”~~“we” or “us”) is a diversified healthcare services company headquartered in Dallas, Texas. ~~Through an expansive~~Our care delivery network ~~that~~ includes our subsidiary USPI Holding Company, Inc. (“USPI”), ~~at September 30, 2021 we~~which operated ~~60 hospitals and approximately 460 other healthcare facilities, including surgical hospitals,~~or had indirect ownership interests in 410 ambulatory surgery centers ~~imaging centers,~~ and ~~other care sites and clinics.~~24 surgical hospitals at June 30, 2022. We hold noncontrolling interests in 165 of these facilities, which are recorded using the equity method of accounting. We also operated 60 acute care and specialty hospitals, 110 other outpatient facilities, a network of employed physicians and a Global Business Center (“GBC”) in Manila, Philippines at June 30, 2022. In addition, we operate Conifer Health Solutions, LLC, in which we own an interest of approximately 76%, through our Conifer Holdings, Inc. subsidiary (“Conifer”) ~~subsidiary,~~

Effective June 30, 2022, we purchased all of the shares previously held by Baylor University Medical Center (“Baylor”) in USPI for $406 million, which increased our ownership interest in USPI’s voting shares from 95% to 100%. See Note 13 for additional information about this transaction.

This quarterly report supplements our Annual Report on Form 10‑K for the year ended December 31, ~~2020~~2021 (“Annual Report”). As permitted by the Securities and Exchange Commission for interim reporting, we have omitted certain notes and disclosures that substantially duplicate those in our Annual Report. For further information, refer to the audited Consolidated Financial Statements and notes included in our Annual Report. Unless otherwise indicated, all financial and statistical data included in these notes to our Condensed Consolidated Financial Statements relate to our continuing operations, with dollar amounts expressed in millions (except per‑share amounts).

Effective January 1, 2022, we adopted the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2020-06, “Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”) using the modified retrospective method. Among other amendments, ASU 2020-06 changed the accounting for diluted earnings‑per‑share for convertible instruments and contracts that may be settled in cash or stock. ASU 2020-06 eliminated an entity’s ability to rebut the presumption of share settlement for convertible instruments and contracts that can be partially or fully settled in cash at the issuer’s election. Additionally, ASU 2020-06 requires that the if‑converted method, which is more dilutive than the treasury stock method, be used for all convertible instruments. As a result of our adoption of ASU 2020-06, diluted weighted average shares outstanding increased by 5000000 shares for the six months ended June 30, 2022. However, because there were also adjustments to net income under the if-converted method, the increase in diluted shares did not result in any change in the reported diluted earnings per share available to Tenet common shareholders for the six-month period.

Although the Condensed Consolidated Financial Statements and related notes within this document are unaudited, we believe all adjustments considered necessary for a fair presentation have been included and are of a normal recurring nature. In preparing our financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”), we are required to make estimates and assumptions that affect the amounts reported in our Condensed Consolidated Financial Statements and these accompanying notes. We regularly evaluate the accounting policies and estimates we use. In general, we base the estimates on historical experience and on assumptions that we believe to be reasonable given the particular circumstances in which we operate. Actual results may vary from those estimates. ~~Financial~~The financial and statistical information we report to other regulatory agencies may be prepared on a basis other than GAAP or using different assumptions or reporting periods and, therefore, may vary from the amounts presented herein. Although we make every effort to ensure that the information we report to those agencies is accurate, complete and consistent with applicable reporting guidelines, we cannot be responsible for the accuracy of the information they make available to the public.

Operating results for the three and ~~nine‑~~six‑month periods ended ~~September~~June 30, ~~2021~~2022 are not necessarily indicative of the results that may be expected for the full year. Reasons for this include, but are not limited to: the impact of the COVID‑19 pandemic

Table of Contents

on our operations, business, financial condition and cash flows; the impact of the demand for, and availability of, qualified medical personnel on compensation costs; the impact of cybersecurity incidents on our operations; overall revenue and cost trends, particularly the timing and magnitude of price changes; fluctuations in contractual allowances and cost report settlements and valuation allowances; managed care contract negotiations, settlements or terminations and payer consolidations; trends in patient accounts receivable collectability and associated implicit price concessions; fluctuations in interest rates; levels of malpractice insurance expense and settlement trends; impairment of long‑lived assets and goodwill; restructuring charges; losses, costs and insurance recoveries related to cybersecurity incidents, natural disasters and other weather‑related occurrences; litigation and investigation costs; acquisitions and dispositions of facilities and other assets; gains (losses) on sales, consolidation and deconsolidation of facilities; income tax rates and deferred tax asset valuation allowance activity; changes in estimates of accruals for annual incentive compensation; the timing and amounts of stock option and restricted stock unit grants to employees and directors; gains (losses) from early extinguishment of debt; and changes in occupancy levels and patient volumes. Factors that affect service mix, revenue mix, patient volumes and, thereby, the results of operations at our ambulatory surgery centers, hospitals and ~~related~~other healthcare facilities include, but are not limited to: changes in federal, state and local healthcare and business regulations, including mandated closures and other operating restrictions; ~~the business environment,~~changes in general economic conditions nationally and ~~demographics~~regionally, including inflation and the impacts of ~~local communities in which we operate;~~the COVID-19 pandemic and other factors on business conditions, the economy and financial markets; the number of uninsured and underinsured individuals in local communities treated at our ~~hospitals;~~facilities; disease hotspots and seasonal cycles of illness; climate and weather conditions; physician recruitment, satisfaction, retention and attrition; advances in technology and treatments that reduce length of ~~stay;~~stay or permit procedures to be performed in an outpatient rather than inpatient setting; local healthcare competitors; utilization pressure by managed care organizations, as well as managed care contract negotiations or terminations; ~~hospital~~ performance data on quality measures and patient satisfaction, as well as standard charges for services; any unfavorable publicity about us, or our joint venture partners, that impacts our relationships with physicians and patients; and changing consumer behavior, including with respect to the timing of elective procedures. These considerations apply to year‑to‑year comparisons as well.

~~Table of Contents~~

Certain prior‑year amounts have been reclassified to conform to the current year presentation. In the accompanying Condensed Consolidated Balance Sheets, income tax receivable has been reclassified to other current assets, as it is no longer significant enough to present separately. In the accompanying Condensed Consolidated Statements of Cash Flows, long‑term assets has been combined with other items, net, as it is no longer significant enough to present separately, but it remains located within cash flows from investing activities.

COVID‑19 Pandemic

~~During 2020,~~The COVID‑19 pandemic has impacted all 3 segments of our business, as well as our patients, communities and employees, in varying degrees since March 2020. Throughout this time, federal, state and local authorities ~~undertook~~have undertaken several actions designed to assist healthcare providers in providing care to COVID‑19 and other patients and to mitigate the adverse economic impact of the COVID‑19 pandemic. ~~Legislative actions taken by the~~Among other things, federal government during 2020 included the Coronavirus Aid, Relief, and Economic Security Act, the Paycheck Protection Program and Health Care Enhancement Act, the Continuing Appropriations Act, 2021 and Other Extensions Act, and the Consolidated Appropriations Act, 2021legislation (collectively, the “COVID Acts”)~~. With the COVID Acts, the federal government~~ authorized ~~funding~~aggregate grant payments of $178 billion to be distributed through the Public Health and Social Services Emergency Fund (“~~Provider Relief Fund” or “PRF”~~PRF”)~~. In June 2021, the U.S. Department of Health~~ to healthcare providers who experienced lost revenues and ~~Human Services (“HHS”) established new deadlines for when recipients of PRF grants must use the funding received, generally 12 to 18 months after receipt~~increased expenses as a result of the ~~grant funds. HHS will recoup PRF grant funds not utilized by the established deadlines.~~pandemic. The COVID Acts also revised the Medicare accelerated payment program ~~in an attempt to disburse payments to hospitals and other care providers more quickly~~(“MAPP”) and permitted employers to defer ~~payment of the 6.2% employer~~payroll Social Security tax ~~beginning March 27, 2020 through December 31,~~payments in 2020. Our participation in these programs and the related accounting policies are summarized below.

Grant ~~Income~~Income–~~. During~~As detailed in the ~~three and nine months ended September 30, 2021,~~table below, we received cash payments ~~of $2 million and $65 million, respectively,~~ from the ~~Provider Relief Fund~~PRF and state and local grant programs including $27 million received by our unconsolidated affiliates during the nine‑month period. During the three and nine months ended September 30, 2020, we received cash payments of $178 million and $890 million, respectively, from the Provider Relief Fund and state and local grant programs, including $4 million and $42 million received by our unconsolidated affiliates during the three and ~~nine‑month periods, respectively.~~ six months ended June 30, 2022 and 2021. Grant funds received by our Hospital Operations segment and those facilities in our Ambulatory Care segment that we consolidate are included in cash flows from operating activities in our condensed consolidated statements of cash flows. Grant funds received by unconsolidated affiliates for which we provide cash management services (“Cash‑Managed Affiliates”) are included in cash flows from financing activities.


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Grant funds received from COVID-19 relief programs:
Included in cash flows from operating activities:
Hospital Operations	$	97	$	5	$	101	$	27
Ambulatory Care	2		—		3		9
	$	99	$	5	$	104	$	36

Included in cash flows from financing activities:
Cash‑Managed Affiliates	$	—	$	(1)	$	—	$	27

As a condition to receiving distributions, providers must agree to certain terms and conditions, including, among other things, that the funds are being used for lost revenues and unreimbursed COVID‑related costs as defined by the U.S. Department of Health and Human Services (“HHS”), and that the providers will not seek collection of out‑of‑pocket payments from a COVID‑19 patient that are greater than what the patient would have otherwise been required to pay if the care had been provided by an in‑network provider. All recipients of PRF payments are required to comply with the reporting

Table of Contents

requirements described in the terms and conditions and as determined by the Secretary of HHS. PRF funds not utilized by the established deadlines, generally 12 to 18 months after receipt of the grant funds, will be recouped by HHS.

We recognize grant payments as income when there is reasonable assurance that we have complied with the conditions associated with the grant. ~~Our~~The estimates we use to recognize grant income could change materially in the future based on our operating performance or fluctuations in the severity of COVID‑19 ~~activities,~~outbreaks at individual locations, as well as the government’s grant compliance guidance. ~~Grant~~ The table below summarizes grant income recognized by our Hospital Operations ~~and other (“Hospital Operations”)~~ and Ambulatory Care segments, which is presented in grant income, and grant income recognized through our unconsolidated affiliates, which is presented in equity in earnings of ~~unconsolidated~~unconsolidated affiliates, in each case in our ~~statement~~condensed consolidated statements of operations. ~~During the three and nine months ended September~~


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021









Grant income recognized from COVID-19 relief programs:
Included in grant income:
Hospital Operations	$	92	$	4	$	96	$	28
Ambulatory Care	2		15		4		22
	$	94	$	19	$	100	$	50

Included in equity in earnings of unconsolidated affiliates:
Unconsolidated affiliates	$	—	$	5	$	—	$	11

At June 30, 2021, we recognized grant income of $2 million and $30 million, respectively, in our Hospital Operations segment, and $1 million and $23 million, respectively, in our Ambulatory Care segment. We recognized an additional $1 million and $12 million of Provider Relief Fund income during these periods, which was classified as equity in earnings of unconsolidated affiliates in the accompanying Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2021, respectively. During the three and nine months ended September 30, 2020, we recognized net grant income of $(57) million and $417 million, respectively, in our Hospital Operations segment, and $(9) million and $28 million, respectively, in our Ambulatory Care segment. Additionally, we recognized $(4) million and $8 million, respectively, of net grant income as equity in earnings of unconsolidated affiliates during the three and nine months ended September 30, 2020. We recognized a reduction of grant income in the three months ended September 30, 2020 to comply with revised grant guidelines HHS published in September 2020. At September 30, 20212022 and December 31, ~~2020,~~2021, we had remaining deferred grant ~~payments remaining~~payment balances of $3$8 million and ~~$18~~$5 million, respectively, which amounts were recorded in other current liabilities in the accompanying Condensed Consolidated Balance Sheets for those periods.

Medicare Accelerated Payment Program (MAPP)–. In certain circumstances, when a ~~hospital~~healthcare facility is experiencing financial difficulty due to delays in receiving payment for the Medicare services it provided, it may be eligible for an accelerated or advance payment pursuant to the ~~Medicare accelerated payment program.~~MAPP. The COVID Acts revised the ~~Medicare accelerated payment program in an attempt~~MAPP to disburse payments to healthcare providers more quickly. Recipients may retain the accelerated payments for one year from the date of receipt before recoupment commences, which is effectuated by a 25% offset of claims payments for 11 months, followed by a 50% offset for the succeeding six months. At the end of the 29‑month period, interest on the ~~unpaid~~unrecouped balance will be assessed at 4.00% per annum. The initial 11‑month recoupment period began in April 2021.

Our Hospital Operations and Ambulatory Care segments ~~both received~~did not receive any additional advance payments from the ~~Medicare accelerated payment program~~MAPP during ~~2020. No additional advances were received in~~ the ~~nine~~six months ended ~~September~~June 30, 2022 or 2021. ~~During~~

The table below summarizes MAPP advances from prior periods recouped during the three and ~~nine~~six months ended ~~September~~June 30, ~~2021, $161 million~~2022 and ~~$302 million, respectively, of advances received by~~2021. Advances to our Hospital Operations segment and ~~$13 million and $24 million, respectively, of advances received by~~those facilities in our Ambulatory Care segment that we consolidate were recouped through a reduction of ~~our~~their respective Medicare claims ~~payments. In addition, $14 million~~payments and ~~$26 million~~are presented in cash flows from operating activities in our condensed consolidated statements of ~~advances received by unconsolidated affiliates for which we provide~~ cash ~~management services~~flows. Advances to our Cash‑Managed Affiliates were

~~Table of Contents~~

recouped through a reduction of those affiliates’ Medicare claims payments ~~during the same three~~ and ~~nine-month periods, respectively.~~ are presented in cash flows from financing activities.


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
MAPP advances recouped:
Included in cash flows from operating activities:
Hospital Operations	$	279	$	141	$	473	$	141
Ambulatory Care	2		11		2		11
	$	281	$	152	$	475	$	152

Included in cash flows from financing activities:
Cash‑Managed Affiliates	$	—	$	12	$	—	$	12

In the accompanying Condensed Consolidated Balance Sheets, advances totaling ~~$1.144 billion~~$405 million and ~~$603~~$880 million were included in contract liabilities at ~~September~~June 30, ~~2021~~2022 and December 31, ~~2020, respectively, and advances totaling $902 million were included in contract liabilities – long term at December 31, 2020.~~2021, respectively.

Deferral of ~~Employer Payroll~~Employment Tax ~~Match Payments.~~ Payments–The COVID Acts permitted employers to defer payment of the 6.2% employer Social Security ~~taxes deferred under the COVID Acts~~tax beginning March 27, 2020 through December 31, 2020. Deferred tax amounts are required to be paid in

Table of Contents

equal amounts over two years, with payments due in December 2021 and December 2022. We ~~had~~paid the first half of the Social Security taxes we deferred in 2020 in December 2021. At both June 30, 2022 and December 31, 2021, deferred Social Security tax payments totaling ~~$130~~$128 million were included in accrued compensation and benefits ~~and $130 million included in other long‑term liabilities~~ in the accompanying Condensed Consolidated Balance ~~Sheets at both September~~Sheets.

Leases

During the six months ended June 30, 2022, we sold several medical office buildings held in our Hospital Operations segment for net cash proceeds of $147 million and concurrently entered into operating lease agreements to continue use of the facilities. We recognized a gain of $69 million from the sale of these buildings, presented in other operating expenses, net in the accompanying Condensed Consolidated Statement of Operations, and we recognized right-of-use assets and lease-related obligations of $109 million related to the leases, in each case in the six months ended June 30, 2022.

During the six months ended June 30, 2022 and 2021, we recorded right‑of‑use assets related to non‑cancellable finance leases of $29 million and ~~December 31, 2020.~~$40 million, respectively, and related to non‑cancellable operating leases of $227 million and $96 million, respectively.

Cash and Cash Equivalents

We treat highly liquid investments with original maturities of three months or less as cash equivalents. Cash and cash equivalents were ~~$2.292~~$1.351 billion and ~~$2.446~~$2.364 billion at ~~September~~June 30, ~~2021~~2022 and December 31, ~~2020,~~2021, respectively. At ~~September~~June 30, ~~2021~~2022 and December 31, ~~2020,~~2021, our book overdrafts were ~~$155~~$145 million and ~~$154~~$226 million, respectively, which were classified as accounts payable.

At ~~September~~June 30, ~~2021~~2022 and December 31, ~~2020, $169~~2021, $165 million and ~~$166~~$188 million, respectively, of total cash and cash equivalents in the accompanying Condensed Consolidated Balance Sheets were intended for the operations of our ~~captive insurance~~insurance‑related subsidiaries.

Also at ~~September~~June 30, ~~2021~~2022 and December 31, ~~2020,~~2021, we had ~~$51~~$72 million and ~~$93~~$95 million, respectively, of property and equipment purchases accrued for items received but not yet paid. Of these amounts, ~~$45~~$58 million and ~~$85~~$88 million, respectively, were included in accounts payable.

~~During~~In June 2022, we acquired all of Baylor’s 5% voting ownership interest in USPI. We paid $11 million from cash on hand and recognized a liability of $377 million, the ~~nine~~present value of the liability, for the remainder of the purchase price. We recorded reductions in redeemable noncontrolling interest of $365 million for the carrying value of Baylor’s ownership interest and $23 million to additional paid-in capital for the difference between the carrying value and present value of the purchase price for the shares. This has been reflected as noncash financing activity in the accompanying Condensed Consolidated Statement of Cash Flows for the six months ended ~~September~~June 30, 2021 and 2020, we recorded right‑of‑use assets related to non‑cancellable finance leases of $81 million and $75 million, respectively, and related to non‑cancellable operating leases of $121 million and $135 million, respectively.2022. See Note 13 for additional information about this transaction.

Other Intangible Assets

The following tables provide information regarding other intangible assets, which were included in the accompanying Condensed Consolidated Balance ~~Sheets at September 30, 2021 and December 31, 2020:~~ Sheets:


		Gross Carrying Amount		Accumulated Amortization		Net Book Value			Gross Carrying Amount		Accumulated Amortization		Net Book Value
At September 30, 2021:
At June 30, 2022:								At June 30, 2022:
Other intangible assets with finite useful lives:								Other intangible assets with finite useful lives:
Capitalized software costs	Capitalized software costs	$	1,732	$	(1,123)	$	609	Capitalized software costs	$	1,751	$	(1,174)	$	577
Contracts								Contracts	295		(138)		157
Other								Other	94		(77)		17
Total other intangible assets with finite lives								Total other intangible assets with finite lives	2,140		(1,389)		751

Other intangible assets with indefinite useful lives:								Other intangible assets with indefinite useful lives:
Trade names	Trade names	102		—		102		Trade names	102		—		102
Contracts	Contracts	870		(124)		746		Contracts	603		—		603
Other	Other	102		(79)		23		Other	6		—		6
Total		$	2,806	$	(1,326)	$	1,480
Total other intangible assets with indefinite lives								Total other intangible assets with indefinite lives	711		—		711
Total other intangible assets								Total other intangible assets	$	2,851	$	(1,389)	$	1,462

Gross Carrying
Amount Accumulated
Amortization Net Book Value
At December 31, 2020:
Capitalized software costs $ 1,800 $ (1,084) $ 716
Trade names 102 — 102
Contracts 872 (111) 761
Other 110 (89) 21
Total $ 2,884 $ (1,284) $ 1,600

Table of Contents


	Gross Carrying Amount		Accumulated Amortization		Net Book Value
At December 31, 2021:
Other intangible assets with finite useful lives:
Capitalized software costs	$	1,770	$	(1,165)	$	605
Contracts	295		(128)		167
Other	95		(81)		14
Total other intangible assets with finite lives	2,160		(1,374)		786

Other intangible assets with indefinite useful lives:
Trade names	102		—		102
Contracts	602		—		602
Other	7		—		7
Total other intangible assets with indefinite lives	711		—		711
Total other intangible assets	$	2,871	$	(1,374)	$	1,497

Estimated future amortization of intangibles with finite useful lives at ~~September~~June 30, ~~2021 is~~2022 was as follows:

Three Months Ending Years Ending Later Years
December 31,
Total 2021 2022 2023 2024 2025
Amortization of intangible assets $ 796 $ 53 $ 124 $ 110 $ 98 $ 83 $ 328


			Six Months Ending		Years Ending								Later Years
					December 31,
	Total		2022		2023		2024		2025		2026
Amortization of intangible assets	$	751	$	83	$	123	$	120	$	100	$	81	$	244

~~Table of Contents~~

We recognized amortization expense of ~~$139~~$92 million and ~~$127~~$95 million in the accompanying Condensed Consolidated Statements of Operations for the ~~nine~~six months ended ~~September~~June 30, 2022 and 2021, ~~and 2020,~~ respectively.

Other Current Assets

The principal components of other current assets in the accompanying Condensed Consolidated Balance Sheets were as follows:


	June 30, 2022		December 31, 2021
Prepaid expenses	$	349	$	252
Contract assets	187		199
Receivables from government programs	446		627
Guarantees	99		104
Non-patient receivables	329		321
Other	58		54
Total other current assets	$	1,468	$	1,557

Investments in Unconsolidated Affiliates

We control ~~232~~269 of the facilities within our Ambulatory Care segment and, therefore, consolidate their results. We account for many of the facilities our Ambulatory Care segment operates ~~(110~~(165 of ~~342~~434 at ~~September~~June 30, ~~2021)~~2022), as well as additional companies in which our Hospital Operations segment holds ownership interests, under the equity method as investments in unconsolidated affiliates and report only our share of net income as equity in earnings of unconsolidated affiliates in the accompanying Condensed Consolidated Statements of Operations. No grant income was recognized during the three and six months ended June 30, 2022 by our unconsolidated affiliates. Equity in earnings of unconsolidated affiliates included $1$5 million and ~~$12~~$11 million of grant income for the three and ~~nine~~six months ended ~~September~~June 30, 2021, ~~respectively, from PRF grants recognized by our Ambulatory Care segment’s unconsolidated affiliates. During the three and nine months ended September 30, 2020, equity in earnings~~respectively.

Table of unconsolidated affiliates included $(4) million and $8 million, respectively, from PRF grants recognized by these unconsolidated affiliates. During the three months ended September 30, 2020, we recognized a reduction of grant income reported in previous periods to comply with revised grant guidelines HHS published in September 2020. Contents

Summarized financial information for these equity method investees is included in the following table. For investments acquired during the reported periods, amounts ~~reflect~~below include 100% of the investee’s results beginning on the date of our acquisition of the investment.


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended June 30,				Six Months Ended June 30,
		2021		2020		2021		2020			2022		2021		2022		2021
Net operating revenues	Net operating revenues	$	720	$	697	$	2,065	$	1,731	Net operating revenues	$	794	$	711	$	1,563	$	1,345
Net income	Net income	$	178	$	167	$	540	$	414	Net income	$	193	$	197	$	362	$	362
Net income available to the investees	Net income available to the investees	$	108	$	101	$	325	$	253	Net income available to the investees	$	109	$	115	$	207	$	217

NOTE 2. ACCOUNTS RECEIVABLE

The principal components of accounts receivable are ~~shown~~presented in the table below:


		September 30, 2021		December 31, 2020			June 30, 2022		December 31, 2021
Continuing operations:

Patient accounts receivable	Patient accounts receivable	$	2,558	$	2,499	Patient accounts receivable	$	2,650	$	2,600
Estimated future recoveries	Estimated future recoveries	139		156		Estimated future recoveries	141		137
Net cost reports and settlements receivable and valuation allowances	Net cost reports and settlements receivable and valuation allowances	44		34		Net cost reports and settlements receivable and valuation allowances	49		33
		2,741		2,689			$	2,840	$	2,770
Discontinued operations		1		1
Accounts receivable, net		$	2,742	$	2,690

We participate in various provider fee programs, which help reduce the amount of uncompensated care from indigent patients and those paying with Medicaid. The following table summarizes the amount and classification of assets and liabilities in the accompanying Condensed Consolidated Balance Sheets related to California’s provider fee ~~program at September 30, 2021 and December 31, 2020:~~program:


		September 30, 2021		December 31, 2020			June 30, 2022		December 31, 2021
Assets:	Assets:					Assets:
Other current assets	Other current assets	$	257	$	378	Other current assets	$	289	$	370
Investments and other assets	Investments and other assets	$	318	$	206	Investments and other assets	$	237	$	213

Liabilities:	Liabilities:					Liabilities:
Other current liabilities	Other current liabilities	$	93	$	110	Other current liabilities	$	121	$	123
Other long-term liabilities	Other long-term liabilities	$	98	$	56	Other long-term liabilities	$	74	$	60

~~Table of Contents~~

The following table ~~shows~~presents our estimated costs (based on selected operating expenses, which include salaries, wages and benefits, supplies and other operating expenses) of caring for our uninsured and charity ~~patients in the three and nine months ended September 30, 2021 and 2020:~~patients:


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended June 30,				Six Months Ended June 30,
		2021		2020		2021		2020			2022		2021		2022		2021
Estimated costs for:	Estimated costs for:									Estimated costs for:
Uninsured patients	Uninsured patients	$	181	$	165	$	507	$	466	Uninsured patients	$	136	$	158	$	258	$	326
Charity care patients	Charity care patients	25		30		74		113		Charity care patients	19		29		40		49
Total	Total	$	206	$	195	$	581	$	579	Total	$	155	$	187	$	298	$	375

NOTE 3. CONTRACT BALANCES

Hospital Operations Segment

Amounts related to services provided to patients for which we have not billed and that do not meet the conditions of unconditional right to payment at the end of the reporting period are contract assets. For our Hospital Operations segment, our contract assets include services that we have provided to patients who are still receiving inpatient care in our facilities at the end of the reporting period. Our Hospital Operations segment’s contract assets were included in other current assets in the accompanying Condensed Consolidated Balance Sheets at ~~September~~June 30, ~~2021~~2022 and December 31, ~~2020.~~2021. Approximately 91% of our Hospital Operations segment’s contract assets meet the conditions for unconditional right to payment and are reclassified to patient receivables within 90 days.

In certain circumstances, when a hospital is experiencing financial difficulty due to delays in receiving payment for the Medicare services it provided, it may be eligible for an accelerated or advance payment pursuant to the Medicare accelerated payment program. As discussed in Note 1, ~~the COVID Acts revised the Medicare accelerated payment program in an attempt to disburse payments to hospitals more quickly. During the year ended December 31, 2020,~~ our Hospital Operations segment received advance payments from the ~~Medicare accelerated payment program~~MAPP following its expansion under the COVID ~~Acts. These~~Acts during the year ended December 31, 2020; however, no additional advances were received during the six months ended June 30, 2022 and 2021. The remaining advance payments were recorded as contract liabilities in the accompanying Condensed Consolidated Balance Sheets at ~~September~~June 30, ~~2021~~2022 and December 31, ~~2020. No additional advances were received in the three and nine months ended September 30,~~ 2021.

Table of Contents

The opening and closing balances of contract assets and contract liabilities for our Hospital Operations segment ~~are~~were as follows:

Contract Liability – Contract Liability –
Current Long-term
Contract Assets Advances from Medicare Advances from Medicare
December 31, 2020 $ 208 $ 510 $ 819
September 30, 2021 190 1,031 —
Increase (decrease) $ (18) $ 521 $ (819)

December 31, 2019 $ 170 $ — $ —
September 30, 2020 171 1,270 —
Increase $ 1 $ 1,270 $ —


	Contract Assets		Contract Liabilities – Current Advances from Medicare		Contract Liabilities – Long-Term Advances from Medicare
December 31, 2021	$	181	$	876	$	—
June 30, 2022	172		403		—
Decrease	$	(9)	$	(473)	$	—

December 31, 2020	$	208	$	510	$	819
June 30, 2021	170		891		301
Increase (decrease)	$	(38)	$	381	$	(518)

During the ~~three and nine~~six months ended ~~September~~June 30, 2022 and 2021, ~~$161~~$473 million and ~~$302~~$141 million, respectively, of Medicare advance payments included in the opening contract liabilities balance for our Hospital Operations segment were recouped through a reduction of our Medicare claims payments.

Ambulatory Care Segment

~~During the year ended December 31, 2020, our~~Our Ambulatory Care segment also received advance payments from the expanded ~~Medicare accelerated payment program. At September 30, 2021, contract liabilities in~~MAPP during the ~~accompanying Condensed Consolidated Balance Sheet included $78 million of Medicare advance payments received by our unconsolidated affiliates for whom we provide cash management services. At~~year ended December 31, ~~2020, contract liabilities~~2020; however, no additional advances were received during the six months ended June 30, 2022 and contract liabilities – long‑term in the accompanying Condensed Consolidated Balance Sheet included $51 million and $62 million, respectively, of Medicare advance payments received by our unconsolidated affiliates for whom we provide cash management services.2021.

~~Table of Contents~~

The opening and closing balances of contract liabilities for our Ambulatory Care segment ~~are~~were as follows:

Contract Liability – Contract Liability –
Current Long-term
Advances from Medicare Advances from Medicare
December 31, 2020 $ 93 $ 83
September 30, 2021 113 —
Increase (decrease) $ 20 $ (83)
December 31, 2019 $ — $ —
September 30, 2020 172 —
Increase $ 172 $ —


	Contract Liabilities – Current Advances from Medicare		Contract Liabilities – Long-Term Advances from Medicare
December 31, 2021	$	4	$	—
June 30, 2022	2		—
Decrease	$	(2)	$	—

December 31, 2020	$	93	$	83
June 30, 2021	106		34
Increase (decrease)	$	13	$	(49)

During the ~~three and nine~~six months ended ~~September~~June 30, 2022 and 2021, ~~$13~~$2 million and ~~$24~~$11 million, respectively, of Medicare advance payments included in the opening contract liabilities balance for our Ambulatory Care segment were recouped through a reduction of ~~our~~ Medicare claims payments. Additionally, ~~$14 million and $26~~$12 million of Medicare ~~advances~~advance payments received by our ~~unconsolidated affiliates for whom we provide cash management services~~Cash‑Managed Affiliates and included in the opening contract liabilities balance were recouped in the same manner during the ~~three and nine~~six months ended ~~September~~June 30, ~~2021, respectively.~~2021. No amounts were recouped from our Cash‑Managed Affiliates during the six months ended June 30, 2022.

Conifer Segment

Conifer enters into contracts with ~~customers~~clients to provide revenue cycle management and other services, such as value‑based care, consulting and ~~project services.~~engagement solutions. The payment terms and conditions in ~~our customer~~Conifer’s client contracts vary. In some cases, ~~customers~~clients are invoiced in advance and (for other than fixed‑price fee arrangements) a true‑up to the actual fee is included on a subsequent invoice. In other cases, payment is due in arrears. In addition, some contracts contain performance incentives, penalties and other forms of variable consideration. When the timing of Conifer’s delivery of services is different from the timing of payments made by ~~the customers,~~its clients, Conifer recognizes either unbilled revenue (performance precedes contractual right to invoice the ~~customer)~~client) or deferred revenue ~~(customer~~(client payment precedes Conifer service performance). In the following table, ~~customers~~clients that prepay prior to obtaining control/benefit of ~~the service~~services are represented by deferred contract revenue until the performance obligations are satisfied. Unbilled revenue represents arrangements in which Conifer has provided services to and the ~~customer~~client has obtained control/benefit of these services prior to the contractual invoice date. Contracts with payment in arrears are recognized as receivables in the month the ~~service is~~services are performed.

Table of Contents

The opening and closing balances of Conifer’s receivables, contract assets and contract liabilities ~~are~~were as follows:


						Contract Liability –		Contract Liability –			Receivables		Contract Assets – Unbilled Revenue		Contract Liabilities – Current Deferred Revenue		Contract Liabilities – Long-Term Deferred Revenue
				Contract Asset –		Current		Long-Term
December 31, 2021										December 31, 2021	$	28	$	18	$	79	$	15
June 30, 2022										June 30, 2022	24		15		69		14
Decrease										Decrease	$	(4)	$	(3)	$	(10)	$	(1)
		Receivables		Unbilled Revenue		Deferred Revenue		Deferred Revenue
December 31, 2020	December 31, 2020	$	56	$	20	$	56	$	16	December 31, 2020	$	56	$	20	$	56	$	16
September 30, 2021		34		14		74		15
June 30, 2021										June 30, 2021	59		15		58		16
Increase (decrease)	Increase (decrease)	$	(22)	$	(6)	$	18	$	(1)	Increase (decrease)	$	3	$	(5)	$	2	$	—

December 31, 2019		$	26	$	11	$	61	$	18
September 30, 2020		29		13		58		17
Increase (decrease)		$	3	$	2	$	(3)	$	(1)

The ~~difference~~differences between the opening and closing balances of Conifer’s contract assets and contract liabilities are primarily related to prepayments for those ~~customers~~clients who are billed in advance, changes in estimates related to metric‑based services, and up‑front integration services that are typically not distinct and are, therefore, recognized over the performance obligation period to which they relate. Our Conifer segment’s receivables and contract assets were reported as part of other current assets in ~~our~~the accompanying Condensed Consolidated Balance Sheets, and its current and long‑term contract liabilities were reported as part of contract liabilities and contract liabilities – long‑term, respectively, in ~~our~~the accompanying Condensed Consolidated Balance Sheets.

In both of the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 and ~~2020,~~2021, Conifer recognized ~~$56~~$55 million ~~and $61 million, respectively,~~ of revenue that was included in the opening current deferred revenue liability. This revenue consists primarily of prepayments for those ~~customers~~clients who are billed in advance, changes in estimates related to metric‑based services, and up‑front integration services that are recognized over the services period.

~~Table of Contents~~

Contract Costs

During both of the three months ended ~~September~~June 30, ~~2021~~2022 and ~~2020,~~2021, we recognized amortization expense related to deferred contract setup costs of $1 ~~million and $2 million, respectively. In~~million. During both of the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 and ~~2020,~~2021, we recognized amortization expense related to deferred contract setup costs of ~~$3 million and $4 million, respectively.~~$2 million. At ~~September~~June 30, ~~2021~~2022 and December 31, ~~2020,~~2021, the unamortized ~~customer~~client contract costs were ~~$23~~$24 million and ~~$24~~$23 million, respectively, and arewere presented as part of investments and other assets in the accompanying Condensed Consolidated Balance Sheets.

NOTE 4. ASSETS AND LIABILITIES HELD FOR SALE

~~We completed~~In April 2022, we completed the sale of ~~5 Miami‑area~~ 1 of our micro‑hospitals located in Arizona and ~~certain related operations~~ held by our Hospital Operations ~~segment in August 2021, resulting in our recognition of~~segment. We recognized a ~~pre‑tax~~ gain onfrom this sale of ~~$409~~$1 million induring the three months ended ~~September~~June 30, ~~2021.~~2022, which was included in net gains on sales, consolidation and deconsolidation of facilities in the accompanying Condensed Consolidated Statement of Operations.

In the three months ended June 30, 2021, we completed the sale of the majority of our urgent care centers operated under the MedPost and CareSpot brands, ~~by our Hospital Operations~~ and ~~Ambulatory Care segments. During the same three‑month period,~~ we also completed the separate sale of a building we owned in the Philadelphia area that was held by our Hospital Operations segment. The assets and liabilities related to the urgent care centers and the building were classified as held for sale at December 31, 2020 in the accompanying Condensed Consolidated Balance Sheet.area. We recorded ~~pre‑tax gains of $14 million and $2 million~~a gain related to the sale of the urgent care centers of $14 million and a gain of $2 million related to the sale of the building in Philadelphia ~~respectively,~~ in the three months ended June 30, 2021.

The table below provides information on significant components of our business that have been recently disposed of:

Three Months Ended
September 30, Nine Months Ended
September 30,
2021 2020 2021 2020
Significant disposals:
Income from continuing operations, before income taxes
Miami area $ 407 $ 6 $ 436 $ 21
Total $ 407 $ 6 $ 436 $ 21


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Significant disposals:
Income from continuing operations, before income taxes:
Miami-area hospitals and certain related operations	$	4	$	16	$	8	$	29

NOTE 5. IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION‑RELATED COSTS

Our impairment tests presume stable, improving or, in some cases, declining operating results in our facilities, which are based on programs and initiatives being implemented that are designed to achieve each facility’s most recent projections. If these projections are not met, or ~~if in the future~~ negative trends occur that impact our future outlook, future impairments of long‑lived assets and goodwill may occur, and we may incur additional restructuring charges, which could be material.

Table of Contents

At ~~September~~June 30, ~~2021,~~2022, our continuing operations consisted of 3 reportable segments – Hospital Operations, Ambulatory Care and Conifer. Our segments are reporting units used to perform our goodwill impairment analysis.

We periodically incur costs to implement restructuring efforts for specific operations, which are recorded in our statement of operations as they are incurred. Our restructuring plans focus on various aspects of operations, including aligning our operations in the most strategic and cost‑effective structure, such as the establishment of offshore support operations at our ~~Global Business Center (“GBC”) in the Philippines.~~GBC. Certain restructuring and acquisition‑related costs are based on estimates. Changes in estimates are recognized as they occur.

During the ~~nine~~six months ended ~~September~~June 30, ~~2021,~~2022, we recorded impairment and restructuring charges and acquisition‑related costs of ~~$55~~$73 million, primarily consisting of ~~$48~~$61 million of restructuring charges, $1$6 million of impairment charges and $6 million of acquisition‑related costs. Restructuring charges consisted of ~~$13~~$21 million of employee severance costs, ~~$16~~$5 million related to the transition of various administrative functions to our GBC, $22 million of contract and lease termination fees, and $13 million of other restructuring costs. Impairment charges for the six months ended June 30, 2022 were comprised of $2 million from each of our Hospital Operations, Ambulatory Care and Conifer segments. Acquisition‑related costs consisted of $6 million of transaction costs.

During the six months ended June 30, 2021, we recorded impairment and restructuring charges and acquisition‑related costs of $40 million, consisting of $34 million of restructuring charges, $1 million of impairment charges and $5 million of acquisition‑related costs. Restructuring charges consisted of $10 million of employee severance costs, $12 million related to the transition of various administrative functions to our GBC and ~~$19~~$12 million of other restructuring costs. ~~Our impairment~~Impairment charges for the ~~nine~~six months ended ~~September~~June 30, 2021 were comprised of $1 million from our Ambulatory Care segment. Acquisition‑related costs consisted of ~~$6 million of transaction costs.~~

During the nine months ended September 30, 2020, we recorded impairment and restructuring charges and acquisition‑related costs of $166 million, consisting of $155 million of restructuring charges, $8 million of impairment charges and $3 million of acquisition‑related costs. Restructuring charges consisted of $53 million of employee severance costs, $40 million related to the transition of various administrative functions to our GBC, $23 million of charges due to the termination of USPI’s previous management equity plan, $15 million of contract and lease termination fees, and $24 million of

~~Table of Contents~~

~~other restructuring costs. Our impairment charges for the nine months ended September 30, 2020 were comprised of~~ $5 ~~million from our Ambulatory Care segment, $2 million from our Hospital Operations segment and $1 million from our Conifer segment. Acquisition‑related costs consisted of $3~~ million of transaction costs.

NOTE 6. LONG-TERM DEBT

The table below ~~shows~~presents our long‑term debt ~~at September 30, 2021 and December 31, 2020:~~included in the accompanying Condensed Consolidated Balance Sheets:


		September 30, 2021		December 31, 2020			June 30, 2022		December 31, 2021
Senior unsecured notes:	Senior unsecured notes:					Senior unsecured notes:

6.750% due 2023						6.750% due 2023	$	—	$	1,872

6.750% due 2023		$	1,872	$	1,872
7.000% due 2025		—		478
6.125% due 2028	6.125% due 2028	2,500		2,500		6.125% due 2028	2,500		2,500
6.875% due 2031	6.875% due 2031	362		362		6.875% due 2031	362		362
Senior secured first lien notes:	Senior secured first lien notes:					Senior secured first lien notes:

4.625% due 2024	4.625% due 2024	770		1,870		4.625% due 2024	770		770
4.625% due 2024	4.625% due 2024	600		600		4.625% due 2024	600		600
7.500% due 2025	7.500% due 2025	700		700		7.500% due 2025	—		700
4.875% due 2026	4.875% due 2026	2,100		2,100		4.875% due 2026	2,100		2,100
5.125% due 2027	5.125% due 2027	1,500		1,500		5.125% due 2027	1,500		1,500
4.625% due 2028	4.625% due 2028	600		600		4.625% due 2028	600		600
4.250% due 2029	4.250% due 2029	1,400		—		4.250% due 2029	1,400		1,400
4.375% due 2030						4.375% due 2030	1,450		1,450
6.125% due 2030						6.125% due 2030	2,000		—
Senior secured second lien notes:	Senior secured second lien notes:					Senior secured second lien notes:

5.125% due 2025		—		1,410

6.250% due 2027	6.250% due 2027	1,500		1,500		6.250% due 2027	1,500		1,500

Finance leases, mortgage and other notes		372		403
Finance leases, mortgages and other notes						Finance leases, mortgages and other notes	433		443
Unamortized issue costs and note discounts	Unamortized issue costs and note discounts	(142)		(176)		Unamortized issue costs and note discounts	(143)		(151)
Total long-term debt	Total long-term debt	14,134		15,719		Total long-term debt	15,072		15,646
Less current portion	Less current portion	125		145		Less current portion	125		135
Long-term debt, net of current portion	Long-term debt, net of current portion	$	14,009	$	15,574	Long-term debt, net of current portion	$	14,947	$	15,511

Senior Unsecured Notes and Senior Secured Notes

On ~~September 10, 2021,~~June 15, 2022, we ~~redeemed approximately $1.100 billion of the then outstanding $1.870~~issued $2.000 billion aggregate principal amount of 6.125% senior secured first lien notes, which will mature on June 15, 2030 (the “2030 Senior Secured First Lien Notes”). We will pay interest on the 2030 Senior Secured First Lien Notes semi‑annually in arrears on June 15 and December 15 of each year, commencing on December 15, 2022. As further discussed below, we used a portion of the issuance proceeds from the 2030 Senior Secured First Lien Notes, after payment of fees and expenses, to finance the redemption of our ~~4.625%~~6.750% senior unsecured notes due 2023 (the “2023 Senior Unsecured Notes”).

Table of Contents

Through a series of open‑market transactions during the six months ended June 30, 2022, we repurchased $124 million aggregate principal amount outstanding of our 2023 Senior Unsecured Notes using cash on hand. Following the issuance of our 2030 Senior Secured First Lien Notes, we used a portion of the proceeds to redeem the then-remaining $1.748 billion aggregate principal outstanding of the 2023 Senior Unsecured Notes in advance of their maturity date. In total, we paid $1.933 billion during the six months ended June 30, 2022 to retire all $1.872 billion aggregate principal amount outstanding of our 2023 Senior Unsecured Notes, and we recorded aggregate losses from early extinguishment of debt of $71 million, primarily related to the difference between the purchase prices and the par value of the notes, as well as the write‑off of associated unamortized issuance costs.

On February 23, 2022, we redeemed all $700 million aggregate principal amount outstanding of our 7.500% senior secured first lien notes due ~~2024~~2025 in advance of their maturity date. We paid ~~$1.113 billion~~$730 million from cash on hand to redeem the ~~notes, which was primarily funded with the proceeds from the sale of 5 Miami‑area hospitals and certain related operations in August 2021.~~notes. In connection with the redemption, we recorded a loss from early extinguishment of debt of ~~$20~~$38 million in the three months ended ~~September 30, 2021,~~March 31, 2022, primarily related to the difference between the purchase price and the par value of the notes, as well as the write‑off of associated unamortized issuance costs.

On June 2, 2021, we issued $1.400 billion aggregate principal amount of 4.250% senior secured first lien notes, which will mature on June 1, 2029 (the “2029 Senior Secured First Lien Notes”). We will pay interest on the 2029 Senior Secured First Lien Notes semi‑annually in arrears on June 1 and December 1 of each year, commencing on December 1, 2021. The proceeds from the sale of the 2029 Senior Secured First Lien Notes were used, after payment of fees and expenses, together with cash on hand, to finance the redemption of all $1.410 billion aggregate principal amount then outstanding of our 5.125% senior secured second lien notes due 2025 (the “2025 Senior Secured Second Lien Notes”) in advance of their maturity date for approximately $1.428 billion. In connection with the redemption, we recorded a loss from early extinguishment of debt of approximately $31 million in the three months ended June 30, 2021, primarily related to the difference between the purchase price and the par value of the 2025 Senior Secured Second Lien Notes, as well as the write‑off of associated unamortized issuance costs.

In March 2021, we retired all $478 million aggregate principal amount outstanding of our 7.000% senior unsecured notes due 2025 in advance of their maturity date. We paid approximately $495 million from cash on hand to retire the notes. In connection with the retirement, we recorded a loss from early extinguishment of debt of $23 million in the three months ended March 31, 2021, primarily related to the difference between the purchase price and the par value of the notes, as well as the write‑off of associated unamortized issuance costs.

~~Table of Contents~~

Credit Agreement

We have a senior secured revolving credit facility that provides for revolving loans in an aggregate principal amount of up to ~~$1.900~~$1.500 billion with a $200 million subfacility for standby letters of credit. We amended our credit agreement (as amended to date, the “Credit Agreement”) in April 2020 to, among other things, (i) increase the aggregate revolving credit commitments from the previous limit of $1.500 billion to $1.900 billion (the “Increased Commitments”), subject to borrowing availability, and (ii) increase the advance rate and raise limits on certain eligible accounts receivable in the calculation of the borrowing base, in each case, for an incremental period of 364 days. In April 2021, we ~~further~~ amended the Credit Agreement to, among other things, extend the availability of the Increased Commitments through April 22, 2022 and reduce the interest rate margins. In March 2022, we further amended our Credit Agreement to, among other things, (i) decrease the aggregate revolving credit commitments from the previous Increased Commitments to aggregate revolving credit commitments not to exceed $1.500 billion, subject to borrowing availability, (ii) extend the scheduled maturity date to March 16, 2027, and (iii) replace the London Interbank Offered Rate (LIBOR) with the Term Secured Overnight Financing Rate (“SOFR”) and Daily Simple SOFR (each, as defined in the Credit Agreement) as the reference interest rate. At ~~September~~June 30, ~~2021,~~2022, we had no cash borrowings outstanding under the Credit Agreement, and we had less than $1 million of standby letters of credit outstanding. Based on our eligible receivables, ~~$1.802~~$1.500 billion was available for borrowing under the revolving credit facility at ~~September~~June 30, ~~2021.~~2022.

~~The Credit Agreement continues to have a scheduled maturity date of September 12, 2024, and obligations~~Obligations under the Credit Agreement continue to be guaranteed by substantially all of our domestic wholly owned hospital subsidiaries and secured by a first‑priority lien on the eligible inventory and accounts receivable owned by us and the subsidiary guarantors, including receivables for Medicaid supplemental payments.

Outstanding revolving loans accrue interest depending on the type of loan at either ~~(i)~~(a) a base rate plus aan applicable margin ranging from 0.25% to 0.75% per annum or ~~(ii)~~(b) Term SOFR, Daily Simple SOFR or the ~~London~~Euro Interbank Offered Rate ~~(LIBOR)~~(EURIBOR) (each, as defined in the Credit Agreement) plus aan applicable margin ranging from 1.25% to 1.75% per annum and (in the case of Term SOFR and Daily Simple SOFR only) a credit spread adjustment of 0.10%, in each case based on available credit. An unused commitment fee payable on the undrawn portion of the revolving loans ranges from 0.25% to 0.375% per annum based on available credit. Our borrowing availability is based on a specified percentage of eligible inventory and accounts receivable, including self‑pay accounts.

Letter of Credit Facility

~~In March 2020, we amended our~~We have a letter of credit facility (as amended to date, the “LC Facility”) that provides for the issuance, from time to ~~extend the~~time, of standby and documentary letters of credit in an aggregate principal amount of up to $200 million. The scheduled maturity date of the LC Facility ~~from March 7, 2021 to~~is September 12, 2024 and to increase the aggregate principal amount of standby and documentary letters of credit that from time to time may be issued thereunder from $180 million to $200 million. On July 29, 2020, we further amended the LC Facility to incrementally increase the maximum secured debt covenant from 4.25 to 1.00 on a quarterly basis up to 6.00 to 1.00 for the quarter ended March 31, 2021, at which point the maximum ratio began to step down incrementally on a quarterly basis through the quarter ending December 31, 2021. At September 30, 2021, the effective maximum secured debt covenant was 5.00 to 1.00.2024. Obligations under the LC Facility are guaranteed and secured by a first‑priority pledge of the capital stock and other ownership interests of certain of our wholly owned domestic hospital subsidiaries on an ~~equal~~ equal‑ranking basis with our senior secured first lien notes.

Drawings under any letter of credit issued under the LC Facility that we have not reimbursed within 3 business days after notice thereof accrue interest at a base rate plus a margin of 0.50% per annum. An unused commitment fee is payable at an initial rate of 0.25% per annum with a step up to 0.375% per annum should our secured‑debt‑to‑EBITDA ratio equal or exceed 3.00 to 1.00 at the end of any fiscal quarter. A fee on the aggregate outstanding amount of issued but undrawn letters of credit accrues at a rate of 1.50% per annum. An issuance fee equal to 0.125% per annum of the aggregate face amount of each outstanding letter of credit is payable to the account of the issuer of the related letter of credit. The LC Facility is subject to an effective maximum secured debt covenant of 4.25 to 1.00. At ~~September~~June 30, ~~2021,~~2022, we had ~~$139~~$127 million of standby letters of credit outstanding under the LC Facility.

Table of Contents

NOTE 7. GUARANTEES

At ~~September~~June 30, ~~2021,~~2022, the maximum potential amount of future payments under our income guarantees to certain physicians who agree to relocate and revenue collection guarantees to hospital‑based physician groups providing certain services at our hospitals was ~~$156~~$111 million. We had a total liability of ~~$108~~$99 million recorded for these guarantees included in other current liabilities in the accompanying Condensed Consolidated Balance Sheet at ~~September~~June 30, ~~2021.~~2022.

At ~~September~~June 30, ~~2021,~~2022, we also had issued guarantees of the indebtedness and other obligations of our investees to third parties, the maximum potential amount of future payments under which was approximately ~~$103~~$113 million. Of the total, ~~$12~~$22 million relates to the obligations of consolidated subsidiaries, which obligations were recorded in the accompanying Condensed Consolidated Balance Sheet at ~~September~~June 30, ~~2021.~~2022.

~~Table of Contents~~

NOTE 8. EMPLOYEE BENEFIT PLANS

Share-Based Compensation Plans

The accompanying Condensed Consolidated Statements of Operations for the ~~nine~~six months ended ~~September~~June 30, 2022 and 2021 ~~and 2020~~ include ~~$43~~$34 million and ~~$38~~$30 million, respectively, of pre-tax compensation costs related to our stock‑based compensation arrangements.

Stock Options

The following table summarizes stock option activity during the ~~nine~~six months ended ~~September~~June 30, ~~2021:~~2022:

Number of
Options Weighted Average
Exercise Price
Per Share Aggregate
Intrinsic Value Weighted Average
Remaining Life
Outstanding at December 31, 2020 912,531 $ 22.51
Exercised (334,907) $ 20.67
Outstanding at September 30, 2021 577,624 $ 23.58 $ 25 6.4 years
Vested and expected to vest at September 30, 2021 577,624 $ 23.58 $ 25 6.4 years
Exercisable at September 30, 2021 381,606 $ 21.16 $ 17 6.0 years


	Number of Options	Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value		Weighted Average Remaining Life
				(In Millions)
Outstanding at December 31, 2021	520,998	$	23.90

Exercised	(60,051)	$	28.26

Outstanding at June 30, 2022	460,947	$	23.33	$	13	5.6 years

There were ~~334,907~~60,051 and ~~472,304~~293,581 stock options exercised during the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 and ~~2020,~~2021, respectively, with aggregate intrinsic values of ~~$12~~$4 million and $3$10 million, respectively. All outstanding options were vested and exercisable at June 30, 2022. We did not grant any stock options during the ~~nine~~six months ended ~~September~~June 30, ~~2021 and 2020.~~

At September 30, 2021, there were less than $1 million of total unrecognized compensation costs related to stock options. These costs are expected to be recognized over a weighted average period of less than one year.2022 or 2021.

The following table summarizes information about our outstanding stock options at ~~September~~June 30, ~~2021:~~2022:


		Options Outstanding				Options Exercisable				Options Outstanding and Exercisable
Range of Exercise Prices	Range of Exercise Prices	Number of Options	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price Per Share		Number of Options	Weighted Average Exercise Price Per Share		Range of Exercise Prices	Number of Options	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price Per Share
$18.99 to $20.609	$18.99 to $20.609	350,422	6.0 years	$	19.89	350,422	$	19.89	$18.99 to $20.609	293,796	5.1 years	$	19.75
$20.61 to $35.430	$20.61 to $35.430	227,202	7.1 years	$	29.26	31,184	$	35.43	$20.61 to $35.430	167,151	6.5 years	$	29.62
		577,624	6.4 years	$	23.58	381,606	$	21.16		460,947	5.6 years	$	23.33

Restricted Stock Units

The following table summarizes activity with respect to restricted stock units (“RSUs”) during the ~~nine~~six months ended ~~September~~June 30, ~~2021:~~2022:


		Number of Restricted Stock Units	Weighted Average Grant Date Fair Value Per Unit			Number of Restricted Stock Units	Weighted Average Grant Date Fair Value Per Unit
Unvested at December 31, 2020		2,095,206	$	25.87
Unvested at December 31, 2021					Unvested at December 31, 2021	2,171,202	$	40.51
Granted	Granted	884,468	$	58.38	Granted	633,880	$	81.25
Vested	Vested	(701,507)	$	29.88	Vested	(814,507)	$	30.81
Forfeited	Forfeited	(28,269)	$	35.48	Forfeited	(46,064)	$	51.61
Unvested at September 30, 2021		2,249,898	$	40.29
Unvested at June 30, 2022					Unvested at June 30, 2022	1,944,511	$	63.21

In the ~~nine~~six months ended ~~September~~June 30, 2022, we granted an aggregate of 633,880 RSUs. Of these, 237,381 will vest and be settled ratably over a three‑year period from the grant date, 53,716 will vest and be settled ratably over 11 quarterly periods from the grant date, 9,215 will vest and be settled ratably over a four‑year period from the grant date, 4,608 will vest on the

Table of Contents

second anniversary of the grant date, and 6,170 will vest evenly on the third and fourth anniversaries of the grant date. We also granted 35,482 RSUs to our non‑employee directors for the 2022-2023 board service year, which units vested immediately and will settle on the third anniversary of the grant date. In addition, we granted 287,308 performance‑based RSUs; the vesting of these RSUs is contingent on our achievement of specified performance goals for the years 2022 to 2024. Provided the goals are achieved, the performance‑based RSUs will vest and settle on the third anniversary of the grant date. The actual number of performance‑based RSUs that could vest will range from 0% to 200% of the 287,308 units granted, depending on our level of achievement with respect to the performance goals.

In the six months ended June 30, 2021, we granted an aggregate of 884,468 RSUs, consisting of 547,421 RSUs that vest based on the passage of time, 297,309 RSUs that vest on a contingent basis, and 39,738 RSUs that were granted to our non‑employee directors and vested immediately.749,110 RSUs. Of ~~the time‑based RSUs granted in the nine months ended September 30, 2021,~~these, 261,997 will vest and be settled ratably over a three‑year period from the grant date, 189,215 will vest and be settled ratably over 8 quarterly periods from the grant date, ~~28,676 will vest~~ and ~~be settled~~14,192 vested on December 31, 2021. We also granted 39,738 RSUs to our non-employee directors. These consisted of 36,681 RSUs for the 2021-2022 board service year, 1,372 RSUs for an initial grant to a then-new member of our board of directors and 1,685 RSUs for a pro‑rata annual grant to the same board member. Both the initial grant and the annual grant vested immediately; however, the initial grant settles upon separation from the board, while the annual grant settles on the third anniversary of the grant ~~date, 53,341 will vest and be settled on~~date. In addition, we granted 243,076 performance‑based RSUs; the ~~fourth anniversary of the grant date, and 14,192 will vest and be settled on December 31, 2021.~~

~~The~~ vesting of ~~243,076 of the performance‑based~~these RSUs ~~granted in the nine months ended September 30, 2021~~ is contingent on our achievement of specified performance goals for the years 2021 to 2023. Provided the goals are achieved, the performance‑based RSUs will vest and settle on the third anniversary of the grant date. The actual number of

~~Table of Contents~~

performance‑based RSUs that could vest will range from 0% to 200% of the 243,076 units granted, depending on our level of achievement with respect to the performance goals. We also granted 53,341 performance‑based RSUs to a senior officer in September 2021. The vesting of this grant is contingent on our achievement of specified performance goals for the years 2021 to 2025 and is subject to the same vesting range as the performance‑based grants described above. Provided the goals are achieved, the performance‑based RSUs issued in September 2021 will vest and settle on the fourth anniversary of the grant date. During the ~~nine~~six months ended ~~September~~June 30, 2021, we also granted 892 RSUs that vested and settled immediately as a result of our level of achievement with respect to certain performance‑based RSUs granted in 2018.

The 39,738 RSUs granted to our non‑employee directors included 36,681 RSUs for the 2021‑2022 board service year, 1,372 for an initial grant to a new member of our board of directors and 1,685 for a pro‑rata annual grant to the same new member. While RSUs granted to our board of directors vest immediately, annual grants settle on the third anniversary of the grant date and initial grants settle upon separation from the board.

In the nine months ended September 30, 2020, we granted an aggregate of 1,720,004 RSUs. Of these, 583,335 will vest and be settled ratably over a three‑year period from the grant date, 104,167 will vest and be settled ratably over a four‑year period from the grant date, 359,713 will vest and be settled ratably over 11 quarterly periods from the grant date and 13,805 will vest and be settled on the third anniversary of the grant date. In addition, we granted 475,422 performance‑based RSUs; the vesting of these RSUs is contingent on our achievement of specified performance goals for the years 2020 to 2022. Provided the goals are achieved, the performance‑based RSUs will vest and settle on the third anniversary of the grant date. The actual number of performance‑based RSUs that could vest will range from 0% to 200% of the 475,422 units granted, depending on our level of achievement with respect to the performance goals. We also granted 80,128 performance‑based RSUs to a Conifer senior officer, which were subsequently forfeited. In addition, in May 2020, we made an annual grant of 103,434 RSUs to ~~our non~~‑~~employee directors for the 2020-2021 board service year, which units vested immediately and will settle in shares of our common stock on third anniversary of the date of the grant.~~

The fair value of an RSU is based on our share price on the grant date. For certain of the performance‑based RSU grants, the number of units that will ultimately vest is subject to adjustment based on the achievement of a market‑based condition. The fair value of these RSUs is estimated through the use of a Monte Carlo simulation. Significant inputs used in our valuation of these RSUs included the following:


		Nine Months Ended September 30,				Six Months Ended June 30,
		2021	2020			2022	2021
Expected volatility	Expected volatility	65.2% - 79.3%	54.7	%	Expected volatility	39.6% - 68.1%	71.8% - 79.3%

Risk-free interest rate	Risk-free interest rate	0.1% - 0.6%	1.2	%	Risk-free interest rate	1.0% - 1.7%	0.1% - 0.2%

At ~~September~~June 30, ~~2021,~~2022, there were ~~$56~~$67 million of total unrecognized compensation costs related to RSUs. These costs are expected to be recognized over a weighted average period of 1.9 years.

USPI Management Equity Plan

USPI maintains a separate management equity plan (the “USPI Management Equity Plan”) under which it grants RSUs representing a contractual right to receive 1 share of USPI’s non‑voting common stock in the future. The vesting of RSUs granted under the plan varies based on the terms of the underlying award agreement. Once the requisite holding period is met, during specified times, ~~(“Repurchase Periods”),~~ the participant can sell the underlying shares to USPI at their estimated fair market ~~value~~. value. At our sole discretion, the purchase of any ~~non~~‑non‑voting common shares can be made in cash or in shares of ~~Tenet~~’sTenet’s common stock.

The following table summarizes RSU activity under ~~USPI’s management equity plan~~the USPI Management Equity Plan during the ~~nine~~six months ended ~~September~~June 30, ~~2021:~~2022:

Number of
Restricted Stock Units Weighted Average Grant
Date Fair Value Per Unit
Unvested at December 31, 2020 2,025,056 $ 34.13
Granted 76,990 $ 34.13
Vested (383,937) $ 34.13
Forfeited (205,794) $ 34.13
Unvested at September 30, 2021 1,512,315 $ 34.13


	Number of Restricted Stock Units	Weighted Average Grant Date Fair Value Per Unit
Unvested at December 31, 2021	1,494,882	$	34.13

Vested	(369,691)	$	34.13
Forfeited	(135,800)	$	34.13
Unvested at June 30, 2022	989,391	$	34.13

InNo new grants were made under the ~~nine~~USPI Management Equity Plan during the six months ended ~~September~~June 30, 2022. During the six months ended June 30, 2021, we granted 76,990 RSUs under ~~USPI’s management equity plan.~~the USPI Management Equity Plan. NaN percent of these RSUs vests on each of the first and second anniversaries of the grant date, and the remaining 60% vests on the third anniversary of the grant date. ~~RSUs granted in 2020 vest 20% in each of the first three years on the anniversary of the grant date with the remaining 40% vesting on the fourth anniversary of the grant date.~~

~~Table of Contents~~

~~The first Repurchase Period opened in August 2021 and will close in November 2021.~~ In the ~~three~~six months ended ~~September~~June 30, ~~2021,~~2022, USPI paid ~~$4.6~~less than $1 million in cash to repurchase a portion of the non‑voting common stock issued under the USPI ~~management equity plan.~~Management Equity Plan. No shares were repurchased ~~through the issuance of Tenet common stock~~ during the ~~three~~six months ended ~~September~~June 30, 2021.

~~Employee Retirement Plans~~

In the nine months ended September 30, 2021 and 2020, we recognized (i) service cost related to 1 of our frozen non‑qualified defined benefit pension plans of less than $1 million for both periods in salaries, wages and benefits expense, and (ii) other components of net periodic pension cost (benefit) and net periodic postretirement benefit cost (benefit) related to our frozen qualified and non‑qualified defined benefit plans of $(4) million and $6 million, respectively, in other non-operating income, net, in the accompanying Condensed Consolidated Statements of Operations.

~~NOTE 9. EQUITY~~

~~Changes in Shareholders’ Equity~~

~~The following tables show the changes in consolidated equity during the nine months ended September 30, 2021 and 2020 (dollars in millions, share amounts in thousands):~~

Common Stock Additional
Paid-In
Capital Accumulated
Other
Comprehensive
Loss Accumulated
Deficit Treasury
Stock Noncontrolling
Interests Total Equity
Shares
Outstanding Issued Par
Amount
Balances at December 31, 2020 106,070 $ 7 $ 4,844 $ (281) $ (2,128) $ (2,414) $ 909 $ 937
Net income — — — — 97 — 44 141
Distributions paid to noncontrolling interests — — — — — — (61) (61)
Other comprehensive loss — — — (1) — — — (1)
Accretion of redeemable noncontrolling interests — — (3) — — — — (3)
Purchases (sales) of businesses and noncontrolling interests, net — — (10) — — — 1 (9)
Stock-based compensation expense and issuance of common stock 617 1 10 — — 1 — 12
Balances at March 31, 2021 106,687 $ 8 $ 4,841 $ (282) $ (2,031) $ (2,413) $ 893 $ 1,016
Net income — — — — 119 — 58 177
Distributions paid to noncontrolling interests — — — — — — (43) (43)
Other comprehensive income — — — 5 — — — 5
Accretion of redeemable noncontrolling interests — — (4) — — — — (4)
Purchases of businesses and noncontrolling interests, net — — 3 — — — — 3
Stock-based compensation expense and issuance of common stock 180 — 14 — — 1 — 15
Balances at June 30, 2021 106,867 $ 8 $ 4,854 $ (277) $ (1,912) $ (2,412) $ 908 $ 1,169
Net income — — — — 449 — 56 505
Distributions paid to noncontrolling interests — — — — — — (51) (51)
Other comprehensive income — — — 3 — — — 3
Accretion of redeemable noncontrolling interests — — (4) — — — — (4)
Purchases of businesses and noncontrolling interests, net — — 3 — — — — 3
Stock-based compensation expense and issuance of common stock 202 — 9 — — 1 — 10
Balances at September 30, 2021 107,069 $ 8 $ 4,862 $ (274) $ (1,463) $ (2,411) $ 913 $ 1,635

Table of Contents

Common Stock Additional
Paid-In
Capital Accumulated
Other
Comprehensive
Loss Accumulated
Deficit Treasury
Stock Noncontrolling
Interests Total Equity
Shares
Outstanding Issued Par
Amount
Balances at December 31, 2019 104,197 $ 7 $ 4,760 $ (257) $ (2,513) $ (2,414) $ 854 $ 437
Net income — — — — 93 — 32 125
Distributions paid to noncontrolling interests — — — — — — (40) (40)
Other comprehensive income — — — 1 — — — 1
Accretion of redeemable noncontrolling interests — — (1) — — — — (1)
Purchases (sales) of businesses and noncontrolling interests, net — — (30) — — — 15 (15)
Cumulative effect of accounting change — — — — (14) — — (14)
Stock-based compensation expense and issuance of common stock 331 — 10 — — — — 10
Balances at March 31, 2020 104,528 $ 7 $ 4,739 $ (256) $ (2,434) $ (2,414) $ 861 $ 503
Net income — — — — 88 — 35 123
Distributions paid to noncontrolling interests — — — — — — (8) (8)
Other comprehensive income — — — 1 — — — 1
Accretion of redeemable noncontrolling interests — — (2) — — — — (2)
Purchases (sales) of businesses and noncontrolling interests, net — — (2) — — — 2 —
Stock-based compensation expense and issuance of common stock 374 — 16 — — — — 16
Balances at June 30, 2020 104,902 $ 7 $ 4,751 $ (255) $ (2,346) $ (2,414) $ 890 $ 633
Net income (loss) — — — — (196) — 48 (148)
Distributions paid to noncontrolling interests — — — — — — (46) (46)
Other comprehensive income — — — 4 — — — 4
Accretion of redeemable noncontrolling interests — — (1) — — — — (1)
Purchases of businesses and noncontrolling interests, net — — 58 — — — 4 62
Stock-based compensation expense and issuance of common stock 505 — 18 — — — — 18
Balances at September 30, 2020 105,407 $ 7 $ 4,826 $ (251) $ (2,542) $ (2,414) $ 896 $ 522

NOTE 9. EQUITY

The following tables present the changes in consolidated equity (dollars in millions, share amounts in thousands):


	Common Stock			Additional Paid-In Capital		Accumulated Other Comprehensive Loss		Accumulated Deficit		Treasury Stock		Noncontrolling Interests		Total Equity
	Shares Outstanding	Issued Par Amount
Balances at December 31, 2021	107,189	$	8	$	4,877	$	(233)	$	(1,214)	$	(2,410)	$	1,026	$	2,054
Net income	—	—		—		—		140		—		46		186
Distributions paid to noncontrolling interests	—	—		—		—		—		—		(71)		(71)

Accretion of redeemable noncontrolling interests	—	—		(95)		—		—		—		—		(95)
Sales of businesses and noncontrolling interests, net	—	—		(7)		—		—		—		(1)		(8)

Stock-based compensation expense and issuance of common stock	499	—		(10)		—		—		—		—		(10)
Balances at March 31, 2022	107,688	$	8	$	4,765	$	(233)	$	(1,074)	$	(2,410)	$	1,000	$	2,056
Net income	—	—		—		—		38		—		58		96
Distributions paid to noncontrolling interests	—	—		—		—		—		—		(38)		(38)
Other comprehensive income	—	—		—		2		—		—		—		2
Accretion of redeemable noncontrolling interests	—	—		(9)		—		—		—		—		(9)
Purchases (sales) of businesses and noncontrolling interests, net	—	—		(23)		—		—		—		7		(16)

Stock-based compensation expense and issuance of common stock	142	—		23		—		—		—		—		23
Balances at June 30, 2022	107,830	$	8	$	4,756	$	(231)	$	(1,036)	$	(2,410)	$	1,027	$	2,114


	Common Stock			Additional Paid-In Capital		Accumulated Other Comprehensive Loss		Accumulated Deficit		Treasury Stock		Noncontrolling Interests		Total Equity
	Shares Outstanding	Issued Par Amount
Balances at December 31, 2020	106,070	$	7	$	4,844	$	(281)	$	(2,128)	$	(2,414)	$	909	$	937
Net income	—	—		—		—		97		—		44		141
Distributions paid to noncontrolling interests	—	—		—		—		—		—		(61)		(61)
Other comprehensive loss	—	—		—		(1)		—		—		—		(1)
Accretion of redeemable noncontrolling interests	—	—		(3)		—		—		—		—		(3)
Purchases (sales) of businesses and noncontrolling interests, net	—	—		(10)		—		—		—		1		(9)

Stock-based compensation expense and issuance of common stock	617	1		10		—		—		1		—		12
Balances at March 31, 2021	106,687	$	8	$	4,841	$	(282)	$	(2,031)	$	(2,413)	$	893	$	1,016
Net income	—	—		—		—		119		—		58		177
Distributions paid to noncontrolling interests	—	—		—		—		—		—		(43)		(43)
Other comprehensive income	—	—		—		5		—		—		—		5
Accretion of redeemable noncontrolling interests	—	—		(4)		—		—		—		—		(4)
Purchases of businesses and noncontrolling interests, net	—	—		3		—		—		—		—		3

Stock-based compensation expense and issuance of common stock	180	—		14		—		—		1		—		15
Balances at June 30, 2021	106,867	$	8	$	4,854	$	(277)	$	(1,912)	$	(2,412)	$	908	$	1,169

Our noncontrolling interests balances at ~~September~~June 30, ~~2021~~2022 and December 31, ~~2020~~2021 were comprised of ~~$130~~$132 million and ~~$116~~$128 million, respectively, from our Hospital Operations segment, and ~~$783~~$895 million and ~~$793~~$898 million, respectively, from our Ambulatory Care segment. Our net income available to noncontrolling interests for the ~~nine~~six months ended ~~September~~June 30, 2022 and

Table of Contents

2021 ~~and 2020~~ in the ~~table~~tables above were comprised of ~~$16~~$95 million and ~~$9 million, respectively, from our Hospital Operations segment, and $142 million and $106~~$93 million, respectively, from our Ambulatory Care ~~segment.~~segment and $9 million from our Hospital Operations segment in each of the six-month periods.

NOTE 10. NET OPERATING REVENUES

Net operating revenues for our Hospital Operations and Ambulatory Care segments primarily consist of net patient service revenues, principally for patients covered by Medicare, Medicaid, managed care and other health plans, as well as certain uninsured patients under our Compact with Uninsured Patients and other uninsured discount and charity programs. Net operating revenues for our Conifer segment primarily consist of revenues from providing revenue cycle management services to health systems, ~~as well as~~ individual hospitals and physician ~~practices, self‑insured organizations, health plans and other entities.~~practices.

~~Table of Contents~~

The table below ~~shows~~presents our sources of net operating revenues less implicit price concessions from continuing operations:


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended June 30,				Six Months Ended June 30,
		2021		2020		2021		2020			2022		2021		2022		2021
Hospital Operations:	Hospital Operations:									Hospital Operations:
Net patient service revenues from hospitals and related outpatient facilities:	Net patient service revenues from hospitals and related outpatient facilities:									Net patient service revenues from hospitals and related outpatient facilities:
Medicare	Medicare	$	616	$	662	$	2,001	$	1,964	Medicare	$	579	$	697	$	1,198	$	1,385
Medicaid	Medicaid	336		251		883		791		Medicaid	248		288		440		547
Managed care	Managed care	2,567		2,374		7,592		6,519		Managed care	2,324		2,545		4,819		5,025
Uninsured	Uninsured	33		50		140		112		Uninsured	36		60		74		107
Indemnity and other	Indemnity and other	159		171		527		491		Indemnity and other	161		192		325		368
Total	Total	3,711		3,508		11,143		9,877		Total	3,348		3,782		6,856		7,432
Other revenues(1)	Other revenues(1)	319		295		929		848		Other revenues(1)	297		313		587		610
Hospital Operations total prior to inter-segment eliminations	Hospital Operations total prior to inter-segment eliminations	4,030		3,803		12,072		10,725		Hospital Operations total prior to inter-segment eliminations	3,645		4,095		7,443		8,042
Ambulatory Care	Ambulatory Care	666		565		1,976		1,423		Ambulatory Care	771		664		1,509		1,310
Conifer	Conifer	314		325		943		962		Conifer	333		319		657		629
Inter-segment eliminations	Inter-segment eliminations	(116)		(136)		(362)		(385)		Inter-segment eliminations	(111)		(124)		(226)		(246)
Net operating revenues	Net operating revenues	$	4,894	$	4,557	$	14,629	$	12,725	Net operating revenues	$	4,638	$	4,954	$	9,383	$	9,735



(1)			Primarily physician practices revenues.

Adjustments for prior‑year cost reports and related valuation allowances, principally related to Medicare and Medicaid, increased revenues in the ~~nine~~six months ended ~~September~~June 30, 2022 and 2021 ~~and 2020~~ by ~~$21~~$7 million and $3$19 million, respectively. Estimated cost report settlements and valuation allowances were included in accounts receivable in the accompanying Condensed Consolidated Balance Sheets (see Note 2). We believe that we have made adequate provision for any adjustments that may result from the final determination of amounts earned under all the above arrangements with Medicare and Medicaid.

The table below ~~shows~~presents the composition of net operating revenues for our Ambulatory Care segment:


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended June 30,				Six Months Ended June 30,
		2021		2020		2021		2020			2022		2021		2022		2021
Net patient service revenues	Net patient service revenues	$	633	$	532	$	1,890	$	1,345	Net patient service revenues	$	741	$	638	$	1,445	$	1,257
Management fees	Management fees	21		23		64		60		Management fees	24		21		53		43
Revenue from other sources	Revenue from other sources	12		10		22		18		Revenue from other sources	6		5		11		10
Net operating revenues	Net operating revenues	$	666	$	565	$	1,976	$	1,423	Net operating revenues	$	771	$	664	$	1,509	$	1,310

The table below ~~shows~~presents the composition of net operating revenues for our Conifer segment:


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended June 30,				Six Months Ended June 30,
		2021		2020		2021		2020			2022		2021		2022		2021
Revenue cycle services – Tenet	Revenue cycle services – Tenet	$	112	$	132	$	350	$	375	Revenue cycle services – Tenet	$	108	$	120	$	220	$	238
Revenue cycle services – other customers		178		170		522		518
Revenue cycle services – other clients										Revenue cycle services – other clients	202		175		391		344
Other services – Tenet	Other services – Tenet	4		4		12		10		Other services – Tenet	3		4		6		8
Other services – other customers		20		19		59		59
Other services – other clients										Other services – other clients	20		20		40		39
Net operating revenues	Net operating revenues	$	314	$	325	$	943	$	962	Net operating revenues	$	333	$	319	$	657	$	629

~~Other services represented approximately 8% and 7%~~

Table of ~~Conifer’s revenue for the nine months ended September 30, 2021 and 2020, respectively, and include value‑based care services, consulting services and other client‑defined projects.~~Contents

Performance Obligations

The following table includes Conifer’s revenue that is expected to be recognized in the future related to performance obligations that are unsatisfied, or partially unsatisfied, at the end of the reporting period. The amounts in the table primarily consist of revenue cycle management fixed fees, which are typically recognized ratably as the performance obligation is satisfied. The estimated revenue does not include volume‑ or contingency‑based contracts, variable‑based rate escalators, performance incentives, penalties or other variable consideration that is considered constrained. Conifer’s contract with Catholic Health Initiatives (“CHI”), a

~~Table of Contents~~

minority interest owner of Conifer Health Solutions, LLC, represents the majority of the fixed‑fee revenue related to remaining performance obligations. Conifer’s contract term with CHI ends December 31, 2032.

Three Months Ending Years Ending Later Years
December 31,
Total 2021 2022 2023 2024 2025
Performance obligations $ 6,302 $ 151 $ 604 $ 603 $ 549 $ 549 $ 3,846


			Six Months Ending		Years Ending								Later Years
					December 31,
	Total		2022		2023		2024		2025		2026
Performance obligations	$	6,294	$	325	$	650	$	591	$	591	$	591	$	3,546

NOTE 11. ~~PROPERTY AND PROFESSIONAL AND GENERAL LIABILITY~~ INSURANCE

~~Property Insurance~~

We have property, business interruption and related insurance coverage to mitigate the financial impact of catastrophic events or perils that is subject to deductible provisions based on the terms of the policies. These policies are on an occurrence basis. For the policy period April 1, ~~2021~~2022 through March 31, ~~2022,~~2023, we have coverage totaling $850 million per occurrence, after deductibles and exclusions, with annual aggregate sub‑limits of $100 million for floods, $200 million for earthquakes and a per‑occurrence sub‑limit of $200 million for named windstorms with no annual aggregate. With respect to fires and other perils, excluding floods, earthquakes and named windstorms, the total $850 million limit of coverage per occurrence applies. Deductibles are 5% of insured values up to a maximum of ~~$40~~$25 million for California earthquakes, $25 million for floods and named windstorms, and 2% of insured values for New Madrid fault earthquakes, with a maximum per claim deductible of $25 million. Floods and certain other covered losses, including fires and other perils, have a minimum deductible of $1$5 million.

~~Professional~~We also purchase cyber liability insurance from third parties. In April 2022, we experienced a cybersecurity incident that temporarily disrupted a subset of our acute care operations and ~~General Liability Reserves~~involved the exfiltration of certain confidential company and patient information (the “Cybersecurity Incident”). We estimate that the Cybersecurity Incident had an adverse pre-tax impact of approximately $100 million during the three months ended June 30, 2022. This estimate includes the costs to remediate the issues, lost revenues from the associated business interruption and other related expenses. We have filed a claim within our policy limits. Insurance recoveries of $5 million related to this claim were recorded during the three months ended June 30, 2022.

We are self‑insured for the majority of our professional and general liability claims, and we purchase insurance from third‑parties to cover catastrophic claims. At ~~September~~June 30, ~~2021~~2022 and December 31, ~~2020,~~2021, the aggregate current and long‑term professional and general liability reserves in the accompanying Condensed Consolidated Balance Sheets were ~~$1.030~~$1.061 billion and ~~$978 million,~~$1.045 billion, respectively. These reserves include the reserves recorded by our captive insurance subsidiaries and our self‑insured retention reserves recorded based on modeled estimates for the portion of our professional and general liability risks, including incurred but not reported claims, for which we do not have insurance coverage. Malpractice expense of $138 million and $179 million was included in other operating expenses, net, in the accompanying Condensed Consolidated Statements of Operations for the six months ended June 30, 2022 and 2021, respectively.

All commercial insurance we purchase is subject to per‑claim and policy period aggregate limits. If the policy period aggregate limit of any of our ~~professional and general liability~~ policies is exhausted, in whole or in part, it could deplete or reduce the limits available to pay any other material claims applicable to that policy period.

Malpractice expense of $269 million and $233 million was included in other operating expenses, net, in the accompanying Condensed Consolidated Statements of Operations for the nine months ended September 30, 2021 and 2020, respectively.

NOTE 12. CLAIMS AND LAWSUITS

We operate in a highly regulated and litigious industry. Healthcare companies are subject to numerous investigations by various governmental agencies. Further, private parties have the right to bring qui tam or “whistleblower” lawsuits against companies that allegedly submit false claims for payments to, or improperly retain overpayments from, the government and, in some states, private payers. We and our subsidiaries have received inquiries in recent years from government agencies, and we may receive similar inquiries in future periods. We are also subject to class action lawsuits, employment‑related claims and other legal actions in the ordinary course of business. Some of these actions may involve large demands, as well as substantial defense costs. We cannot predict the outcome of current or future legal actions against us or the effect that judgments or settlements in such matters may have on us.

Table of Contents

We record accruals for estimated losses relating to claims and lawsuits when available information indicates that a loss is probable and we can reasonably estimate the amount of the loss or a range of loss. Significant judgment is required in both the determination of the probability of a loss and the determination as to whether a loss is reasonably estimable. These determinations are updated at least quarterly and are adjusted to reflect the effects of negotiations, settlements, rulings, advice of legal counsel and technical experts, and other information and events pertaining to a particular matter, but are subject to significant uncertainty regarding numerous factors that could affect the ultimate loss levels. If a loss on a material matter is reasonably possible and estimable, we disclose an estimate of the loss or a range of loss. In cases where we have not disclosed an estimate, we have concluded that the loss is either not reasonably possible or the loss, or a range of loss, is not reasonably estimable, based on available information. Given the inherent uncertainties associated with these matters, especially those involving governmental agencies, and the indeterminate damages sought in some cases, there is significant uncertainty as to the

~~Table of Contents~~

ultimate liability we may incur from these matters, and an adverse outcome in one or more of these matters could be material to our results of operations or cash flows for any particular reporting period.

Government Investigation of Detroit Medical Center

Detroit Medical Center (“DMC”) is subject to an ongoing investigation commenced in October 2017 by the U.S. Attorney’s Office for the Eastern District of Michigan and the Civil Division of the U.S. Department of Justice (“DOJ”) for potential violations of the Stark law, the Medicare and Medicaid anti‑kickback and anti‑fraud and abuse amendments codified under Section 1128B(b) of the Social Security Act, and the federal False Claims Act related to DMC’s employment of nurse practitioners and physician assistants (“Mid‑Level Practitioners”) from 2006 through 2017. As previously disclosed, a media report was published in August 2017 alleging that 14 Mid‑Level Practitioners were terminated by DMC earlier in 2017 due to compliance concerns. ~~On September 28, 2021, the~~The DOJ issued a civil investigative demand to DMC for documents and ~~interrogatories.~~interrogatories in September 2021. We are cooperating with the ~~investigation; however, we are unable to determine the potential exposure, if any, at this time.~~investigation.

Other Matters

In July 2019, certain of the entities that purchased ~~from us~~ the operations of Hahnemann University Hospital and St. Christopher’s Hospital for Children in Philadelphia from us commenced Chapter 11 bankruptcy proceedings. ~~As previously disclosed in our Form 8‑K filed September 1, 2017,~~In the ~~purchasers assumed our funding~~three months ended December 31, 2021, we established a reserve of $23 million for certain obligations ~~under the Pension Fund for Hospital and Health Care Employees of Philadelphia and Vicinity (the “Fund”), a pension plan~~ related to the ~~operations at Hahnemann University Hospital. Pursuant to rules under~~sale of the ~~Employee Retirement Income Security Act~~hospitals and the subsequent bankruptcy proceedings of ~~1974, as amended (“ERISA”), under certain circumstances we could become liable for withdrawal liability in~~ the event a withdrawal is triggered with respect to the Fund. In addition, pursuant to applicable ERISA rules, we could become secondarily liable if the purchasers fail to satisfy their obligations to the Fund.buyers.

We are also subject to claims and lawsuits arising in the ordinary course of business, including potential claims related to, among other things, the care and treatment provided at our hospitals and outpatient facilities, the application of various federal and state labor and privacy laws, tax audits and other matters. Although the results of these claims and lawsuits cannot be predicted with certainty, we believe that the ultimate resolution of these ordinary course claims and lawsuits will not have a material effect on our business or financial condition.

New claims or inquiries may be initiated against us from time to time, including lawsuits from patients, employees and others exposed to COVID‑19 at our facilities. These matters could ~~(1)~~(i) require us to pay substantial damages or amounts in judgments or settlements, which, individually or in the aggregate, could exceed amounts, if any, that may be recovered under our insurance policies where coverage applies and is available, ~~(2)~~(ii) cause us to incur substantial expenses, ~~(3)~~(iii) require significant time and attention from our management, and ~~(4)~~(iv) cause us to close or sell hospitals or otherwise modify the way we conduct business.

The following table presents reconciliations of the beginning and ending liability balances in connection with legal settlements and related costs recorded in continuing ~~operations during the nine months ended September 30, 2021 and 2020.~~operations:

Balances at
Beginning
of Period Litigation and
Investigation
Costs Cash
Payments Other Balances at
End of
Period
Nine Months Ended September 30, 2021 $ 26 $ 64 $ (44) $ (5) $ 41
Nine Months Ended September 30, 2020 $ 86 $ 13 $ (84) $ — $ 15


	Balances at Beginning of Period		Litigation and Investigation Costs		Cash Payments		Other		Balances at End of Period
Six Months Ended June 30, 2022	$	78	$	38	$	(58)	$	3	$	61
Six Months Ended June 30, 2021	$	26	$	35	$	(29)	$	—	$	32

NOTE 13. REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES

~~We have a put~~ Our put/call agreement (the “Baylor Put/Call Agreement”) with Baylor ~~University Medical Center (“Baylor”) that contains~~contained put and call options with respect to the 5% ownership interest Baylor ~~holds~~held in ~~USPI. Each year starting in 2021,~~USPI until June 30, 2022. The Baylor ~~may~~Put/Call Agreement gave Baylor the option to annually put up to ~~one‑third~~one-third of ~~their~~its total shares in USPI ~~held as~~(the “Baylor Shares”) over a period of ~~April 1, 2017 by delivering notice by~~three years beginning in 2021. We had the ~~end of January of such year. In each year that Baylor does not put the full 33.3% of USPI’s shares allowable, we may~~right to call the difference between the number of shares Baylor put each year and the maximum number of shares ~~they~~it could have ~~put that year. In addition,~~put. Based on the nature of the Baylor Put/Call Agreement, ~~contains~~Baylor’s minority interest in USPI was classified as a ~~call option pursuant~~redeemable noncontrolling interest in the accompanying Condensed Consolidated Balance Sheet at December 31, 2021. During

Table of Contents

the six months ended June 30, 2022 and 2021, we recognized accretion totaling $102 million and $5 million, respectively, and a corresponding decrease in additional paid-in capital related to ~~which we have the ability to acquire all~~Baylor’s minority interest in USPI.

In each of Baylor’s ownership interest by 2024. We have the ability to choose whether to settle the purchase price for the Baylor put/call, which is mutually agreed‑upon fair market value, in cash or shares of our common stock. Baylor did not deliver a put notice to us in January 2021. In February 2021 and 2022, we notified Baylor of our intention to exercise our call option to purchase 33.3% of the ~~USPI shares held by~~ Baylor ~~as of April 1, 2017. Based on~~Shares for that year (66.6% in total). In June 2022, we entered into an agreement with Baylor (the “Share Purchase Agreement”) to complete the ~~nature~~purchase of the Baylor ~~Put/Call~~Shares we called in 2021 and 2022 and to accelerate the acquisition of the remaining Baylor Shares eligible to be put/called in 2023. Under the terms of the Share Purchase Agreement, ~~Baylor’s minority~~we agreed to pay Baylor $406 million to buy its entire 5% voting ownership interest in ~~USPI was~~

~~Table~~USPI. We paid $11 million upon execution of ~~Contents~~

~~classified~~the Share Purchase Agreement and will make 35 additional non-interest bearing monthly payments of approximately $11 million beginning in August 2022. We recorded the present value of the purchase price as a liability on our balance sheet, with an offset to redeemable noncontrolling interest of $365 million for the carrying amount of the shares and $23 million to additional paid-in capital for the difference between the carrying value and present value of the purchase price for the shares. At June 30, 2022, we had liabilities of $124 million recorded in other current liabilities and $253 million in other long-term liabilities in the accompanying Condensed Consolidated Balance ~~Sheets at September 30, 2021 and December 31, 2020.~~Sheet for the purchase of these shares.

The following table ~~shows~~presents the changes in redeemable noncontrolling interests in equity of consolidated ~~subsidiaries~~subsidiaries:


	Six Months Ended June 30,
	2022		2021
Balances at beginning of period	$	2,203	$	1,952
Net income	177		161
Distributions paid to noncontrolling interests	(201)		(108)
Accretion of redeemable noncontrolling interests	104		7
Purchases and sales of businesses and noncontrolling interests, net	(286)		22
Balances at end of period	$	1,997	$	2,034

Distributions paid to noncontrolling interests during the ~~nine~~six months ended ~~September~~June 30, ~~2021 and 2020:~~

Nine Months Ended
September 30,
2021 2020
Balances at beginning of period $ 1,952 $ 1,506
Net income 234 122
Distributions paid to noncontrolling interests (161) (90)
Accretion of redeemable noncontrolling interests 11 4
Purchases (sales) of businesses and noncontrolling interests, net 12 (63)
Balances at end of period $ 2,048 $ 1,479
2022 included $61 million of proceeds related to the sale of several medical office buildings previously owned by our Hospital Operations segment.

The following ~~tables show~~table presents the composition by segment of our redeemable noncontrolling interests ~~balances at September 30, 2021 and December 31, 2020, as well as~~balances:


	June 30, 2022		December 31, 2021
Hospital Operations	$	236	$	297
Ambulatory Care	1,245		1,425
Conifer	516		481
Redeemable noncontrolling interests	$	1,997	$	2,203

The following table presents our net income available to redeemable noncontrolling interests ~~for the nine months ended September 30, 2021 and 2020:~~by segment:

September 30, 2021 December 31, 2020
Hospital Operations $ 292 $ 267
Ambulatory Care 1,292 1,273
Conifer 464 412
Redeemable noncontrolling interests $ 2,048 $ 1,952


		Nine Months Ended September 30,					Six Months Ended June 30,
		2021		2020			2022		2021
Hospital Operations	Hospital Operations	$	18	$	(17)	Hospital Operations	$	24	$	16
Ambulatory Care	Ambulatory Care	164		94		Ambulatory Care	118		112
Conifer	Conifer	52		45		Conifer	35		33
Net income available to redeemable noncontrolling interests	Net income available to redeemable noncontrolling interests	$	234	$	122	Net income available to redeemable noncontrolling interests	$	177	$	161

NOTE 14. INCOME TAXES

During the three months ended ~~September~~June 30, ~~2021,~~2022, we recorded income tax expense of ~~$197~~$86 million in continuing operations on pre-tax income of ~~$774~~$265 million compared to ~~an income tax benefit of $197~~$61 million on a pre-tax ~~loss~~income of ~~$304~~$319 million during the three months ended ~~September~~June 30, ~~2020.~~2021. During the ~~nine~~six months ended ~~September~~June 30, ~~2021,~~2022, we recorded income tax expense of ~~$303~~$185 million in continuing operations on pre-tax income of ~~$1.360 billion~~$643 million compared to ~~an income tax benefit of $227~~$106 million on a pre-tax ~~loss~~income of $5$586 million during the ~~nine~~six months ended ~~September~~June 30, ~~2020. For the nine months ended September 30, 2021, the~~2021. Our provision for income taxes ~~was~~during interim reporting periods is calculated by applying an estimate of the annual effective tax rate ~~for the full year~~ to “ordinary” income or loss ~~(pre‑tax~~(pre-tax income or loss excluding unusual or infrequently occurring discrete items) for the reporting period. In calculating “ordinary” income, non‑taxable income or loss attributable to noncontrolling interests was deducted from pre-tax income or loss in the determination of the annualized effective tax rate used to calculate income taxes for the quarter. For the nine months ended September 30, 2020, we utilized the discrete effective tax rate method, as allowed by the Financial Accounting Standards Board Accounting Standards Codification 740‑270‑30‑18, “Income Taxes–Interim Reporting,” to calculate the interim income tax provision. The discrete method is applied when application of the estimated annual effective tax rate is impractical because it is not possible to reliably estimate the annual effective tax rate. The discrete method treats the year‑to‑date period as if it were the annual period and determines the income tax expense or benefit on that basis. We believe that the use of this discrete method in 2020 was more appropriate than the annual effective tax rate method as the estimated annual effective tax rate method was not reliable due to the high degree of uncertainty in estimating annual pre‑tax income due to the impact of the COVID‑19 pandemic and the evolving guidance by the government on utilization of grant funds.income.

Table of Contents

~~The~~A reconciliation between the amount of ~~recorded~~reported income tax expense ~~(benefit)~~ and the amount ~~calculated at~~computed by multiplying income from continuing operations before income taxes by the statutory federal tax rate is ~~shown in the following table:~~presented below:

Three Months Ended
September 30, Nine Months Ended
September 30,
2021 2020 2021 2020
Tax expense (benefit) at statutory federal rate of 21% $ 163 $ (64) $ 286 $ (1)
State income taxes, net of federal income tax benefit 29 (6) 56 9
Tax benefit attributable to noncontrolling interests (26) (18) (79) (48)
Nondeductible goodwill 28 — 35 —
Nontaxable gains — — — 3
Stock-based compensation (1) 1 (4) 1
Change in valuation allowance — (113) — (201)
Other items 4 3 9 10
Income tax expense (benefit) $ 197 $ (197) $ 303 $ (227)


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Tax expense at statutory federal rate of 21%	$	56	$	67	$	135	$	123
State income taxes, net of federal income tax benefit	11		14		25		26
Tax benefit attributable to noncontrolling interests	(28)		(28)		(57)		(53)
Nondeductible goodwill	1		7		1		7



Stock-based compensation tax benefit	(1)		(2)		(3)		(3)
Changes in valuation allowance	45		—		77		—

Other items	2		3		7		6
Income tax expense	$	86	$	61	$	185	$	106

AsDuring the six months ended June 30, 2022, we recorded income tax expense of $77 million to increase the valuation allowance for interest expense carryforwards, including $39 million due to a ~~result of the~~ change in the business interest expense disallowance rules under the COVID Acts, we recorded an income tax benefit of $88 million during the nine months ended September 30, 2020 to decrease the valuation allowance for interest expense carryforwards due to the additional deduction of interest expense.in 2022.

~~During the nine months ended September 30, 2021, there were no adjustments to~~We increased our estimated liabilities for uncertain tax ~~positions.~~positions during the six months ended June 30, 2022 by $1 million. The total amount of unrecognized tax benefits ~~at September~~as of June 30, ~~2021~~2022 was ~~$31~~$35 million, of which ~~$29~~$33 million, if recognized, would ~~impact~~affect our effective tax rate and income tax expense ~~(benefit)~~ from continuing operations.

Our practice is to recognize interest and penalties related to income tax matters in income tax expense in our ~~statement~~condensed consolidated statements of operations. ~~There were no accrued~~We did not have any interest ~~and~~or penalties on unrecognized tax benefits accrued at ~~September~~June 30, ~~2021.~~2022.

~~At September~~As of June 30, ~~2021,~~2022, no significant changes in unrecognized federal and state tax benefits were expected in the next 12 months as a result of the settlement of audits, the filing of amended tax returns or the expiration of statutes of limitations.

NOTE 15. EARNINGS ~~(LOSS)~~ PER COMMON SHARE

The following ~~table is a reconciliation of~~tables reconcile the numerators and denominators of our basic and diluted earnings ~~(loss)~~ per common share calculations for our continuing ~~operations for three and nine months ended September 30, 2021 and 2020.~~operations. Net income available ~~(loss attributable)~~ to our common shareholders is expressed in millions and weighted average shares are expressed in thousands.


		Net Income Available (Loss Attributable) to Common Shareholders (Numerator)		Weighted Average Shares (Denominator)	Per-Share Amount			Net Income Available to Common Shareholders (Numerator)		Weighted Average Shares (Denominator)	Per-Share Amount
Three Months Ended September 30, 2021
Three Months Ended June 30, 2022							Three Months Ended June 30, 2022
Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share							Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share	$	38	107,790	$	0.35
Effect of dilutive stock options, restricted stock units, deferred compensation units, convertible instruments and dividends on preferred stock							Effect of dilutive stock options, restricted stock units, deferred compensation units, convertible instruments and dividends on preferred stock	—		960	—
Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share							Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share	$	38	108,750	$	0.35

Three Months Ended June 30, 2021							Three Months Ended June 30, 2021
Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share	Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share	$	448	107,050	$	4.18	Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share	$	120	106,822	$	1.12
Effect of dilutive stock options, restricted stock units and deferred compensation units	Effect of dilutive stock options, restricted stock units and deferred compensation units	—		1,711	(0.06)		Effect of dilutive stock options, restricted stock units and deferred compensation units	—		1,747	(0.01)
Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share	Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share	$	448	108,761	$	4.12	Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share	$	120	108,569	$	1.11

Three Months Ended September 30, 2020
Net loss attributable to Tenet Healthcare Corporation common shareholders for basic loss per share		$	(197)	105,263	$	(1.87)
Effect of dilutive stock options, restricted stock units and deferred compensation units		—		—	—
Net loss attributable to Tenet Healthcare Corporation common shareholders for diluted loss per share		$	(197)	105,263	$	(1.87)

Table of Contents


		Net Income Available (Loss Attributable) to Common Shareholders (Numerator)		Weighted Average Shares (Denominator)	Per-Share Amount			Net Income Available to Common Shareholders (Numerator)		Weighted Average Shares (Denominator)	Per-Share Amount
Nine Months Ended September 30, 2021

Six Months Ended June 30, 2022							Six Months Ended June 30, 2022
Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share							Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share	$	177	107,636	$	1.64
Effect of dilutive stock options, restricted stock units, deferred compensation units, convertible instruments and dividends on preferred stock							Effect of dilutive stock options, restricted stock units, deferred compensation units, convertible instruments and dividends on preferred stock	9		6,418	(0.01)
Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share							Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share	$	186	114,054	$	1.63

Six Months Ended June 30, 2021							Six Months Ended June 30, 2021
Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share	Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share	$	665	106,727	$	6.23	Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share	$	217	106,566	$	2.04
Effect of dilutive stock options, restricted stock units and deferred compensation units	Effect of dilutive stock options, restricted stock units and deferred compensation units	—		1,738	(0.10)		Effect of dilutive stock options, restricted stock units and deferred compensation units	—		1,751	(0.04)
Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share	Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share	$	665	108,465	$	6.13	Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share	$	217	108,317	$	2.00

Nine Months Ended September 30, 2020
Net loss attributable to Tenet Healthcare Corporation common shareholders for basic loss per share		$	(15)	104,803	$	(0.14)
Effect of dilutive stock options, restricted stock units and deferred compensation units		—		—	—
Net loss attributable to Tenet Healthcare Corporation common shareholders for diluted loss per share		$	(15)	104,803	$	(0.14)

~~All potentially dilutive securities were excluded from the calculation of diluted loss per share for~~During the three and ~~nine~~six months ended ~~September~~June 30, ~~2020 because~~2022, our convertible instruments consisted of (i) the Baylor Put/Call Agreement, (ii) an agreement related to the ownership interest in a Hospital Operations segment joint venture, and (iii) RSUs issued under the USPI Management Equity Plan. As further discussed in Note 13, we ~~did not report income from continuing operations available to common shareholders~~purchased all of the shares underlying the Baylor Put/Call Agreement in ~~those periods. In circumstances where we do not have income from continuing operations available to common shareholders,~~June 2022. See Note 8 for additional information about the ~~effect of stock options and other potentially dilutive securities is anti‑dilutive; that is, a loss from continuing operations attributable to common shareholders has~~RSUs issued under the effect of making the diluted loss per share less than the basic loss per share. Had we generated income from continuing operations available to common shareholders in the three and nine months ended September 30, 2020, the effect (in thousands) of employee stock options, restricted stock units and deferred compensation units on the diluted shares calculation would have been an increase in shares of 1,240 and 1,135 in the three and nine months ended September 30, 2020, respectively.USPI Management Equity Plan.

NOTE 16. FAIR VALUE MEASUREMENTS

Fair Value Measurements

We are required to provide additional disclosures about fair value measurements as part of our financial statements for each major category of assets and liabilities measured at fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities, which generally are not applicable to non‑financial assets and liabilities. Fair values determined by Level 2 inputs utilize data points that are observable, such as definitive sales agreements, appraisals or established market values of comparable assets. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability and include situations where there is little, if any, market activity for the asset or liability, such as internal estimates of future cash flows.

Our non‑financial assets and liabilities not permitted or required to be measured at fair value on a recurring basis typically relate to long‑lived assets held and used, long‑lived assets held for sale and goodwill. The following table presents information about assets measured at fair value at December 31, 2020 and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair values. There were no such assets ~~measured at~~or liabilities requiring fair value ~~on a non‑recurring basis~~measurement at ~~September~~June 30, ~~2021.~~2022.

Total Quoted Prices
in Active
Markets for
Identical Assets
(Level 1) Significant Other
Observable Inputs
(Level 2) Significant
Unobservable
Inputs
(Level 3)
At December 31, 2020:
Long-lived assets held for sale $ 140 $ — $ 140 $ —
Long-lived assets held and used 483 — 483 —
$ 623 $ — $ 623 $ —

~~Table of Contents~~

Financial Instruments

The fair value of our long‑term debt (except for borrowings under the Credit Agreement) is based on quoted market prices (Level 1). The inputs used to establish the fair value of the borrowings outstanding under the Credit Agreement are considered to be Level 2 inputs, which include inputs other than quoted prices included in Level 1 that are observable, either directly or indirectly. At ~~September~~June 30, ~~2021~~2022 and December 31, ~~2020,~~2021, the estimated fair value of our long‑term debt was approximately ~~104.2%~~90.2% and ~~104.5%~~103.3%, respectively, of the carrying value of the debt.

Table of Contents

NOTE 17. ACQUISITIONS

Preliminary purchase price allocations (representing the fair value of the consideration conveyed) for all acquisitions made during the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 and ~~2020~~2021 are as follows:


		Nine Months Ended September 30,					Six Months Ended June 30,
		2021		2020			2022		2021
Current assets	Current assets	$	20	$	7	Current assets	$	6	$	9
Property and equipment	Property and equipment	26		15		Property and equipment	26		27
Other intangible assets	Other intangible assets	1		8		Other intangible assets	2		1
Goodwill	Goodwill	65		78		Goodwill	206		76
Other long-term assets, including previously held equity method investments		8		6
Other long-term assets						Other long-term assets	22		9
Previously held investments in unconsolidated affiliates						Previously held investments in unconsolidated affiliates	(73)		—
Current liabilities	Current liabilities	(15)		(4)		Current liabilities	(9)		(16)
Long-term liabilities	Long-term liabilities	(10)		(6)		Long-term liabilities	(38)		(11)
Redeemable noncontrolling interests in equity of consolidated subsidiaries	Redeemable noncontrolling interests in equity of consolidated subsidiaries	(28)		(30)		Redeemable noncontrolling interests in equity of consolidated subsidiaries	(68)		(28)
Noncontrolling interests	Noncontrolling interests	(2)		(13)		Noncontrolling interests	(9)		(2)
Cash paid, net of cash acquired	Cash paid, net of cash acquired	(64)		(61)		Cash paid, net of cash acquired	(66)		(64)
Gains on consolidations		$	1	$	—
Gains (losses) on consolidations						Gains (losses) on consolidations	$	(1)	$	1

The goodwill generated from these transactions, the majority of which will be deductible for income tax purposes, can be attributed to the benefits that we expect to realize from operating efficiencies and growth strategies. The goodwill total of ~~$65~~$206 million from acquisitions completed during the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 was recorded in our Ambulatory Care segment. Approximately $6 million and $3$5 million in transaction costs related to prospective and closed acquisitions were expensed during the ~~nine‑~~six‑month periods ended ~~September~~June 30, ~~2021~~2022 and ~~2020,~~2021, respectively, and were included in impairment and restructuring charges, and acquisition‑related costs in the accompanying Condensed Consolidated Statements of Operations.

We are required to allocate the purchase prices of acquired businesses to assets acquired or liabilities assumed and, if applicable, noncontrolling interests based on their fair values. The excess of the purchase price allocated over those fair values is recorded as goodwill. The purchase price allocations for certain acquisitions completed in 2022 and 2021 are preliminary. We are in the process of assessing working capital balances, as well as obtaining and evaluating valuations of the acquired property and equipment, management contracts and other intangible assets, and noncontrolling ~~interests for some of our 2021 and 2020 acquisitions.~~interests. Therefore, those purchase price allocations, including goodwill, recorded in the accompanying Condensed Consolidated Financial Statements are subject to adjustment once the assessments and valuation work are completed and evaluated. Such adjustments ~~are~~will be recorded as soon as practical and within the measurement period as defined by the accounting literature.

During the six months ended June 30, 2022, we adjusted the initial purchase allocation of certain acquisitions completed in 2021 based on the results of completed valuations. These adjustments resulted in a net increase in goodwill of $16 million.

NOTE 18. SEGMENT INFORMATION

Our business consists of our Hospital Operations segment, our Ambulatory Care segment and our Conifer segment. The factors for determining the reportable segments include the manner in which management evaluates operating performance combined with the nature of the individual business activities.

Our Hospital Operations segment is comprised of acute care and specialty hospitals, imaging centers, ancillary outpatient facilities, micro‑hospitals ~~imaging centers,~~and physician ~~practices, and other care sites and clinics.~~practices. At ~~September~~June 30, ~~2021,~~2022, our subsidiaries operated 60 hospitals serving primarily urban and suburban communities in 9 states. On April 1, 2021, we transferred 24 imaging centers from our Ambulatory Care segment to our Hospital Operations segment. The total assets associated with the imaging centers transferred to our Hospital Operations segment constituted less than 1% of our consolidated total assets at March 31, 2021. InAlso in April 2021, we ~~also~~ completed the sale of the majority of the urgent care centers then held by our Hospital Operations segment to an unaffiliated urgent care provider. In addition, we completed the sale of 5 Miami‑area hospitals and certain related operations in August 2021. ~~Certain~~In April 2022, we completed the sale of ~~the facilities in our~~a Hospital Operations segment ~~were classified as held for sale in the accompanying Condensed Consolidated Balance Sheet at December 31, 2020.~~micro-hospital.

~~Table of Contents~~

Our Ambulatory Care segment is comprised of the operations of USPI. At ~~September~~June 30, ~~2021,~~2022, USPI had interests in ~~318~~410 ambulatory surgery centers ~~(227~~(261 consolidated) and 24 surgical hospitals (5(8 consolidated) in 3134 states. ~~At December 31, 2020,~~In April 2021, we completed the sale of 40 urgent care centers then held by our Ambulatory Care segment ~~included 40~~to an unaffiliated urgent care provider and, as noted above, transferred 24 imaging centers ~~that were classified as~~from our Ambulatory Care segment to our Hospital Operations segment. Effective June 30, 2022, we purchased all of the shares previously held by Baylor in USPI for ~~sale. We completed the divestiture~~$406 million, which increased

Table of ~~these urgent care centers~~Contents

our ownership interest in ~~April 2021. At September 30, 2021, we owned approximately~~USPI’s voting shares from 95% ~~of USPI.~~to 100%. See Note 13 for additional information about this transaction.

Our Conifer segment provides revenue cycle management and value‑based care services to hospitals, health systems, physician practices, employers and other clients. At ~~September~~June 30, ~~2021,~~2022, Conifer provided services to approximately ~~650~~660 Tenet and non‑Tenet hospitals and other clients nationwide. ~~In 2012, we entered into an agreement documenting the terms and conditions of various services~~ Conifer provides ~~to Tenet hospitals (“RCM Agreement”), as well as an agreement documenting certain~~revenue management, administrative services our Hospital Operations segment provides to Conifer. In March 2021, we entered into a month‑to‑month agreement amending the RCM Agreement effective January 1, 2021 (“Amended RCM Agreement”) to update certain terms and ~~conditions related to the revenue cycle management~~various other services ~~Conifer provides~~ to Tenet hospitals. We believe the pricing terms for ~~the~~these services ~~provided under the Amended RCM Agreement~~ are commercially reasonable and consistent with estimated third‑party terms. At ~~September~~June 30, ~~2021,~~2022, we owned approximately 76% of Conifer Health Solutions, LLC, which is Conifer’s principal subsidiary.

The following tables include amounts for each of our reportable segments and the reconciling items necessary to agree to amounts reported in the accompanying Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Operations, as applicable:


		September 30, 2021		December 31, 2020			June 30, 2022		December 31, 2021
Assets:	Assets:					Assets:
Hospital Operations	Hospital Operations	$	17,126	$	18,048	Hospital Operations	$	16,111	$	17,173
Ambulatory Care	Ambulatory Care	7,846		8,048		Ambulatory Care	9,600		9,473
Conifer	Conifer	941		1,010		Conifer	910		933
Total	Total	$	25,913	$	27,106	Total	$	26,621	$	27,579

Three Months Ended
September 30, Nine Months Ended
September 30,
2021 2020 2021 2020
Capital expenditures:
Hospital Operations $ 95 $ 71 $ 295 $ 328
Ambulatory Care 14 11 49 32
Conifer 2 4 10 14
Total $ 111 $ 86 $ 354 $ 374
Net operating revenues:
Hospital Operations total prior to inter-segment eliminations $ 4,030 $ 3,803 $ 12,072 $ 10,725
Ambulatory Care 666 565 1,976 1,423
Conifer
Tenet 116 136 362 385
Other clients 198 189 581 577
Total Conifer revenues 314 325 943 962
Inter-segment eliminations (116) (136) (362) (385)
Total $ 4,894 $ 4,557 $ 14,629 $ 12,725
Equity in earnings of unconsolidated affiliates:
Hospital Operations $ 2 $ 3 $ 11 $ 1
Ambulatory Care 43 41 130 102
Total $ 45 $ 44 $ 141 $ 103
Adjusted EBITDA:
Hospital Operations $ 496 $ 240 $ 1,379 $ 1,074
Ambulatory Care 274 215 826 538
Conifer 85 96 261 256
Total $ 855 $ 551 $ 2,466 $ 1,868


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Capital expenditures:
Hospital Operations	$	130	$	90	$	262	$	200
Ambulatory Care	19		27		40		35
Conifer	3		5		5		8
Total	$	152	$	122	$	307	$	243

Net operating revenues:
Hospital Operations total prior to inter-segment eliminations	$	3,645	$	4,095	$	7,443	$	8,042
Ambulatory Care	771		664		1,509		1,310
Conifer
Tenet	111		124		226		246
Other clients	222		195		431		383
Total Conifer revenues	333		319		657		629
Inter-segment eliminations	(111)		(124)		(226)		(246)
Total	$	4,638	$	4,954	$	9,383	$	9,735

Equity in earnings of unconsolidated affiliates:
Hospital Operations	$	2	$	5	$	6	$	9
Ambulatory Care	52		49		94		87
Total	$	54	$	54	$	100	$	96

Adjusted EBITDA:
Hospital Operations	$	431	$	449	$	945	$	883
Ambulatory Care	319		295		601		552
Conifer	93		90		185		176
Total	$	843	$	834	$	1,731	$	1,611

Depreciation and amortization:
Hospital Operations	$	179	$	188	$	346	$	378
Ambulatory Care	28		23		55		48
Conifer	9		10		18		19
Total	$	216	$	221	$	419	$	445

Table of Contents

Three Months Ended
September 30, Nine Months Ended
September 30,
2021 2020 2021 2020
Depreciation and amortization:
Hospital Operations $ 177 $ 184 $ 555 $ 536
Ambulatory Care 23 21 71 60
Conifer 9 10 28 28
Total $ 209 $ 215 $ 654 $ 624
Adjusted EBITDA $ 855 $ 551 $ 2,466 $ 1,868
Depreciation and amortization (209) (215) (654) (624)
Impairment and restructuring charges, and acquisition-related costs (15) (57) (55) (166)
Litigation and investigation costs (29) (9) (64) (13)
Interest expense (227) (263) (702) (761)
Loss from early extinguishment of debt (20) (312) (74) (316)
Other non-operating income, net 7 — 16 3
Net gains on sales, consolidation and deconsolidation of facilities 412 1 427 4
Income (loss) from continuing operations, before income taxes $ 774 $ (304) $ 1,360 $ (5)


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021

































Adjusted EBITDA	$	843	$	834	$	1,731	$	1,611

Depreciation and amortization	(216)		(221)		(419)		(445)
Impairment and restructuring charges, and acquisition-related costs	(57)		(20)		(73)		(40)
Litigation and investigation costs	(18)		(22)		(38)		(35)
Interest expense	(222)		(235)		(449)		(475)
Loss from early extinguishment of debt	(66)		(31)		(109)		(54)
Other non-operating income (expense), net	—		(1)		—		9
Net gains on sales, consolidation and deconsolidation of facilities	1		15		—		15
Income from continuing operations, before income taxes	$	265	$	319	$	643	$	586

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

INTRODUCTION TO MANAGEMENT’S DISCUSSION AND ANALYSIS

The purpose of this section, Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”), is to provide a narrative explanation of our financial statements that enables investors to better understand our business, to enhance our overall financial disclosures, to provide the context within which our financial information may be analyzed, and to provide information about the quality of, and potential variability of, our financial condition, results of operations and cash flows. MD&A, which should be read in conjunction with the accompanying Condensed Consolidated Financial Statements, includes the following sections:

•Management Overview

•Forward-Looking Statements

•Sources of Revenue for Our Hospital Operations Segment

•Results of Operations

•Liquidity and Capital Resources

•~~Off-Balance Sheet Arrangements~~

•Critical Accounting Estimates

Our business consists of our Hospital Operations and other (“Hospital Operations”) segment, our Ambulatory Care segment and our Conifer segment. Our Hospital Operations segment is comprised of acute care and specialty hospitals, imaging centers, ancillary outpatient facilities, micro‑hospitals ~~imaging centers,~~and physician ~~practices, and other care sites and clinics.~~practices. At ~~September~~June 30, ~~2021,~~2022, our subsidiaries operated 60 hospitals serving primarily urban and suburban communities in nine states. In April 2021, we completed the sale of the majority of the urgent care centers then held by our Hospital Operations segment to an unaffiliated urgent care provider. In addition, in August 2021, we completed the sale of five Miami‑area hospitals and certain related operations (the “Miami Hospitals”) then held by our Hospital Operations segment. In April 2022, we completed the sale of a Hospital Operations segment ~~in August 2021.~~ micro‑hospital.

Our Ambulatory Care segment is comprised of the operations of USPI Holding Company, Inc. (“USPI”)~~, in which we hold an ownership interest of approximately 95%~~. ~~At September 30, 2021,~~ USPI had indirect ownership interests in ~~318~~410 ambulatory surgery centers ~~(227~~(each, an “ASC”) (261 consolidated) and 24 surgical hospitals ~~(five~~(eight consolidated) in ~~31 states. At December 31, 2020, our Ambulatory Care segment also included 40 urgent care centers that were classified as held for sale and 24 imaging centers.~~34 states at June 30, 2022. In April 2021, we completed the ~~divestiture~~sale of ~~the~~ 40 urgent care centers then held by our Ambulatory Care segment to an unaffiliated urgent care provider and transferred ~~the~~ 24 imaging centers from our Ambulatory Care segment to our Hospital Operations segment. Effective June 30, 2022, we purchased all of the shares previously held by Baylor University Medical Center (“Baylor”) in USPI for $406 million, which increased our ownership interest in USPI’s voting shares from 95% to 100%. See Note 13 to the accompanying Condensed Consolidated Financial Statements and the “Liquidity and Capital Resources” section of MD&A for additional information about this transaction.

Our Conifer segment provides revenue cycle management and value‑based care services to hospitals, health systems, physician practices, employers and other clients through our Conifer Holdings, Inc. subsidiary (“Conifer”) ~~subsidiary.~~. At ~~September~~June 30, ~~2021,~~2022, Conifer provided services to approximately ~~650~~660 Tenet and non‑Tenet hospitals and other clients nationwide. ~~At September 30, 2021, we owned approximately 76%~~Nearly all of the services comprising the operations of our Conifer segment are provided by Conifer Health Solutions, LLC, in which ~~is Conifer’s principal subsidiary.~~we own an interest of approximately 76%, or by one of its direct or indirect wholly owned subsidiaries.

Unless otherwise indicated, all financial and statistical information included in MD&A relates to our continuing operations, with dollar amounts expressed in millions (except ~~per adjusted patient~~ per‑adjusted‑patient‑admission and ~~per adjusted patient~~ per‑adjusted‑patient‑day amounts). Continuing operations information includes the results of our same 60 hospitals operated throughout the ~~nine~~six months ended ~~September~~June 30, 2022 and 2021, ~~and 2020, and~~as well as the ~~five Miami‑area hospitals and certain related operations we~~Miami Hospitals sold in August ~~2021.~~2021 and the Arizona micro‑hospital sold in April 2022. Continuing operations information excludes the results of our hospitals and other businesses that have been classified as discontinued operations for accounting purposes. We believe this information is useful to investors because it includes the operations of all facilities in continuing operations for the period of time that we owned and operated them, and it reflects the recent trends we are experiencing with respect to volumes, revenues and expenses. We present certain metrics as a percentage of net operating revenues because a significant portion of our operating expenses are variable. In addition, we present certain metrics on a per‑adjusted-patient‑admission and per‑adjusted‑patient‑day basis to show trends other than volume.

In certain cases, information presented in MD&A for our Hospital Operations segment is described as presented on a same‑hospital basis, which includes the results of our same 60 hospitals operated throughout the six months ended June 30, 2022 and 2021, and excludes the results of the Miami Hospitals we sold in August 2021, the results of the Arizona micro‑hospital sold in April 2022 and the results of our discontinued operations. We present same‑hospital data because we believe it provides investors with useful information regarding the performance of our current portfolio of hospitals and other

Table of Contents

operations that are comparable for the periods presented, as well as reflects recent trends we are experiencing with respect to volumes, revenues and expenses.

MANAGEMENT OVERVIEW

RECENT DEVELOPMENTS

Formation of New Joint Venture—On July 15, 2022, USPI completed the previously announced formation of a new joint venture with United Urology Group (“UUG”), including the purchase of ownership interests in 22 new and established ASCs located in Maryland, Colorado and Arizona, which USPI will manage and consolidate. USPI paid $105 million in connection with this transaction.

IMPACT OF THE COVID-19 PANDEMIC

The spread of COVID‑19 and the ensuing response of federal, state and local authorities beginning in March 2020 resulted in a material reduction in our patient volumes and also adversely affected our net operating revenues in the year ended December 31, 2020. Restrictive measures, including travel bans, social distancing, quarantines and shelter‑in‑place orders, reduced the number of procedures performed at our facilities, as well as the volume of emergency room and physician office visits. We began experiencing improvement in patient volumes in May 2020 as various states eased stay‑at‑home restrictions and our facilities were permitted to resume elective surgeries and other procedures; however, the COVID‑19 pandemic ~~generally and, most recently, the spread of the Delta variant, continues~~continued to adversely impact all three segments of our business, as well as our patients, communities and ~~employees.~~employees, in the six months ended June 30, 2022. Broad economic factors resulting from the pandemic ~~including increased unemployment rates and reduced consumer spending, continue to impact~~affected our patient volumes, service mix and revenue mix. ~~The~~In addition, the pandemic ~~has also~~ continued to have an adverse ~~effect~~impact on certain of our operating expenses to varying degrees in 2021. As further described below, we have been required to utilize higher‑cost temporary labor and pay premiums above standard compensation for essential workers. In addition, we have experienced significant price increases in medical supplies, particularly for personal protective equipment (“PPE”), and we have encountered supply chain disruptions, including shortages and delays.

~~Table of Contents~~

during the six months ended June 30, 2022.

~~As described in the Management’s Discussion and Analysis of Financial Condition and Results of Operations section in Part II of our Annual Report on Form 10‑K~~Various federal legislative actions, including additional funding for the ~~year ended December 31, 2020~~Public Health and Social Services Emergency Fund (“~~Annual Report”~~PRF”) ~~and below under “Sources of Revenue for Our Hospital Operations Segment,” various legislative actions~~, have mitigated some of the economic disruption caused by the COVID‑19 pandemic on our business. ~~Additional funding for the Public Health and Social Services Emergency Fund (“Provider Relief Fund” or “PRF”) was among the provisions of the COVID‑19 relief legislation.~~ In the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 and ~~2020,~~2021, we received cash payments ~~of $65~~from the PRF and state and local grant programs totaling $104 million and ~~$890~~$63 million, respectively, including $27 million received during the six-month period in 2021 by our unconsolidated affiliates for whom we provide cash management services. We recognized ~~approximately $53~~$100 million and ~~$445~~$50 million, respectively, from these funds as grant income during the six-month periods in 2022 and 2021, respectively. In addition, we recognized ~~$12 million and $8~~$11 million in equity in earnings of unconsolidated affiliates ~~respectively,~~ in ~~our~~the accompanying Condensed Consolidated ~~Statements~~Statement of Operations ~~due to grants from~~during the ~~Provider Relief Fund and other state and local grant programs.~~six months ended June 30, 2021.

Throughout MD&A, we have provided additional information on the impact of the COVID‑19 pandemic on our results of operations and the steps we have taken, and are continuing to take, in response. The ultimate extent and scope of the pandemic ~~remains~~and its future impact on our business remain unknown. For information about risks and uncertainties related to COVID‑19 that could affect our results of operations, financial condition and cash flows, see the Risk Factors section in Part I of our Annual ~~Report.~~Report on Form 10-K for the year ended December 31, 2021 (“Annual Report”) and in Part II of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 (“Q1’22 Report”).

CYBERSECURITY INCIDENT

In April 2022, we experienced a cybersecurity incident that temporarily disrupted a subset of our acute care operations and involved the exfiltration of certain confidential company and patient information (the “Cybersecurity Incident”). During this time, our hospitals remained operational and continued to deliver patient care safely and effectively, utilizing well‑established back‑up processes. We immediately suspended user access to impacted information technology applications, executed extensive cybersecurity protection protocols, and took steps to restrict further unauthorized activity. We have restored impacted information technology operations, and we have taken additional measures to protect patient, employee and other data, as appropriate, in response to the Cybersecurity Incident.

Disruption from the Cybersecurity Incident placed pressure on our Hospital Operations segment’s volumes and earnings in April and May 2022. We believe a significant portion of the 5.3% decline in our adjusted patient admissions on a same-hospital basis in the three months ended June 30, 2022 as compared to the same period in 2021 is due to business interruption from the incident. In addition, we estimate that the Cybersecurity Incident had an adverse pre-tax impact of approximately $100 million during the three months ended June 30, 2022. This estimate includes the costs to remediate the issues, lost revenues from the associated business interruption and other related expenses. We have insurance coverage and have filed a claim within our policy limits for these losses. We are unable to predict or control the timing or amount of insurance recoveries.

TRENDS AND STRATEGIES

As described above and throughout MD&A, we ~~experienced a significant disruption to our business in 2020 due to the COVID‑19 pandemic. Although we have seen improvement in our patient volumes, we~~ continue to experience negative impacts of the pandemic on our business in varying degrees. Most recently, in the three months ended September 30, 2021, we experienced a significant acceleration in COVID‑19 cases associated with the Delta variant, with a peak in such cases in late August 2021. Throughout the COVID‑19 pandemic, we have taken, and we continue to take, various actions to increase our liquidity and mitigate the impact of reductions in our patient volumes and ~~operating revenues.~~changes in our service mix and revenue mix. We have issued new senior unsecured notes and senior secured first lien notes, redeemed existing senior unsecured notes and senior secured first lien notes, including those with the highest interest ~~rate and nearest maturity date~~rates of all of our long‑term debt, and amended our

Table of Contents

senior secured revolving credit ~~facility.~~facility (as amended to date, the “Credit Agreement”). We also decreased our employee headcount throughout the organization at the outset of the COVID-19 pandemic, and we deferred certain operating expenses that were not expected to impact our response to the ~~COVID‑19~~ pandemic. In addition, we reduced certain variable costs across the enterprise. ~~We believe these actions, together~~Together with government relief packages, we believe these actions supported our ability to ~~the extent available to us, will help us to continue operating~~provide essential patient services during the initial uncertainty caused by the ~~COVID‑19 pandemic.~~COVID-19 pandemic and continue to do so. For further information on our liquidity, see “Liquidity and Capital Resources” below.

~~Moreover, we are experiencing~~We have experienced, and continue to experience, increased competition with other healthcare providers in recruiting and retaining qualified personnel responsible for the ~~day‑to‑day operations~~operation of our facilities. There is a limited availability of experienced medical support personnel nationwide, which drives up the wages and benefits required to recruit and retain employees. In particular, like others in the healthcare industry, we continue to experience a shortage of critical‑care nurses in certain disciplines and geographic ~~areas, which~~areas. This shortage has been exacerbated by the COVID‑19 ~~pandemic. We are treating patients with COVID‑19 in our hospitals and, in~~pandemic as more nurses choose to retire early, leave the workforce or take travel assignments. In some areas, the increased demand for care ~~is putting~~of COVID‑19 patients in our hospitals, as well as the direct impact of COVID‑19 on physicians, employees and their families, have put a strain on our resources and ~~staff,~~staff. Over the past two years, we have had to rely on higher-cost temporary contract labor, which ~~has required us~~we compete with other healthcare providers to ~~utilize higher‑cost temporary labor~~secure, and pay premiums above standard compensation for essential workers. ~~The length~~In addition, we have experienced significant price increases in medical supplies, particularly for personal protective equipment (“PPE”), and ~~extent of the~~we have encountered supply‑chain disruptions, ~~caused by the COVID‑19 pandemic are currently unknown; however, we expect such disruptions to continue in 2022~~including shortages and ~~potentially through the duration of the pandemic.~~delays.

~~In addition, we~~We believe that several key trends are ~~shaping~~also continuing to shape the demand for healthcare services: ~~(1)~~(i) consumers, employers and insurers are actively seeking lower‑cost solutions and better value as they focus more on healthcare spending; ~~(2)~~(ii) patient volumes are shifting from inpatient to outpatient settings due to technological advancements and demand for care that is more convenient, affordable and accessible; ~~(3)~~(iii) the growing aging population requires greater chronic disease management and higher‑acuity treatment; and ~~(4)~~(iv) consolidation continues across the entire healthcare sector. In ~~recent years,~~addition, the healthcare industry, in general, and the acute care hospital business, in particular, have ~~also~~ experienced significant regulatory uncertainty based, in large part, on administrative, legislative and judicial efforts to ~~significantly modify~~limit, alter or repeal ~~and potentially replace~~ the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (“Affordable Care Act” ~~or “ACA”~~). It is difficult to predict the full impact of regulatory uncertainty on our future revenues and operations.

Expansion of Our Ambulatory Care Segment—In response to these trends, we continue to focus on opportunities to expand our Ambulatory Care segment through acquisitions, organic growth, construction of new outpatient centers and strategic partnerships. During the years ended December 31, 2021 and 2020, we invested $1.315 billion and $1.200 billion, respectively, to acquire ownership interests in new ASCs, increase our ownership interests in existing facilities and invest in de novo facilities. This activity included the acquisition of ownership interests in 86 ASCs and related ambulatory support services (collectively, the “SCD Centers”) from Surgical Center Development #3, LLC and Surgical Center Development #4, LLC (“SCD”) in December 2021. USPI and SCD’s principals have also entered into a joint venture and development agreement under which USPI will have the exclusive option to partner with affiliates of SCD on the future development of a minimum target of 50 de novo ASCs over a period of five years. During the six months ended June 30, 2022, we opened three new ASCs in partnership with the affiliates of SCD. In addition, USPI formed a new joint venture with UUG and acquired ownership interests in 22 new and established ASCs in July 2022. The ASCs, which will be managed and consolidated by USPI, are located in Arizona, Colorado and Maryland.

Also during the six months ended June 30, 2022, we acquired controlling interests in three ASCs in Florida and one in each of Arizona and New Hampshire, and we acquired noncontrolling interests in an ASC in each of New Jersey and Texas. During the same period, we also acquired controlling ownership interests in nine previously unconsolidated ASCs in seven geographically diverse states. In addition, we opened six ASCs in various states in the first half of 2022, including the ASCs opened in partnership with affiliates of SCD as noted above. We believe USPI’s ASCs and surgical hospitals offer many advantages to patients and physicians, including greater affordability, predictability, flexibility and convenience. Moreover, due in part to advancements in medical technology and due to the lower cost structure and greater efficiencies that are attainable at a specialized outpatient site, we believe the volume and complexity of surgical cases performed in an outpatient setting will continue to increase. Historically, our outpatient services have generated significantly higher margins for us than inpatient services.

Driving Growth in Our Hospital Systems—We ~~are~~remain committed to better positioning our hospital systems and competing more effectively in the ever‑evolving healthcare environment by focusing on driving performance through operational effectiveness, increasing capital efficiency and margins, investing in our physician enterprise, particularly our specialist network, enhancing patient and physician satisfaction, growing our higher‑demand and higher‑acuity clinical service lines (including outpatient lines), expanding patient and physician access, and optimizing our portfolio of assets. Over the past several years, we have undertaken enterprise‑wide cost‑~~reduction~~efficiency measures, ~~comprised primarily of workforce reductions~~and we continue to transition certain support

2829

Table of Contents

(including streamlining corporate overhead and centralized support functions), the renegotiation of contracts with suppliers and vendors, and the consolidation of office locations. Moreover, we establishedoperations offshore ~~support operations at~~to our Global Business Center (“GBC”) in the Philippines. We incurred restructuring charges in conjunction with these initiatives ~~and our cost‑saving efforts in response to the COVID‑19 pandemic~~ in the ~~nine~~six months ended ~~September~~June 30, ~~2021,~~2022, and we ~~expect to~~could incur additional such charges ~~through~~in the ~~remainder of 2021.~~future.

We regularly review the marginal costs of providing certain services, and we manage our operations and make staffing decisions based on those analyses. We also continue to exit service lines, businesses and markets that we believe are no longer a core part of our long‑term growth strategy. In April 2021, we divested the majority of our urgent care centers operated under the MedPost and CareSpot brands by our Hospital Operations and Ambulatory Care segments. In addition, we completed the sale of the Miami Hospitals in August 2021 ~~we sold five Miami‑area hospitals~~ and ~~certain related operations.~~the sale of an Arizona micro-hospital in April 2022. We intend ~~to continue~~ to further refine our portfolio of hospitals and other healthcare facilities when we believe such refinements will help us improve profitability, allocate capital more effectively in areas where we have a stronger presence, deploy proceeds on higher‑return investments across our business, enhance cash flow generation, reduce our debt and lower our ratio of debt‑to‑Adjusted EBITDA.

Improving the Customer Care Experience—As consumers continue to become more engaged in managing their health, we recognize that understanding what matters most to them and earning their loyalty is imperative to our success. As such, we have enhanced our focus on treating our patients as traditional customers by: ~~(1)~~(i) establishing networks of physicians and facilities that provide convenient access to services across the care continuum; ~~(2)~~(ii) expanding service lines aligned with growing community demand, including a focus on aging and chronic disease patients; ~~(3)~~(iii) offering greater affordability and predictability, including simplified registration and discharge procedures, particularly in our outpatient centers; ~~(4)~~(iv) improving our culture of service; and ~~(5)~~(v) creating health and benefit programs, patient education and health literacy materials that are customized to the needs of the communities we serve. Through these efforts, we intend to improve the customer care experience in every part of our operations.

~~Expansion of Our Ambulatory Care Segment—~~We continue to focus on opportunities to expand our Ambulatory Care segment through organic growth, building new outpatient centers, corporate development activities and strategic partnerships. In December 2020, we acquired controlling ownership interests in 45 ambulatory surgery centers from SurgCenter Development (the “SCD Centers”), which significantly increased USPI’s presence in the musculoskeletal surgery market, a high‑demand clinical service line, particularly for an aging population. In the nine months ended September 30, 2021, we acquired controlling ownership interests in four ambulatory surgery centers in Maryland, two in Georgia and one in Florida. We also opened three new ambulatory surgery centers – one each in Nevada, New Mexico and Montana. We believe USPI’s surgery centers and surgical hospitals offer many advantages to patients and physicians, including greater affordability, predictability, flexibility and convenience. Moreover, due in part to advancements in medical technology, and due to the lower cost structure and greater efficiencies that are attainable at a specialized outpatient site, we believe the volume and complexity of surgical cases performed in an outpatient setting will continue to increase following the containment of the COVID‑19 pandemic. Historically, our outpatient services have generated significantly higher margins for us than inpatient services.

Driving Conifer’s ~~Growth While Pursuing a Tax-Free Spin-Off—~~Growth—We previously announced a number of actions to support our goals of improving financial performance and enhancing shareholder value, including the exploration of strategic alternatives for Conifer. In July 2019, we announced our intention to pursue a tax‑free spin‑off of Conifer as a separate, independent, publicly traded company. Completion of the proposed spin‑off is subject to a number of conditions, including, among others, assurance that the separation will be tax‑free for U.S. federal income tax purposes, finalization of Conifer’s capital structure, the effectiveness of appropriate filings with the Securities and Exchange Commission (“SEC”), and final approval from our board of directors. Although in March 2021 we entered into a month‑to‑month agreement amending and updating certain terms and conditions related to the revenue cycle management services Conifer provides to Tenet hospitals (“Amended RCM Agreement”), the execution of a comprehensive amendment to and restatement of the master services agreement between Conifer and Tenet remains an additional prerequisite to the spin‑off of Conifer. We are continuing to pursue the Conifer spin‑off; however, there can be no assurance regarding the timeframe for completion, the allocation of assets and liabilities between Tenet and Conifer, that the other conditions of the spin‑off will be met, or that it will be completed at all.

Conifer serves approximately ~~650~~660 Tenet and non‑Tenet hospitals and other clients nationwide. In addition to providing revenue cycle management services to health systems and physicians, Conifer provides support to both providers and self‑insured employers seeking assistance with clinical integration, financial risk management and population health management. Conifer remains focused on driving growth by continuing to market and expand its revenue cycle management and value‑based care solutions businesses. We believe that our success in growing Conifer and increasing its profitability depends in part on our success in executing the following strategies: ~~(1)~~(i) attracting hospitals and other healthcare providers that currently handle their revenue cycle management processes internally as new clients; ~~(2)~~(ii) generating new client relationships through opportunities from USPI and Tenet’s acute care hospital acquisition and divestiture activities; ~~(3)~~(iii) expanding revenue cycle management and value‑based care service offerings through organic development and small acquisitions; and

~~Table of Contents~~

~~(4)~~ (iv) leveraging data from tens of millions of patient interactions for continued enhancement of the value‑based care environment to drive competitive differentiation.

Improving Profitability—As we return to more normal operations, we ~~will~~ continue to focus on growing patient volumes and effective cost management as a means to improve profitability. We believe our inpatient admissions have been constrained in recent years (prior to the COVID‑19 pandemic) by increased competition, utilization pressure by managed care organizations, new delivery models that are designed to lower the utilization of acute care hospital services, the effects of higher patient co‑pays, co‑insurance amounts and deductibles, changing consumer behavior, and adverse economic conditions and demographic trends in certain of our markets. Our business has also been impacted by the rise in inflation and its effects on elective procedures, wages and costs. However, we also believe that emphasis on higher‑demand clinical service lines (including outpatient services), focus on expanding our ambulatory care business, cultivation of our culture of service, participation in Medicare Advantage health plans that have been experiencing higher growth rates than traditional Medicare, and contracting strategies that create shared value with payers should help us grow our patient volumes over time. We are also continuing to explore new opportunities to enhance efficiency, including further integration of enterprise‑wide centralized support functions, outsourcing additional functions unrelated to direct patient care, and reducing clinical and vendor contract variation.

Reducing Our Leverage Over Time—All of our ~~outstanding~~ long‑term debt has a fixed rate of interest, except for outstanding borrowings, if any, under our ~~revolving credit facility,~~Credit Agreement, and the maturity dates of our notes are staggered from ~~2023~~2024 through 2031. We believe that our capital structure minimizes the near‑term impact of increased interest rates, and the staggered maturities of our debt allow us to refinance our debt over time. It isremains our long‑term objective to reduce our debt and lower our ratio of debt‑to‑Adjusted EBITDA, primarily through more efficient capital allocation and Adjusted EBITDA growth, which should lower our refinancing risk.

During the ~~nine~~six months ended ~~September~~June 30, ~~2021,~~2022, we ~~retired approximately $2.988~~redeemed or repurchased $2.572 billion aggregate principal amount of ~~certain of~~ our senior ~~unsecured~~secured first lien and senior ~~secured notes. These~~unsecured notes ~~were retired using~~in advance of their maturity dates. We used the proceeds from ~~the June 2021 sale~~our issuance of ~~$1.400~~$2.000 billion aggregate principal amount of ~~4.250%~~6.125% senior secured first lien notes ~~which will mature on June 1, 2029~~due 2030 (the ~~“2029~~“2030 Senior Secured First Lien Notes”)~~, the proceeds from the August 2021 sale of five Miami‑area hospitals~~ and cash on ~~hand. These transactions reduced future annual cash interest expense payments by approximately $96 million.~~hand to finance these transactions.

Table of Contents

Our ability to execute on our strategies and respond to the aforementioned trends is subject to the extent and scope of the impact on our operations of the COVID‑19 pandemic, as well as a number of other risks and uncertainties, all of which may cause actual results to be materially different from expectations. For information about risks and uncertainties that could affect our results of operations, see the ~~Forward‑Looking Statements~~Risk Factors section in ~~this report, as well as~~Part II of our Q1’22 Report and the Forward‑Looking Statements and Risk Factors sections in Part I of our Annual Report.

~~Table of Contents~~

RESULTS OF OPERATIONS—OVERVIEW

~~We have provided below certain~~The following tables present selected operating statistics for ~~the three months ended September 30, 2021~~our Hospital Operations and ~~2020~~Ambulatory Care segments, as well as consolidated net operating revenues and expenses on a continuing operations basis. The following tables also show information about facilities in our Ambulatory Care segment that we control and, therefore, consolidate. We believe this information is useful to investors because it reflects our current portfolio of operations and the recent trends we are experiencing with respect to volumes, revenues and expenses. We present certain metrics on a per adjusted patient admission basis to show trends other than volume.basis:


		Continuing Operations Three Months Ended September 30,				Increase (Decrease)				Three Months Ended June 30,				Increase (Decrease)
Selected Operating Statistics	Selected Operating Statistics	2021		2020					Selected Operating Statistics	2022		2021
Hospital Operations – hospitals and related outpatient facilities:	Hospital Operations – hospitals and related outpatient facilities:								Hospital Operations – hospitals and related outpatient facilities:
Number of hospitals (at end of period)	Number of hospitals (at end of period)	60		65		(5)		(1)	Number of hospitals (at end of period)	60		65		(5)		(1)
Total admissions	Total admissions	145,412		150,690		(3.5)	%		Total admissions	128,068		153,319		(16.5)	%
Adjusted patient admissions(2)	Adjusted patient admissions(2)	256,250		257,704		(0.6)	%		Adjusted patient admissions(2)	239,031		273,824		(12.7)	%
Paying admissions (excludes charity and uninsured)	Paying admissions (excludes charity and uninsured)	136,932		141,300		(3.1)	%		Paying admissions (excludes charity and uninsured)	121,722		143,864		(15.4)	%
Charity and uninsured admissions	Charity and uninsured admissions	8,480		9,390		(9.7)	%		Charity and uninsured admissions	6,346		9,455		(32.9)	%
Admissions through emergency department	Admissions through emergency department	110,675		112,131		(1.3)	%		Admissions through emergency department	96,137		114,911		(16.3)	%
Emergency department visits, outpatient	Emergency department visits, outpatient	578,734		463,836		24.8	%		Emergency department visits, outpatient	541,096		541,417		(0.1)	%
Total emergency department visits	Total emergency department visits	689,409		575,967		19.7	%		Total emergency department visits	637,233		656,328		(2.9)	%
Total surgeries	Total surgeries	91,707		94,128		(2.6)	%		Total surgeries	87,387		101,023		(13.5)	%
Patient days — total	Patient days — total	770,175		784,013		(1.8)	%		Patient days — total	658,995		757,003		(12.9)	%
Adjusted patient days(2)	Adjusted patient days(2)	1,335,610		1,302,605		2.5	%		Adjusted patient days(2)	1,192,999		1,328,952		(10.2)	%
Average length of stay (days)	Average length of stay (days)	5.30		5.20		1.9	%		Average length of stay (days)	5.15		4.94		4.3	%
Average licensed beds	Average licensed beds	15,987		17,242		(7.3)	%		Average licensed beds	15,382		17,170		(10.4)	%
Utilization of licensed beds(3)	Utilization of licensed beds(3)	52.4	%	49.4	%	3.0	%	(1)	Utilization of licensed beds(3)	47.1	%	48.4	%	(1.3)	%	(1)
Total visits	Total visits	1,523,726		1,402,346		8.7	%		Total visits	1,413,222		1,653,430		(14.5)	%
Paying visits (excludes charity and uninsured)	Paying visits (excludes charity and uninsured)	1,423,068		1,302,529		9.3	%		Paying visits (excludes charity and uninsured)	1,331,959		1,540,577		(13.5)	%
Charity and uninsured visits	Charity and uninsured visits	100,658		99,817		0.8	%		Charity and uninsured visits	81,263		112,853		(28.0)	%
Ambulatory Care:	Ambulatory Care:								Ambulatory Care:
Total consolidated facilities (at end of period)	Total consolidated facilities (at end of period)	232		244		(12)		(1)	Total consolidated facilities (at end of period)	269		232		37		(1)
Total consolidated cases	Total consolidated cases	295,026		544,279		(45.8)	%		Total consolidated cases	317,437		352,972		(10.1)	%



(1)			The change is the difference between the ~~2021~~2022 and ~~2020~~2021 amounts shown.
(2)			Adjusted patient admissions/days represents actual patient admissions/days adjusted to include outpatient services provided by facilities in our Hospital Operations segment by multiplying actual patient admissions/days by the sum of gross inpatient revenues and outpatient revenues and dividing the results by gross inpatient revenues.
(3)			Utilization of licensed beds represents patient days divided by number of days in the period divided by average licensed beds.

Total admissions decreased by ~~5,278,~~25,251, or ~~3.5%~~16.5%, and total surgeries decreased by 13,636, or 13.5%, in the three months ended ~~September~~June 30, ~~2021~~2022 compared to the three months ended ~~September~~June 30, ~~2020, and total surgeries decreased by 2,421, or 2.6%, in the 2021 period compared to the 2020 period.~~2021. Total emergency department visits ~~increased 19.7%~~decreased 2.9% in the three months ended ~~September~~June 30, ~~2021~~2022 compared to the same period in ~~the prior year. The decrease~~2021. These decreases in our patient volumes ~~from continuing operations in the three months ended September 30, 2021 compared to the three months ended September 30, 2020 is~~are primarily attributable to the impact of the Cybersecurity Incident on certain of our hospitals and the sale of ~~five Miami‑area hospitals and certain related operations~~the Miami Hospitals in August 2021. The decrease ofin Ambulatory Care total consolidated cases of ~~45.8%~~10.1% in the three months ended ~~September~~June 30, ~~2021 compared to the 2020 period is primarily due to the divestiture of USPI’s urgent care centers and the realignment of its imaging centers under our Hospital Operations segment.~~

Continuing Operations
Three Months Ended September 30, Increase
(Decrease)
Revenues 2021 2020
Net operating revenues:
Hospital Operations prior to inter-segment eliminations $ 4,030 $ 3,803 6.0 %
Ambulatory Care 666 565 17.9 %
Conifer 314 325 (3.4) %
Inter-segment eliminations (116) (136) (14.7) %
Total $ 4,894 $ 4,557 7.4 %

~~Net operating revenues increased by $337 million, or 7.4%, in the three months ended September 30, 2021~~2022 compared to the same period in ~~2020,~~2021 is due primarily ~~due~~ to ~~continued high patient acuity, USPI’s acquisition~~the sale of the ~~SCD Centers~~Ambulatory Care segment’s urgent care centers to a third party in ~~December 2020, favorable payer mix~~April 2021 and ~~negotiated commercial rate increases, partially offset by~~ the ~~loss~~impact of ~~revenues from~~ the COVID-19 pandemic.


	Three Months Ended June 30,				Increase (Decrease)
Revenues	2022		2021
Net operating revenues:
Hospital Operations prior to inter-segment eliminations	$	3,645	$	4,095	(11.0)	%
Ambulatory Care	771		664		16.1	%
Conifer	333		319		4.4	%
Inter-segment eliminations	(111)		(124)		(10.5)	%
Total	$	4,638	$	4,954	(6.4)	%

Table of Contents

~~five Miami‑area hospitals~~Consolidated net operating revenues decreased by $316 million, or 6.4%, in the three months ended June 30, 2022 compared to the same period in 2021, primarily due to the adverse impact of the Cybersecurity Incident and the loss of revenues in our Hospital Operations segment from the Miami Hospitals we sold in August ~~2021.~~2021, partially offset by high patient acuity and negotiated commercial rate increases. On a consolidated basis, the decrease in net operating revenues was further offset by higher revenues from our Ambulatory Care segment, which increased $107 million, or 16.1%, in the 2022 period compared to the 2021 period. This increase was largely driven by our recently acquired ASCs and negotiated commercial rate increases. Conifer’s revenues, net of intercompany eliminations, increased $27 million, or 13.8%, during the three months ended June 30, 2022 compared to the same period in 2021, primarily due to contractual rate increases and new business expansion. During the three months ended ~~September~~June 30, ~~2021~~2022 and ~~2020,~~2021, we recognized net grant income of $3$94 million and ~~$(66)~~$19 million, respectively, which amounts are not included in net operating revenues. In the three months ended September 30, 2020, we recognized a reduction of grant income reported in previous periods to comply with revised grant guidelines the U.S. Department of Health and Human Services (“HHS”) published in September 2020.

Our accounts receivable days outstanding (“AR Days”) from continuing operations were ~~56.4~~59.8 days at ~~September~~June 30, ~~2021~~2022 and ~~55.6~~57.0 days at December 31, ~~2020, compared~~2021. The increase was primarily due to ~~our~~revenue recognized in the six months ended June 30, 2022 related to a recently approved Texas Medicaid supplemental funding program, which revenue has not yet been entirely collected. Our AR Days target ofis less than 55 days. AR Days are calculated as our accounts receivable from continuing operations on the last date in the quarter divided by our net operating revenues from continuing operations for the quarter ended on that date divided by the number of days in the quarter. This calculation includes our Hospital Operations segment’s contract assets. The AR Days calculation excludes (i) urgent care centers operated under the MedPost and CareSpot brands, which we divested in April 2021, (ii) ~~five Miami‑area hospitals and certain related operations,~~the Miami Hospitals, which we sold in August 2021, and (iii) our California provider fee revenues.

Continuing Operations
Three Months Ended September 30, Increase
(Decrease)
Selected Operating Expenses 2021 2020
Hospital Operations:
Salaries, wages and benefits $ 1,872 $ 1,818 3.0 %
Supplies 656 656 — %
Other operating expenses 894 899 (0.6) %
Total $ 3,422 $ 3,373 1.5 %
Ambulatory Care:
Salaries, wages and benefits $ 169 $ 157 7.6 %
Supplies 170 128 32.8 %
Other operating expenses 97 97 — %
Total $ 436 $ 382 14.1 %
Conifer:
Salaries, wages and benefits $ 168 $ 167 0.6 %
Supplies 1 — N/A
Other operating expenses 60 62 (3.2) %
Total $ 229 $ 229 — %
Total:
Salaries, wages and benefits $ 2,209 $ 2,142 3.1 %
Supplies 827 784 5.5 %
Other operating expenses 1,051 1,058 (0.7) %
Total $ 4,087 $ 3,984 2.6 %
Rent/lease expense(1):

Hospital Operations $ 73 $ 72 1.4 %
Ambulatory Care 24 24 — %
Conifer 2 3 (33.3) %
Total $ 99 $ 99 — %

The following table provides information about certain operating expenses by segment on a continuing operations basis:


	Three Months Ended June 30,				Increase (Decrease)
Selected Operating Expenses	2022		2021
Hospital Operations:
Salaries, wages and benefits	$	1,752	$	1,941	(9.7)	%
Supplies	605		689		(12.2)	%
Other operating expenses	840		901		(6.8)	%
Total	$	3,197	$	3,531	(9.5)	%
Ambulatory Care:
Salaries, wages and benefits	$	201	$	169	18.9	%
Supplies	205		169		21.3	%
Other operating expenses	100		95		5.3	%
Total	$	506	$	433	16.9	%
Conifer:
Salaries, wages and benefits	$	173	$	170	1.8	%
Supplies	1		1		—	%
Other operating expenses	66		58		13.8	%
Total	$	240	$	229	4.8	%
Total:
Salaries, wages and benefits	$	2,126	$	2,280	(6.8)	%
Supplies	811		859		(5.6)	%
Other operating expenses	1,006		1,054		(4.6)	%
Total	$	3,943	$	4,193	(6.0)	%
Rent/lease expense(1):
Hospital Operations	$	68	$	75	(9.3)	%
Ambulatory Care	28		24		16.7	%
Conifer	3		3		—	%
Total	$	99	$	102	(2.9)	%



(1)			Included in other operating expenses.

Continuing Operations
Three Months Ended September 30, Increase
(Decrease)
Selected Operating Expenses per Adjusted Patient Admission 2021 2020
Hospital Operations:
Salaries, wages and benefits per adjusted patient admission(1)
$ 7,308 $ 7,054 3.6 %
Supplies per adjusted patient admission(1)
2,563 2,546 0.7 %
Other operating expenses per adjusted patient admission(1)
3,488 3,487 — %
Total per adjusted patient admission $ 13,359 $ 13,087 2.1 %

Table of Contents

The following table provides information about certain of our Hospital Operations segment’s operating expenses per adjusted patient admission on a continuing operations basis:


	Three Months Ended June 30,				Increase (Decrease)
Selected Operating Expenses per Adjusted Patient Admission	2022		2021
Hospital Operations:
Salaries, wages and benefits per adjusted patient admission(1)	$	7,331	$	7,090	3.4	%
Supplies per adjusted patient admission(1)	2,534		2,519		0.6	%
Other operating expenses per adjusted patient admission(1)	3,509		3,289		6.7	%
Total per adjusted patient admission	$	13,374	$	12,898	3.7	%



(1)			Adjusted patient admissions represents actual patient admissions adjusted to include outpatient services provided by facilities in our Hospital Operations segment by multiplying actual patient admissions by the sum of gross inpatient revenues and outpatient revenues and dividing the results by gross inpatient revenues.

Salaries, wages and benefits expense for our Hospital Operations segment ~~increased $54~~decreased $189 million, or ~~3.0%~~9.7%, in the three months ended ~~September~~June 30, ~~2021~~2022 compared to the same period in ~~2020.~~2021. This change was primarily attributable to ~~increased contract labor~~the sale of the Miami Hospitals in August 2021, lower incentive compensation and employee benefits costs, and our continued focus on cost-efficiency measures, partially offset by increased overtime expense and annual merit increases for certain of our ~~employees and a greater number of employed~~

~~Table of Contents~~

~~physicians. These increases were partially offset by our continued focus on cost‑reduction measures and corporate efficiencies, and the sale of five Miami‑area hospitals in August 2021.~~employees. On a ~~per adjusted patient admission~~per‑adjusted‑patient-admission basis, salaries, wages and benefits increased ~~3.6%~~3.4% in the three months ended ~~September~~June 30, ~~2021~~2022 compared to the three months ended ~~September~~June 30, ~~2020,~~2021, primarily due to ~~the increase in expense noted above.~~lower adjusted patient admissions.

Supplies expense for our Hospital Operations segment decreased $84 million, or 12.2%, during the three months ended ~~September~~June 30, ~~2021 was consistent with~~2022 compared to the three months ended ~~September~~June 30, ~~2020.~~2021. This ~~consistency is~~decrease was primarily attributable ~~to cost efficiencies and the reduction in volumes due~~ to the sale of ~~five Miami‑area hospitals,~~the Miami Hospitals, the decrease in patient volumes during the 2022 period and our cost-efficiency measures, partially offset by increased costs for certain supplies as a result of the ~~COVID‑19~~COVID-19 pandemic and ~~growth in our higher‑acuity, supply‑intensive surgical services.~~high patient acuity. On a ~~per adjusted patient~~ per‑adjusted-patient‑admission basis, supplies expense increased ~~0.7%~~0.6% in the three months ended ~~September~~June 30, ~~2021~~2022 compared to the three months ended ~~September~~June 30, ~~2020.~~2021.

Other operating expenses for our Hospital Operations segment decreased $5$61 million, or ~~0.6%~~6.8%, in the three months ended ~~September~~June 30, ~~2021~~2022 compared to the same period in ~~2020.~~2021. The decrease was primarily attributable to ~~cost efficiencies and the~~ sale of ~~five Miami‑area hospitals.~~the Miami Hospitals and our continued focus on cost-efficiency measures. On a ~~per adjusted patient~~ per‑adjusted‑patient‑admission basis, other operating expenses in the three months ended ~~September~~June 30, 2022 increased 6.7% compared to the same period in 2021, ~~were consistent with~~primarily due to lower adjusted patient admissions and the ~~three months ended September 30, 2020.~~proportionally higher level of fixed costs (e.g., rent expense) in other operating expenses.

LIQUIDITY AND CAPITAL RESOURCES OVERVIEW

Cash and cash equivalents were ~~$2.292 billion at September 30, 2021 compared to $2.194~~$1.351 billion at June 30, ~~2021~~.2022 compared to $1.405 billion at March 31, 2022.

S~~ignificant~~Significant cash flow items in the three months ended ~~September~~June 30, ~~2021~~2022 included:

•Net cash provided by operating activities before interest, taxes, discontinued operations, and restructuring charges, acquisition‑related costs, and litigation costs and settlements of ~~$662~~$543 million (including $2$99 million from federal ~~state~~ and ~~local~~state grants);

•Proceeds from the sale of facilities and other assets of ~~$1.111 billion;~~$61 million;

•Debt payments of $1.865 billion, including $1.826 billion of cash to redeem $1.769 billion aggregate principal amount outstanding of our 6.750% senior unsecured notes due 2023 (the “2023 Senior Unsecured Notes”);

•Proceeds from the issuance of $2.000 billion aggregate principal amount of our 2030 Senior Secured First Lien Notes;

•Interest payments of $250 million;

•Income tax payments of $132 million;

•Capital expenditures of ~~$111~~$152 million;

•$~~104~~175 million of distributions paid to noncontrolling interests;

•~~Payments for restructuring charges, acquisition‑related costs, and litigation costs and settlements of $31 million;~~

•~~Interest payments of $178 million; and~~

•Debt payments of $1.171 billion, including $1.113 billion of cash to redeem $1.100 billion of the $1.870 billion aggregate principal amount of 4.625% senior secured first lien notes due 2024 (“2024 Senior Secured First Lien Notes”).

~~Net cash provided by operating activities was $1.211 billion in the nine months ended September 30, 2021 compared to $2.961 billion in the nine months ended September 30, 2020. Key factors contributing to the change between the 2021 and 2020 periods include the following:~~

•An increase in operating income before net losses on sales, consolidation and deconsolidation of facilities; litigation and investigation costs; impairment and restructuring charges and acquisition-related costs; depreciation and amortization; and income recognized from government relief packages of $986 million;

•$326 million of Medicare accelerated payments recouped in the nine months ended September 30, 2021 compared to $1.380 billion of Medicare accelerated payments received in the nine months ended September 30, 2020;

•~~$38 million of cash received from federal, state and local grants in the 2021 period compared to $848 million received in the 2020 period;~~

•~~Lower interest payments of $93 million in the 2021 period;~~

•~~A $178 million deferral of our payroll tax match in the 2020 period pursuant to COVID‑19 stimulus legislation;~~

•~~Higher income tax payments of $44 million in the 2021 period;~~

Table of Contents

•~~A decrease of $136~~Payments totaling $42 million ~~in payments on reserves~~ for restructuring charges, acquisition‑related costs, and litigation costs and settlements; and

•$26 million of payments for purchases of businesses or joint venture interests.

Net cash provided by operating activities was $347 million in the six months ended June 30, 2022 compared to $779 million in the six months ended June 30, 2021. Key factors contributing to the change between the 2022 and 2021 periods include the following:

•$475 million of Medicare advances recouped in the six months ended June 30, 2022 compared to $152 million recouped during the same period in 2021;

•$104 million of cash received from grants in the six months ended June 30, 2022 compared to $36 million received in the six months ended June 30, 2021;

•Lower interest payments of $70 million in 2022 period;

•Higher income tax payments of $106 million in the 2022 period;

•Decreased cash receipts of $56 million related to supplemental Medicaid programs in California and Texas; and

•The timing of other working capital items.

FORWARD-LOOKING STATEMENTS

This report includes “forward‑looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. All statements, other than statements of historical or present facts, that address activities, events, outcomes, business strategies and other matters that we plan, expect, intend, assume, believe, budget, predict, forecast, project, target, estimate or anticipate (and other similar expressions) will, should or may occur in the future are forward‑looking statements, including (but not limited to) disclosure regarding (i) the impact of the COVID-19 pandemic, (ii) our future earnings, financial position, and operational and strategic initiatives, and (iii) developments in the healthcare industry. Forward‑looking statements represent management’s expectations, based on currently available information, as to the outcome and timing of future events, but, by their nature, address matters that are indeterminate. They involve known and unknown risks, uncertainties and other factors, many of which we are unable to predict or control, that may cause our actual results, performance or achievements to be materially different from those expressed or implied by forward‑looking statements. Such factors include, but are not limited to, the risks described in the Forward‑Looking Statements and Risk Factors sections in Part I of our Annual Report and the Risk Factors section in Part II of our Q1’22 Report.

When considering forward‑looking statements, you should keep in mind the risk factors and other cautionary statements in our Annual Report and in this report. Should one or more of the risks and uncertainties described in these reports occur, or should underlying assumptions prove incorrect, our actual results and plans could differ materially from those expressed in any forward‑looking statement. We specifically disclaim any obligation to update any information contained in a forward‑looking statement or any forward‑looking statement in its entirety except as required by law.

All forward‑looking statements attributable to us are expressly qualified in their entirety by this cautionary information.

SOURCES OF REVENUE FOR OUR HOSPITAL OPERATIONS SEGMENT

We earn revenues for patient services from a variety of sources, primarily managed care payers and the federal Medicare program, as well as state Medicaid programs, indemnity‑based health insurance companies and uninsured patients (that is, patients who do not have health insurance and are not covered by some other form of third‑party arrangement).

Table of Contents

The following table ~~shows~~presents the sources of net patient service revenues less implicit price concessions for our hospitals and related outpatient facilities, expressed as percentages of net patient service revenues less implicit price concessions from all sources:


Net Patient Service Revenues Less Implicit Price Concessions from:	Net Patient Service Revenues Less Implicit Price Concessions from:	Three Months Ended September 30,				Increase (Decrease)(1)				Nine Months Ended September 30,								Increase (Decrease)(1)		Net Patient Service Revenues Less Implicit Price Concessions from:			Three Months Ended June 30,								Increase (Decrease)(1)				Six Months Ended June 30,								Increase (Decrease)(1)
		2021		2020				2021				2020									2022				2021								2022				2021
Medicare	Medicare	16.6	%	18.9	%			(2.3)	%			18.0	%			19.9	%			(1.9)	%	Medicare			17.3	%			18.4	%			(1.1)	%			17.5	%			18.6	%			(1.1)	%
Medicaid	Medicaid	9.0	%	7.1	%	1.9	%			7.9	%			8.0	%			(0.1)	%	Medicaid			7.4	%			7.6	%			(0.2)	%			6.4	%			7.4	%			(1.0)	%
Managed care(2)	Managed care(2)	69.2	%	67.7	%	1.5	%			68.1	%			66.0	%			2.1	%	Managed care(2)			69.4	%			67.3	%			2.1	%			70.3	%			67.6	%			2.7	%
Uninsured	Uninsured	0.9	%	1.4	%	(0.5)	%			1.3	%			1.1	%			0.2	%	Uninsured			1.1	%			1.6	%			(0.5)	%			1.1	%			1.4	%			(0.3)	%
Indemnity and other	Indemnity and other	4.3	%	4.9	%	(0.6)	%			4.7	%			5.0	%			(0.3)	%	Indemnity and other			4.8	%			5.1	%			(0.3)	%			4.7	%			5.0	%			(0.3)	%



(1)			The change is the difference between the 2022 and 2021 ~~and 2020~~ percentages ~~shown.~~presented.
(2)			Includes Medicare and Medicaid managed care programs.

~~Table of Contents~~

Our payer mix on an admissions basis for our hospitals, ~~and related outpatient facilities,~~ expressed as a percentage of total admissions from all sources, is ~~shown~~presented below:


		Three Months Ended September 30,				Increase (Decrease)(1)				Nine Months Ended September 30,								Increase (Decrease)(1)					Three Months Ended June 30,									Increase (Decrease)(1)					Six Months Ended June 30,										Increase (Decrease)(1)
Admissions from:	Admissions from:	2021		2020				2021				2020				Admissions from:				2022				2021						2022							2021
Medicare	Medicare	19.6	%	21.9	%			(2.3)	%			20.6	%			23.0	%				(2.4)	%	Medicare			20.7		%			20.7		%			—		%			21.1		%			21.1		%			—	%
Medicaid	Medicaid	6.1	%	6.4	%	(0.3)	%			5.8	%			6.3	%			(0.5)	%	Medicaid			5.6		%		5.7		%				(0.1)		%			5.6		%			5.7		%			(0.1)		%
Managed care(2)	Managed care(2)	65.2	%	62.7	%	2.5	%			64.4	%			61.6	%			2.8	%	Managed care(2)			65.7		%		64.3		%			1.4		%			65.3		%			64.0		%			1.3		%
Charity and uninsured	Charity and uninsured	5.8	%	6.2	%	(0.4)	%			6.0	%			6.3	%			(0.3)	%	Charity and uninsured			5.0		%		6.2		%			(1.2)		%			4.8		%			6.1		%			(1.3)		%
Indemnity and other	Indemnity and other	3.3	%	2.8	%	0.5	%			3.2	%			2.8	%			0.4	%	Indemnity and other			3.0		%		3.1		%			(0.1)		%			3.2		%			3.1		%			0.1		%



(1)			The change is the difference between the 2022 and 2021 ~~and 2020~~ percentages ~~shown.~~presented.
(2)			Includes Medicare and Medicaid managed care programs.

GOVERNMENT PROGRAMS

~~The Centers for Medicare and Medicaid Services (“CMS”),~~CMS is an agency of ~~HHS,~~the U.S. Department of Health and Human Services (“HHS”) that administers a number of government programs authorized by federal law; it is the single largest payer of healthcare services in the United States. Approximately 63 million individuals rely on healthcare benefits through Medicare, and approximately 82 million individuals are enrolled in Medicaid and the Children’s Health Insurance Program (“CHIP”). These three programs are authorized by federal law and administered by CMS. Medicare is a federally funded health insurance program primarily for individuals 65 years of age and older, as well as some younger people with certain disabilities and conditions, and is provided without regard to income or assets. Medicaid is co‑administered by the states and is jointly funded by the federal government and state governments. Medicaid is the nation’s main public health insurance program for people with low incomes and is the largest source of health coverage in the United States. The ~~CHIP,~~Children’s Health Insurance Program (“CHIP”), which is also co‑administered by the states and jointly funded, provides health coverage to children in families with incomes too high to qualify for Medicaid, but too low to afford private coverage. Unlike Medicaid, the CHIP is limited in duration and requires the enactment of reauthorizing legislation. Funding for the CHIP has been reauthorized through federal fiscal year ~~(“FFY”)~~ 2027.

Medicare

Medicare offers its beneficiaries different ways to obtain their medical benefits. One option, the Original Medicare Plan (which includes “Part A” and “Part B”), is a fee‑for‑service (“FFS”) payment system. The other option, called Medicare Advantage (sometimes called “Part C” or “MA Plans”), includes health maintenance organizations (“HMOs”), preferred provider organizations (“PPOs”), private FFS Medicare special needs plans and Medicare medical savings account plans. Our total net patient service revenues from continuing operations of the hospitals and related outpatient facilities in our Hospital Operations segment for services provided to patients enrolled in the Original Medicare Plan were ~~$616~~$579 million and ~~$662~~$697 million for the three months ended ~~September~~June 30, ~~2021~~2022 and ~~2020,~~2021, respectively, and ~~$2.001~~$1.198 billion and ~~$1.964~~$1.385 billion for the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 and ~~2020,~~2021, respectively.

A general description of the types of payments we receive for services provided to patients enrolled in the Original Medicare Plan is provided in our Annual Report. Recent regulatory and legislative updates to the terms of these payment systems and their estimated effect on our revenues can be found under “Regulatory and Legislative Changes” below.

Table of Contents

Medicaid

Medicaid programs and the corresponding reimbursement methodologies vary from state‑to‑state and from year‑to‑year. Even prior to the COVID‑19 pandemic, several states in which we operate faced budgetary challenges that resulted in reduced Medicaid funding levels to hospitals and other providers. Because most states must operate with balanced budgets, and the Medicaid program is generally a significant portion of a state’s budget, states can be expected to adopt or consider adopting future legislation designed to reduce or not increase their Medicaid expenditures. In addition, some states delay issuing Medicaid payments to providers to manage state expenditures. As an alternative means of funding provider payments, many of the states in which we operate have adopted supplemental payment programs authorized under the Social Security Act. Continuing pressure on state budgets and other factors, including legislative and regulatory changes, could ~~adversely affect the~~result in future reductions to Medicaid payments, payment delays or changes to Medicaid supplemental ~~payments~~payment programs. Federal government denials or delayed approvals of waiver applications or extension requests by the states in which we operate could materially impact our ~~hospitals receive.~~Medicaid funding levels.

Estimated revenues under various state Medicaid programs, including state‑funded Medicaid managed care programs, constituted approximately ~~18.2%~~19.2% and ~~17.9%~~17.3% of total net patient service revenues less implicit price concessions of our acute care hospitals and related outpatient facilities for the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 and ~~2020,~~2021, respectively. We also receive disproportionate share hospital (“DSH”) and other supplemental revenues under various state Medicaid programs. For the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 and ~~2020,~~2021, our total Medicaid revenues attributable to DSH and other supplemental

~~Table of Contents~~

revenues were approximately ~~$631~~$292 million and ~~$533~~$392 million, respectively. The ~~2021 period included $153~~decrease between the two six‑month periods was primarily attributable to $77 million ~~related to the California provider fee program, $190 million related to the Michigan provider fee program, $35 million~~of assessments we recognized related to the Texas ~~Section 1115 waiver program, $126~~Comprehensive Hospital Increase Reimbursement Program (“CHIRP”) following its approval in 2022. During the six months ended June 30, 2022, we also recognized $155 million of revenue related to CHIRP that is included in Managed Medicaid revenue rather than the DSH and other supplemental revenues classification due to the structure of the program.

Medicaid revenues attributable to DSH and other supplemental payment programs ~~in multiple states, and $127 million from a number of other state and local programs.~~included the following:


	Six Months Ended June 30,
		2022		2021




Medicaid DSH		$	59	$	69

Other Medicaid supplemental payment programs, net		310		323
		369		392

CHIRP assessments		(77)		—
		$	292	$	392

Total Medicaid and Managed Medicaid net patient service revenues from continuing operations recognized by the hospitals and related outpatient facilities in our Hospital Operations segment ~~from Medicaid‑related programs in the states in which our facilities are located, as well as from Medicaid programs in neighboring states,~~ for the ~~nine~~six months ended ~~September~~June 30, 2022 and 2021 ~~and 2020~~ were ~~$2.023~~$1.315 billion and ~~$1.773~~$1.287 billion, respectively. During the ~~nine~~six months ended ~~September~~June 30, ~~2021,~~2022, Medicaid and Managed Medicaid revenues comprised ~~44%~~33% and ~~56%~~67%, respectively, of our Medicaid‑related net patient service revenues from continuing operations recognized by the hospitals and related outpatient facilities in our Hospital Operations segment. ~~These~~All Medicaid and Managed Medicaid patient service revenues are presented net of provider taxes or assessments paid by our hospitals, which are reported as an offset reduction to FFS Medicaid revenue.

Because we cannot predict what actions the federal government or the states may take under existing or future legislation and/or regulatory changes to address budget gaps, deficits, Medicaid expansion, provider fee programs or Medicaid Section 1115 waivers, we are unable to assess the effect that any such legislation or regulatory action might have on our business; however, the impact on our future financial position, results of operations or cash flows could be material.

Table of Contents

Regulatory and Legislative Changes

Material updates to the information set forth in our Annual Report about the Medicare and Medicaid payment systems, as well as other government programs impacting our business, are provided below.

Proposed Payment and Policy Changes to the Medicare Inpatient Prospective Payment Systems—Section 1886(d) of the Social Security Act requires CMS to update Medicare inpatient FFS payment rates for hospitals reimbursed under the inpatient prospective payment systems (“IPPS”) annually. The updates generally become effective October 1, the beginning of the federal fiscal ~~year.~~year (“FFY”). In ~~August 2021,~~April 2022, CMS issued ~~final~~proposed changes to the Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and Fiscal Year ~~2022~~2023 Rates (“~~Final~~Proposed IPPS Rule”). The ~~Final~~Proposed IPPS Rule includes the following proposed payment and policy changes:

•A market basket increase of ~~2.7%~~3.1% for Medicare severity‑adjusted diagnosis‑related group (“MS‑DRG”) operating payments for hospitals reporting specified quality measure data and that are meaningful users of electronic health record technology; CMS also ~~finalized~~proposed a ~~0.7%~~0.4% multifactor productivity reduction required by the ~~ACA~~Affordable Care Act and a 0.5% increase required by the Medicare Access and CHIP Reauthorization Act that ~~collectively~~together result in a net operating payment update of ~~2.5%~~3.2% before budget neutrality adjustments;

•Changes to the hospital Value‑Based Purchasing (“VBP”) and Hospital-Acquired Condition (“HAC”) programs for FFY 2023 due to the impact of the COVID-19 Public Health Emergency, including the implementation of a special scoring methodology for the VBP program that results in each hospital receiving a value‑based incentive payment amount equal to its 2% reduction to the operating standardized amount; and suppression of all measures in the HAC reduction program resulting in no hospitals being penalized for FFY 2023;

•An increase in the cost outlier threshold from $30,988 to $43,214;

•A 1.63% net increase in the capital federal MS‑DRG rate; and

•Updates to the three factors used to determine the amount and distribution of Medicare uncompensated care disproportionate share hospital (“UC‑DSH”) ~~payments;~~

•~~A 1.37% net increase in the capital federal MS‑DRG rate;~~

•~~An increase in the cost outlier threshold from $29,064 to $30,988;~~

•An extension of the New COVID‑19 Treatments Add‑on Payment for certain eligible products through the end of the FFY in which the public health emergency as declared by the Secretary of HHS ends; and

•The establishment of new requirements and the revision of existing requirements for the Hospital Value‑Based Purchasing, Hospital Readmissions Reduction and Hospital Acquired Condition Reduction programs.payments.

According to CMS, the combined impact of the proposed payment and policy changes in the ~~Final~~Proposed IPPS Rule for operating costs will yield an average ~~2.6%~~1.4% increase in Medicare operating ~~MS-DRG~~MS‑DRG FFS payments for hospitals in urban areas, and an average ~~2.6%~~2.3% increase in such payments for proprietary hospitals in FFY ~~2022.~~2023. We estimate that all of the ~~final~~proposed payment and policy changes affecting operating ~~MS-DRG~~MS‑DRG and ~~UC-DSH~~UC‑DSH payments will result in an estimated ~~1.4%~~2.3% increase in our annual Medicare FFS IPPS payments, which yields an estimated increase of approximately ~~$27~~$45 million. Because of the uncertainty associated with various factors that may influence our future IPPS payments by individual hospital, including legislative, regulatory or legal actions, admission volumes, length of stay and case mix, as well as potential changes to the Proposed IPPS Rule, we cannot provide any assurances regarding our ~~estimates~~estimate of the impact of the proposed payment and policy changes.

~~Table of Contents~~

Proposed Payment and Policy Changes to the Medicare Outpatient Prospective Payment and Ambulatory Surgery Center Payment Systems—In July ~~2021,~~2022, CMS released proposed policy changes and payment rates for the Hospital Outpatient Prospective Payment System (“OPPS”) and Ambulatory Surgical Center ~~(“ASC”)~~ Payment System for calendar year (“CY”) ~~2022~~2023 (“Proposed OPPS/ASC Rule”). The Proposed OPPS/ASC Rule includes the following proposed payment and policy changes:

•An estimated net increase of ~~2.3%~~2.7% for the OPPS rates based on an estimated market basket increase of ~~2.5%~~3.1%, reduced by a multifactor productivity adjustment required by the ~~ACA~~Affordable Care Act of ~~0.2%~~0.4%;

•~~Continuation~~Removal of the current policy of paying an adjusted amount of average sales price (“ASP”) minus 22.5% for drugs acquired under the 340B program (which program is the subject of litigation discussed in greater detail below);

•~~Cessation of the elimination of~~10 services from the Inpatient Only List ~~(“IPO List”)~~ (which is the list of procedures that must be performed on an inpatient basis)~~; efforts to eliminate the IPO List commenced in CY 2021 and were scheduled to be completed over a transitional period ending in CY 2024; in addition, CMS is proposing to reinstate the 298~~ after determining such services ~~removed from the IPO List in CY 2021 to the IPO List beginning in CY 2022;~~meet established criteria for removal;

•~~Various modifications to~~Establishment of an exemption for rural Sole Community Hospitals from the ~~hospital price transparency requirements that took effect on January 1, 2021, including significant increases to~~site-neutral Medicare reduced payment rate for clinic visits furnished in exempt off-campus, provider-based departments and payment for such visits at the ~~civil monetary penalty for noncompliance, as well as prohibitions to specific barriers to accessing machine‑readable price transparency files;~~full OPPS rate; and

•A ~~2.3%~~2.7% increase to the ~~ASC~~Ambulatory Surgical Center payment ~~rates; and~~rates.

•Table of Contents~~Re‑adoption~~

In addition, the Proposed OPPS/ASC Rule acknowledges that additional changes would be forthcoming with respect to CMS’ 340B program, which allows certain hospitals (i.e., only nonprofit organizations with specific federal designations and/or funding) (“340B Hospitals”) to purchase drugs at discounted rates from drug manufacturers (“340B Drugs”). In the CY 2018 final rule regarding OPPS payment and policy changes, CMS reduced the payment for 340B Drugs from the average sales price (“ASP”) plus 6% to the ASP minus 22.5% and made a corresponding budget‑neutral increase to payments to all hospitals for other drugs and services reimbursed under the OPPS (the “340B Payment Adjustment”). CMS retained the same 340B Payment Adjustment in the final rules regarding OPPS payment and policy changes for CYs 2019 through 2022. Certain hospital associations and hospitals commenced litigation challenging CMS’ authority to impose the 340B Payment Adjustment for CYs 2018, 2019 and 2020. Following the initial court decisions and a series of appeals, the U.S. Supreme Court (the “Supreme Court”) unanimously ruled in June 2022 that the decision to impose the 340B Payment Adjustment in CYs 2018 and 2019 was unlawful. The case was remanded to the lower courts to determine the appropriate remedy, and it is expected that 340B Hospitals will be permitted to reclaim at least some portion of the 340B payments that were previously withheld. The Proposed OPPS/ASC ~~Covered Procedures List (“ASC CPL”) criteria~~Rule states that CMS did not have sufficient time to account for the Supreme Court decision in ~~effect~~the CY 2023 proposed rates and budget neutrality calculations; however, CMS has indicated that it does anticipate applying the ASP plus 6% for 340B Drugs in the CY ~~2020 and removal of 258~~2023 final rule, in lieu of the ~~267 procedures that were added~~current payment policy of ASP minus 22.5%. CMS is still evaluating how to apply the Supreme Court ruling to the ~~ASC CPL in CY 2021.~~prior cost years and is seeking comments on potential remedies.

CMS projects that the combined impact of the proposed payment and policy changes in the Proposed OPPS/ASC Rule under the current 340B payment policy (of ASP minus 22.5%) will yield an average ~~1.8%~~2.9% increase in Medicare FFS OPPS payments for hospitals in urban areas and an average ~~2.0%~~3.5% increase in Medicare FFS OPPS payments for proprietary hospitals. Based on CMS’ estimates under the current 340B payment policy, the projected annual impact of the payment and policy changes in the Proposed OPPS/ASC Rule on our hospitals is an increase to Medicare FFS hospital outpatient revenues of approximately ~~$14~~$21 million, which represents an increase of approximately ~~2.0%~~3.7%.

However, CMS projects that the combined impact of the proposed payment and policy changes in the Proposed OPPS/ASC Rule under the anticipated final 340B payment policy (of ASP plus 6%) will yield an average 4% increase in Medicare FFS OPPS payments for hospitals in urban areas and an average 0.5% increase in Medicare FFS OPPS payments for proprietary hospitals. Based on CMS’ estimates under the anticipated final 340B payment policy, the projected annual impact of the payment and policy changes in the Proposed OPPS/ASC Rule on our hospitals is an increase to Medicare FFS hospital outpatient revenues of approximately $3 million, which represents an increase of approximately 0.5%.

Because of the uncertainty associated with various factors that may influence our future OPPS payments, including legislative or legal actions, volumes and case mix, as well as potential changes to the proposed rule, we cannot provide any assurances regarding our estimate of the impact of the proposed payment and policy changes. In addition, it remains unclear at this time how CMS will finance any retroactive payments for 340B payments that were previously withheld given that the original policy was budget‑neutral and HHS already redistributed the savings. We cannot predict the remedy that will be imposed, the timing thereof, or what further actions CMS or Congress might take with respect to the 340B program; however, it is possible that reversal of the 340B Payment Adjustments could have an adverse effect on our future net operating revenues and cash flows.

Proposed Payment and Policy Changes to the Medicare Physician Fee ~~Schedule~~Schedule——In July ~~2021,~~2022, CMS released the CY ~~2022~~2023 Medicare Physician Fee Schedule (“MPFS”) Proposed Rule (“MPFS Proposed Rule”). The MPFS Proposed Rule includes updates to payment policies, payment rates and other provisions for services reimbursed under the MPFS ~~on and after~~from January 1 ~~2022.~~through December 31, 2023. Under the MPFS Proposed Rule, the CY ~~2022~~2023 conversion factor, which is the base rate that is used to convert relative units into payment rates, would be reduced from ~~$34.89~~$34.61 to ~~$33.58,~~$33.08, due in part to the expiration of the ~~one‑time 3.75% MPFS~~one-time 3% payment increase provided for in CY ~~2021~~2022 by the ~~Consolidated Appropriations~~Protecting Medicare and American Farmers from Sequester Cuts Act, ~~2021,~~ as well as budget neutrality rules. This change would result in an annual reduction of approximately $7$8 million to our FFS MPFS revenues. Because of the uncertainty associated with various factors that may influence our future MPFS payments, including legislative, regulatory or legal actions, volumes and case mix, as well as potential changes to the MPFS Proposed Rule, we cannot provide any assurances regarding our estimate of the impact of the proposed payment and policy changes.

Public Health and Social Services Emergency ~~Fund~~—Fund—During the ~~three~~six months ended ~~September~~June 30, 2022 and 2021, our Hospital Operations and Ambulatory Care segments together recognized ~~approximately $2~~a total of $87 million and $38 million, respectively, of ~~Provider Relief Fund~~PRF grant income associated with lost revenues and COVID‑related costs. We recognized an additional $1 million of Provider Relief Fund grant income from our unconsolidated affiliates during this period. During the nine months ended September 30, 2021, our Hospital Operations and Ambulatory Care segments recognized approximately $40 million of Provider Relief Fund grant income associated with lost revenues and COVID‑related costs. We recognized an additional $12 million of Provider Relief Fund grant income from our unconsolidated affiliates during this period. Our Hospital Operations ~~and Ambulatory Care segments~~segment also recognized $1$13 million and ~~$13~~$12 million of grant income from state and local grant programs during the ~~three~~same six‑month periods in 2022 and ~~nine~~2021, respectively. In addition, we recognized $11 million of grant income through our unconsolidated affiliates during the six months ended ~~September~~June 30, ~~2021, respectively.~~2021. Grant income recognized by our Hospital Operations and Ambulatory Care segments is presented in grant income, and grant income recognized through our unconsolidated affiliates is presented in equity in earnings of unconsolidated affiliates, in each case in our ~~accompanying Condensed Consolidated Statement~~condensed consolidated statements of ~~Operations for the three and nine months ended September 30, 2021. Based on the uncertainty regarding future estimates of lost revenues and~~operations. We cannot predict whether

3738

Table of Contents

~~COVID‑related costs or the impact~~additional distributions of ~~further updates to HHS guidance, if any,~~grant funds will be authorized, and we cannot provide ~~any~~ assurances regarding the amount of grant income, if any, to be recognized in the future.

Medicare and Medicaid Payment Policy Ch~~anges~~—Changes—The federally mandated 2% sequestration reduction on Medicare FFS and Medicare Advantage payments to hospitals, physicians and other providers was suspended effective May 1, ~~2020. It was scheduled to resume on~~ ~~April 1, 2021; however, on April 14, 2021, President Biden signed H.R. 1868, which included an extension of the suspension of the 2% sequestration reduction~~2020 through December 31, 2021. The Protecting Medicare and American Farmers from Sequester Cuts Act (the “Sequester Cuts Act”), which was signed into law in December 2021, extended the 2% Medicare sequestration moratorium through March 31, 2022, and adjusted the sequestration to 1% for the period April 1, 2022 through June 30, 2022, after which the full 2% reduction will be restored unless further legislation is passed. The impact of the ~~suspension~~Sequester Cuts Act on our operations was an increase of approximately ~~$58~~$39 million of revenues in the ~~nine~~six months ended ~~September~~June 30, ~~2021. We expect the suspension to result in an increase of approximately $80 million~~ ~~of revenues for the year ending~~ ~~December 31, 2021~~.2022. Because of the uncertainty associated with various factors that may influence our future Medicare and Medicaid payments, including future legislative, legal or regulatory actions, or changes in volumes and case mix, there is a risk that actual payments received under, or the ultimate impact of, these programs will differ materially from our expectations.

~~The American Rescue Plan Act of 2021~~—~~In March 2021, President Biden signed into law the American Rescue Plan Act of 2021 (“ARPA”), a $1.9 trillion COVID~~‑~~19 relief package, which includes a number of provisions that affect hospitals and health systems, specifically:~~

•~~Additional funding for rural health care providers for COVID~~‑~~19 relief;~~

•An incentive for states that have not already done so to expand Medicaid by temporarily increasing each respective state’s Federal Medical Assistance Percentage for their base program by five percentage points for two years;

•~~Federal subsidies valued at 100% of the health insurance premium for eligible individuals and families to remain on their employer~~‑~~based coverage through September 30, 2021;~~

•~~Additional COVID~~‑~~19 funding for vaccines, treatment, PPE, testing, contact tracing and workforce development; and~~

•~~Funding to the Department of Labor for worker protection activities.~~

~~Significant Litigation~~

~~340B Litigation~~

The 340B program allows certain hospitals (i.e., only nonprofit organizations with specific federal designations and/or funding) (“340B Hospitals”) to purchase drugs at discounted rates from drug manufacturers. In the final rule regarding OPPS payment and policy changes for CY 2018, CMS reduced the payment for 340B Drugs from the ASP plus 6% to ASP minus 22.5% and made a corresponding budget‑neutral increase to payments to all hospitals for other drugs and services reimbursed under the OPPS (the “340B Payment Adjustment”). In the final rules regarding OPPS payment and policy changes for CYs 2019, 2020 and 2021, CMS continued the 340B Payment Adjustment. Certain hospital associations and hospitals commenced litigation challenging CMS’ authority to impose the 340B Payment Adjustment for CYs 2018, 2019 and 2020. Previously, the U.S. District Court for the District of Columbia (the “District Court”) held that the adoption of the 340B Payment Adjustment in the CYs 2018 and 2019 OPPS Final Rules exceeded CMS’ statutory authority by reducing drug reimbursement rates for 340B Hospitals. In July 2020, the U.S. Court of Appeals for the District of Columbia Circuit (the “Appeals Court”) reversed the District Court’s holding, finding that HHS’ decision to reduce the payment rate for 340B Drugs was based on a reasonable interpretation of the Medicare statute. The Appeals Court subsequently denied the 340B Hospital’s petition for a rehearing. The 340B Hospitals filed a timely petition asking the U.S. Supreme Court (“Supreme Court”) to reverse the Appeals Court’s decision and, on July 2, 2021, the Supreme Court agreed to review the case. We cannot predict what further actions the Supreme Court, CMS or Congress might take with respect to the 340B program; however, a reversal of the current payment policy and return to the prior 340B payment methodology could have an adverse effect on our net operating revenues and cash flows.

PRIVATE INSURANCE

Managed Care

We currently have thousands of managed care contracts with various HMOs and PPOs. HMOs generally maintain a full‑service healthcare delivery network comprised of physician, hospital, pharmacy and ancillary service providers that HMO members must access through an assigned “primary care” physician. The member’s care is then managed by his or her primary care physician and other network providers in accordance with the HMO’s quality assurance and utilization review guidelines

~~Table of Contents~~

so that appropriate healthcare can be efficiently delivered in the most cost‑effective manner. HMOs typically provide reduced benefits or reimbursement (or none at all) to their members who use non‑contracted healthcare providers for non‑emergency care.

PPOs generally offer limited benefits to members who use non‑contracted healthcare providers. PPO members who use contracted healthcare providers receive a preferred benefit, typically in the form of lower co‑pays, co‑insurance or deductibles. As employers and employees have demanded more choice, managed care plans have developed hybrid products that combine elements of both HMO and PPO plans, including high‑deductible healthcare plans that may have limited benefits, but cost the employee less in premiums.

The amount of our managed care net patient service revenues, including Medicare and Medicaid managed care programs, from our hospitals and related outpatient facilities during the ~~nine~~six months ended ~~September~~June 30, 2022 and 2021 ~~and 2020~~ was ~~$7.592~~$4.819 billion and ~~$6.519~~$5.025 billion, respectively. Our top 10 managed care payers generated ~~61%~~62% of our managed care net patient service revenues for the ~~nine~~six months ended ~~September~~June 30, ~~2021.~~2022. During the same period, national payers generated 43% of our managed care net patient service ~~revenues. The~~revenues; the remainder came from regional or local payers. At both ~~September~~June 30, ~~2021~~2022 and December 31, ~~2020, 66%~~2021, 67% of our net accounts receivable for our Hospital Operations segment were due from managed care payers.

Revenues under managed care plans are based primarily on payment terms involving predetermined rates per diagnosis, per‑diem rates, discounted FFS rates and/or other similar contractual arrangements. These revenues are also subject to review and possible audit by the payers, which can take several years before they are completely resolved. The payers are billed for patient services on an individual patient basis. An individual patient’s bill is subject to adjustment on a patient‑by‑patient basis in the ordinary course of business by the payers following their review and adjudication of each particular bill. We estimate the discounts for contractual allowances at the individual hospital level utilizing billing data on an individual patient basis. At the end of each month, on an individual hospital basis, we estimate our expected reimbursement for patients of managed care plans based on the applicable contract terms. We believe it is reasonably likely for there to be an approximately 3% increase or decrease in the estimated contractual allowances related to managed care plans. Based on reserves at ~~September~~June 30, ~~2021,~~2022, a 3% increase or decrease in the estimated contractual allowance would impact the estimated reserves by approximately ~~$18~~$16 million. Some of the factors that can contribute to changes in the contractual allowance estimates include: ~~(1)~~(i) changes in reimbursement levels for procedures, supplies and drugs when threshold levels are triggered; ~~(2)~~(ii) changes in reimbursement levels when stop‑loss or outlier limits are reached; ~~(3)~~(iii) changes in the admission status of a patient due to physician orders subsequent to initial diagnosis or testing; ~~(4)~~(iv) final coding of in‑house and discharged‑not‑final‑billed patients that change reimbursement levels; ~~(5)~~(v) secondary benefits determined after primary insurance payments; and ~~(6)~~(vi) reclassification of patients among insurance plans with different coverage and payment levels. Contractual allowance estimates are periodically reviewed for accuracy by taking into consideration known contract terms, as well as payment history. We believe our estimation and review process enables us to identify instances on a timely basis where such estimates need to be revised. We do not believe there were any adjustments to estimates of patient bills that were material to our revenues. In addition, on a corporate‑wide basis, we do not record any general provision for adjustments to estimated contractual allowances for managed

Table of Contents

care plans. Managed care accounts, net of contractual allowances recorded, are further reduced to their net realizable value through implicit price concessions based on historical collection trends for these payers and other factors that affect the estimation process.

We expect managed care governmental admissions to continue to increase as a percentage of total managed care admissions over the near term. However, the managed Medicare and Medicaid insurance plans typically generate lower yields than commercial managed care plans, which have been experiencing an improved pricing trend. Although we have benefited from solid year‑over‑year aggregate managed care pricing improvements for some time, we have seen these improvements moderate in recent years, and we believe this moderation could continue into the future. In the ~~nine~~six months ended ~~September~~June 30, ~~2021,~~2022, our commercial managed care net inpatient revenue per admission from the hospitals in our Hospital Operations segment was approximately ~~84%~~81% higher than our aggregate yield on a ~~per~~ per‑admission basis from government payers, including managed Medicare and Medicaid insurance plans.

Indemnity

An indemnity‑based agreement generally requires the insurer to reimburse an insured patient for healthcare expenses after those expenses have been incurred by the patient, subject to policy conditions and exclusions. Unlike an HMO member, a patient with indemnity insurance is free to control his or her utilization of healthcare and selection of healthcare providers.

~~Table of Contents~~

Legislative Changes

~~In December 2020,~~As more fully described in Item 1, Business — Healthcare Regulation and Licensing, of Part I of our Annual Report, the No Surprises Act (“NSA”) ~~was signed~~and the rules promulgated thereunder went into ~~law as part of the Consolidated Appropriations Act of 2021.~~effect on January 1, 2022. The NSA is intended to address unexpected gaps in insurance coverage that result in “surprise medical bills” when patients unknowingly obtain medical services from physicians and other providers outside their health insurance network, including certain emergency services, anesthesiology services and air ambulance transportation. After the protections go into effect on January 1, 2022, patients will be liable only for their in‑network cost‑sharing amount, and providers and insurers will be given the opportunity to negotiate reimbursement through an independent dispute resolution process. The NSA does not set a benchmark reimbursement amount.

On July 1, 2021, HHS, along with the U.S. Department of Labor, the U.S. Department of Treasury and the Office of Personnel Management (collectively, the “Agencies”) issued “Requirements Related to Surprise Billing; Part I” (“Part I”), an interim final rule implementing several provisions of the NSA. Part I addresses (i) the ban on balance billing for certain out‑of‑network services, (ii) the notice and consent process that some providers may use to bill patients for out‑of‑network services, (iii) patient cost‑sharing calculations, and (iv) a complaint process for any potential violations of the provisions in the law. Notably, the regulations contain strong language against health plan actions to deny coverage of emergency services.

On September 30, 2021, the Agencies released the interim final rule “Requirements Related to Surprise Billing; Part II” (“Part II”), which addresses (i) the independent dispute resolution process that providers and plans may use to adjudicate any outstanding reimbursement disputes, (ii) the good-faith cost estimates providers must share with uninsured or self‑pay patients for scheduled services, (iii) a process to resolve any disputes between uninsured/self‑pay patients and providers about the cost estimates, and (iv) an external review process as part of the oversight of health plan/issuer compliance with the law and regulations. The Agencies also established a website where an interested party may go to apply to serve as an independent dispute resolution entity and where providers and plans may initiate the process. While the provisions in Part I and Part II generally go into effect on January 1, 2022, the Agencies will accept stakeholder comments for 60 days. At this time, we are unable to assess the effect that the NSA or regulations relating to the NSA might have on our business, financial position, results of operations or cash flows.

UNINSURED PATIENTS

Uninsured patients are patients who do not qualify for government programs payments, such as Medicare and Medicaid, do not have some form of private insurance and, therefore, are responsible for their own medical bills. A significant number of our uninsured patients are admitted through our hospitals’ emergency departments and often require high‑acuity treatment that is more costly to provide and, therefore, results in higher billings, which are the least collectible of all accounts.

Self‑pay accounts receivable, which include amounts due from uninsured patients, as well as co‑pays, co‑insurance amounts and deductibles owed to us by patients with insurance, pose significant collectability problems. At ~~both September~~June 30, ~~2021~~2022 and December 31, ~~2020, approximately~~2021, 3% and 4%, respectively, of our net accounts receivable for our Hospital Operations segment was self‑pay. Further, a significant portion of our implicit price concessions relates to self‑pay amounts. We provide revenue cycle management services through Conifer, which is subject to various statutes and regulations regarding consumer protection in areas including finance, debt collection and credit reporting activities. For additional information, see Item 1, Business — Regulations Affecting Conifer’s Operations, of Part I of our Annual Report.

Conifer has performed systematic analyses to focus our attention on the drivers of bad debt expense for each hospital. While emergency department use is the primary contributor to our implicit price concessions in the aggregate, this is not the case at all hospitals. As a result, we have increased our focus on targeted initiatives that concentrate on non‑emergency department patients as well. These initiatives are intended to promote process efficiencies in collecting self‑pay accounts, as well as co‑pay, co‑insurance and deductible amounts owed to us by patients with insurance, that we deem highly collectible. We leverage a statistical‑based collections model that aligns our operational capacity to maximize our collections performance. We are dedicated to modifying and refining our processes as needed, enhancing our technology and improving staff training throughout the revenue cycle process in an effort to increase collections and reduce accounts receivable.

Over the longer term, several other initiatives we have previously announced should also help address the challenges associated with serving uninsured patients. For example, our Compact with Uninsured Patients (“Compact”) is designed to offer managed care‑style discounts to certain uninsured patients, which enables us to offer lower rates to those patients who historically had been charged standard gross charges. Under the Compact, the discount offered to uninsured patients is recognized as a contractual allowance, which reduces net operating revenues at the time the self‑pay accounts are recorded. The uninsured patient accounts, net of contractual allowances recorded, are further reduced to their net realizable value through

~~Table of Contents~~

implicit price concessions based on historical collection trends for self‑pay accounts and other factors that affect the estimation process.

Table of Contents

We also provide financial assistance through our charity and uninsured discount programs to uninsured patients who are unable to pay for the healthcare services they receive. Our policy is not to pursue collection of amounts determined to qualify for financial assistance; therefore, we do not report these amounts in net operating revenues. Most states include an estimate of the cost of charity care in the determination of a hospital’s eligibility for Medicaid DSH payments. These payments are intended to mitigate our cost of uncompensated care. Some states have also developed provider fee or other supplemental payment programs to mitigate the shortfall of Medicaid reimbursement compared to the cost of caring for Medicaid patients.

The initial expansion of health insurance coverage under the Affordable Care Act resulted in an increase in the number of patients using our facilities with either health insurance exchange or government healthcare insurance program coverage. However, we continue to have to provide uninsured discounts and charity care due to the failure of certain states to expand Medicaid coverage and for persons living in the country who are not permitted to enroll in a health insurance exchange or government healthcare insurance program.


		Three Months Ended September 30,				Nine Months Ended September 30,
		2021		2020		2021		2020			Three Months Ended June 30,				Six Months Ended June 30,
Estimated costs for:	Estimated costs for:									Estimated costs for:	2022		2021		2022		2021

Uninsured patients	Uninsured patients	$	181	$	165	$	507	$	466	Uninsured patients	$	136	$	158	$	258	$	326
Charity care patients	Charity care patients	25		30		74		113		Charity care patients	19		29		40		49
Total	Total	$	206	$	195	$	581	$	579	Total	$	155	$	187	$	298	$	375

RESULTS OF OPERATIONS

The following ~~two~~ tables ~~summarize~~present our consolidated net operating revenues, operating expenses and operating income, ~~from continuing operations,~~ both in dollar amounts and as percentages of net operating revenues, ~~for the three and nine months ended September 30, 2021 and 2020. We present metrics as~~on a ~~percentage of net operating revenues because a significant portion of our costs are variable.~~continuing operations basis:


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended June 30,				Six Months Ended June 30,
		2021		2020		2021		2020			2022		2021		2022		2021
Net operating revenues:	Net operating revenues:									Net operating revenues:
Hospital Operations	Hospital Operations	$	4,030	$	3,803	$	12,072	$	10,725	Hospital Operations	$	3,645	$	4,095	$	7,443	$	8,042
Ambulatory Care	Ambulatory Care	666		565		1,976		1,423		Ambulatory Care	771		664		1,509		1,310
Conifer	Conifer	314		325		943		962		Conifer	333		319		657		629
Inter-segment eliminations	Inter-segment eliminations	(116)		(136)		(362)		(385)		Inter-segment eliminations	(111)		(124)		(226)		(246)
Net operating revenues	Net operating revenues	4,894		4,557		14,629		12,725		Net operating revenues	4,638		4,954		9,383		9,735
Grant income	Grant income	3		(66)		53		445		Grant income	94		19		100		50
Equity in earnings of unconsolidated affiliates	Equity in earnings of unconsolidated affiliates	45		44		141		103		Equity in earnings of unconsolidated affiliates	54		54		100		96
Operating expenses:	Operating expenses:									Operating expenses:
Salaries, wages and benefits	Salaries, wages and benefits	2,209		2,142		6,690		6,193		Salaries, wages and benefits	2,126		2,280		4,308		4,481
Supplies	Supplies	827		784		2,490		2,158		Supplies	811		859		1,596		1,663
Other operating expenses, net	Other operating expenses, net	1,051		1,058		3,177		3,054		Other operating expenses, net	1,006		1,054		1,948		2,126
Depreciation and amortization	Depreciation and amortization	209		215		654		624		Depreciation and amortization	216		221		419		445
Impairment and restructuring charges, and acquisition-related costs	Impairment and restructuring charges, and acquisition-related costs	15		57		55		166		Impairment and restructuring charges, and acquisition-related costs	57		20		73		40
Litigation and investigation costs	Litigation and investigation costs	29		9		64		13		Litigation and investigation costs	18		22		38		35
Net gains on sales, consolidation and deconsolidation of facilities	Net gains on sales, consolidation and deconsolidation of facilities	(412)		(1)		(427)		(4)		Net gains on sales, consolidation and deconsolidation of facilities	(1)		(15)		—		(15)
Operating income	Operating income	$	1,014	$	271	$	2,120	$	1,069	Operating income	$	553	$	586	$	1,201	$	1,106

Table of Contents


											Three Months Ended June 30,				Six Months Ended June 30,
											2022		2021		2022		2021

		Three Months Ended September 30,				Nine Months Ended September 30,
		2021		2020		2021		2020
Net operating revenues	Net operating revenues	100.0	%	100.0	%	100.0	%	100.0	%	Net operating revenues	100.0	%	100.0	%	100.0	%	100.0	%
Grant income	Grant income	0.1	%	(1.4)	%	0.4	%	3.5	%	Grant income	2.0	%	0.4	%	1.1	%	0.5	%
Equity in earnings of unconsolidated affiliates	Equity in earnings of unconsolidated affiliates	0.9	%	1.0	%	1.0	%	0.8	%	Equity in earnings of unconsolidated affiliates	1.2	%	1.1	%	1.1	%	1.0	%
Operating expenses:	Operating expenses:									Operating expenses:
Salaries, wages and benefits	Salaries, wages and benefits	45.1	%	47.1	%	45.8	%	48.6	%	Salaries, wages and benefits	45.8	%	46.0	%	45.9	%	46.0	%
Supplies	Supplies	16.9	%	17.2	%	17.0	%	17.0	%	Supplies	17.5	%	17.4	%	17.0	%	17.1	%
Other operating expenses, net	Other operating expenses, net	21.5	%	23.2	%	21.7	%	24.0	%	Other operating expenses, net	21.7	%	21.3	%	20.8	%	21.8	%
Depreciation and amortization	Depreciation and amortization	4.3	%	4.7	%	4.5	%	4.9	%	Depreciation and amortization	4.7	%	4.5	%	4.5	%	4.6	%
Impairment and restructuring charges, and acquisition-related costs	Impairment and restructuring charges, and acquisition-related costs	0.3	%	1.3	%	0.4	%	1.3	%	Impairment and restructuring charges, and acquisition-related costs	1.2	%	0.4	%	0.8	%	0.4	%
Litigation and investigation costs	Litigation and investigation costs	0.6	%	0.2	%	0.4	%	0.1	%	Litigation and investigation costs	0.4	%	0.4	%	0.4	%	0.4	%
Net gains on sales, consolidation and deconsolidation of facilities	Net gains on sales, consolidation and deconsolidation of facilities	(8.4)	%	—	%	(2.9)	%	—	%	Net gains on sales, consolidation and deconsolidation of facilities	—	%	(0.3)	%	—	%	(0.2)	%
Operating income	Operating income	20.7	%	5.9	%	14.5	%	8.4	%	Operating income	11.9	%	11.8	%	12.8	%	11.4	%

~~Total~~The following tables present our net operating revenues, ~~increased~~operating expenses and operating income, both in dollar amounts and as percentages of net operating revenues, by ~~$337~~operating segment on a continuing operations basis:


	Three Months Ended June 30, 2022									Six Months Ended June 30, 2022
	Hospital Operations			Ambulatory Care			Conifer			Hospital Operations			Ambulatory Care			Conifer


Net operating revenues	$	3,534		$	771		$	333		$	7,217		$	1,509		$	657
Grant income	92			2			—			96			4			—
Equity in earnings of unconsolidated affiliates	2			52			—			6			94			—
Operating expenses:
Salaries, wages and benefits	1,752			201			173			3,572			395			341
Supplies	605			205			1			1,188			406			2
Other operating expenses, net	840			100			66			1,614			205			129
Depreciation and amortization	179			28			9			346			55			18
Impairment and restructuring charges, and acquisition-related costs	42			5			10			54			8			11
Litigation and investigation costs	18			—			—			26			—			12
Net gains on sales, consolidation and deconsolidation of facilities	(1)			—			—			—			—			—
Operating income	$	193		$	286		$	74		$	519		$	538		$	144

Net operating revenues	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%
Grant income	2.6		%	0.3		%	—		%	1.3		%	0.3		%	—		%
Equity in earnings of unconsolidated affiliates	0.1		%	6.7		%	—		%	0.1		%	6.2		%	—		%
Operating expenses:
Salaries, wages and benefits	49.6		%	26.1		%	52.0		%	49.5		%	26.2		%	51.9		%
Supplies	17.1		%	26.6		%	0.3		%	16.5		%	26.9		%	0.3		%
Other operating expenses, net	23.7		%	13.0		%	19.8		%	22.3		%	13.6		%	19.7		%
Depreciation and amortization	5.1		%	3.6		%	2.7		%	4.8		%	3.6		%	2.7		%
Impairment and restructuring charges, and acquisition-related costs	1.2		%	0.6		%	3.0		%	0.7		%	0.5		%	1.7		%
Litigation and investigation costs	0.5		%	—		%	—		%	0.4		%	—		%	1.8		%
Net gains on sales, consolidation and deconsolidation of facilities	—		%	—		%	—		%	—		%	—		%	—		%
Operating income	5.5		%	37.1		%	22.2		%	7.2		%	35.7		%	21.9		%

Table of Contents


	Three Months Ended June 30, 2021									Six Months Ended June 30, 2021
	Hospital Operations			Ambulatory Care			Conifer			Hospital Operations			Ambulatory Care			Conifer


Net operating revenues	$	3,971		$	664		$	319		$	7,796		$	1,310		$	629
Grant income	4			15			—			28			22			—
Equity in earnings of unconsolidated affiliates	5			49			—			9			87			—
Operating expenses:
Salaries, wages and benefits	1,941			169			170			3,798			343			340
Supplies	689			169			1			1,335			326			2
Other operating expenses, net	901			95			58			1,817			198			111
Depreciation and amortization	188			23			10			378			48			19
Impairment and restructuring charges, and acquisition-related costs	10			4			6			20			8			12
Litigation and investigation costs	19			3			—			28			6			1
Net gains on sales, consolidation and deconsolidation of facilities	(2)			(13)			—			(2)			(13)			—
Operating income	$	234		$	278		$	74		$	459		$	503		$	144

Net operating revenues	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%
Grant income	0.1		%	2.3		%	—		%	0.4		%	1.7		%	—		%
Equity in earnings of unconsolidated affiliates	0.1		%	7.4		%	—		%	0.1		%	6.6		%	—		%
Operating expenses:
Salaries, wages and benefits	48.9		%	25.5		%	53.3		%	48.7		%	26.2		%	54.1		%
Supplies	17.4		%	25.5		%	0.3		%	17.1		%	24.9		%	0.3		%
Other operating expenses, net	22.6		%	14.2		%	18.2		%	23.3		%	15.0		%	17.6		%
Depreciation and amortization	4.7		%	3.5		%	3.1		%	4.8		%	3.7		%	3.0		%
Impairment and restructuring charges, and acquisition-related costs	0.3		%	0.6		%	1.9		%	0.3		%	0.6		%	1.9		%
Litigation and investigation costs	0.5		%	0.5		%	—		%	0.4		%	0.5		%	0.2		%
Net gains on sales, consolidation and deconsolidation of facilities	(0.1)		%	(2.0)		%	—		%	—		%	(1.0)		%	—		%
Operating income	5.9		%	41.9		%	23.2		%	5.9		%	38.4		%	22.9		%

Consolidated net operating revenues decreased by $316 million and ~~$1.904 billion,~~$352 million, or ~~7.4%~~6.4% and ~~15.0%~~3.6%, for the three and ~~nine~~six months ended ~~September~~June 30, ~~2021,~~2022, respectively, compared to the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, respectively. Hospital Operations net operating revenues net of inter‑segment eliminations ~~increased~~decreased by ~~$247~~$437 million and ~~$1.370 billion,~~$579 million, or ~~6.7%~~11.0% and ~~13.2%~~7.4%, for the three and ~~nine~~six months ended ~~September~~June 30, ~~2021,~~2022, respectively, compared to the same three and ~~nine‑~~six‑month periods in ~~2020.~~2021, respectively. These ~~increases~~decreases were primarily due to ~~increased patient volumes on a same‑hospital basis,~~the adverse impact of the Cybersecurity Incident and the loss of revenues in our Hospital Operations segment from the Miami Hospitals we sold in August 2021, partially offset by high patient acuity ~~favorable payer mix~~ and negotiated commercial rate ~~increases, partially offset by the loss of revenues from the five Miami‑area hospitals and certain related operations we sold in August 2021.~~increases. Our Hospital Operations segment also recognized grant income from federal ~~state~~ and ~~local~~state grants totaling $2$92 million and ~~$30~~$96 million during the three and ~~nine~~six months ended ~~September~~June 30, ~~2021,~~2022, respectively, which ~~was~~is not included in net operating revenues.

Ambulatory Care net operating revenues increased by ~~$101~~$107 million and ~~$553~~$199 million, or ~~17.9%~~16.1% and ~~38.9%~~15.2%, for the three and ~~nine~~six months ended ~~September~~June 30, ~~2021,~~2022, respectively, compared to the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, respectively. The change in ~~2021~~2022 revenues for the three‑month period was driven by an increase from acquisitions of $83 million, as well as an increase in same‑facility net operating revenues of ~~$27~~$32 million due primarily to negotiated commercial rate increases. These increases were partially offset by a decrease of $8 million due primarily to the sale of the Ambulatory Care segment’s urgent care centers to a third party in April 2021. The change in 2022 revenues for the six‑month period was driven by an increase from acquisitions of $174 million, as well as an increase in same‑facility net operating revenues of $84 million due primarily to higher surgical patient volumes and ~~acuity, incremental revenue from new service lines and~~ negotiated commercial rate ~~increases, as well as an increase from acquisitions of $124 million.~~increases. These increases were partially offset by a decrease of ~~$50~~$59 million due primarily to the aforementioned sale of ~~our~~ urgent care centers and the transfer of imaging centers to the Hospital Operations ~~segment. The change~~segment in 2021 revenues for the nine‑month period was driven by an increase in same‑facility net operating revenues of $271 million due primarily to higher surgical patient volumes and acuity, incremental revenue from new service lines and negotiated commercial rate increases, as well as an increase from acquisitions of $365 million. These increases were partially offset by a decrease of $83 million due to the sale of our urgent care centers, the transfer of imaging centers to the Hospital Operations segment and the deconsolidation of a facility.April 2021. Our Ambulatory Care segment also recognized income from federal grants totaling $1$2 million and ~~$23~~$4 million during the three and ~~nine~~six months ended ~~September~~June 30, ~~2021,~~2022, respectively, which ~~was~~is not included in net operating revenues.

Conifer’s total net operating revenues decreased by $11 million and $19 million, or 3.4% and 2.0%, for the three and nine months ended September 30, 2021, respectively, compared to the three and nine months ended September 30, 2020, respectively. The decrease in both the three and nine‑month periods was due to the revised terms in the Amended RCM Agreement, partially offset by volume recovery by its clients. The portion of Conifer’s revenues from third‑party customers, which revenues are not eliminated in consolidation, increased $9 million and $4 million, or 4.8% and 0.7%, for the three and nine months ended September 30, 2021, respectively, compared to the same three and nine‑month periods in 2020. These increases were primarily driven by the transition of the five Miami‑area hospitals sold in August 2021 to a third‑party customer and new business expansion, partially offset by expected client attrition.

4243

Table of Contents

Conifer’s net operating revenues increased by $14 million and $28 million, or 4.4% and 4.5%, for the three and six months ended June 30, 2022, respectively, compared to the three and six months ended June 30, 2021, respectively. Conifer’s revenues from third‑party clients, which revenues are not eliminated in consolidation, increased $27 million and $48 million, or 13.8% and 12.5%, for the three and six months ended June 30, 2022, respectively, compared to the same three and six‑month periods in 2021, respectively. This increase was primarily due to contractual rate increases, new business expansion and the transition of the Miami Hospitals to third‑party clients.

The following table ~~shows~~presents selected operating expenses of our three ~~reportable business~~operating segments. Information for our Hospital Operations segment is presented on a same‑hospital basis, ~~which includes the results of~~whereas information presented for our ~~same 60 hospitals operated throughout the three~~Ambulatory Care and ~~nine months ended September 30, 2021 and 2020 and excludes five Miami‑area hospitals and certain related~~Conifer segments is presented on a continuing operations we sold in August 2021. We present same‑hospital data because we believe it provides investors with useful information regarding the performance of our hospitals and other operations that are comparable for the periods presented.basis.


		Three Months Ended September 30,				Increase (Decrease)			Nine Months Ended September 30,						Increase (Decrease)			Three Months Ended June 30,					Increase (Decrease)				Six Months Ended June 30,						Increase (Decrease)
Selected Operating Expenses	Selected Operating Expenses	2021		2020				2021			2020			Selected Operating Expenses			2022		2021			2022					2021
Hospital Operations — Same-Hospital:	Hospital Operations — Same-Hospital:																	Hospital Operations — Same-Hospital:
Salaries, wages and benefits	Salaries, wages and benefits	$	1,827	$	1,697	7.7	%		$	5,397		$	4,902		10.1	%	Salaries, wages and benefits	$	1,741	$	1,828			(4.8)		%		$	3,553		$	3,570		(0.5)		%
Supplies	Supplies	638		613		4.1	%		1,885			1,722			9.5	%	Supplies	603		644			(6.4)		%		1,184			1,247			(5.1)		%
Other operating expenses	Other operating expenses	850		818		3.9	%		2,513			2,384			5.4	%	Other operating expenses	825		820			0.6		%		1,586			1,663			(4.6)		%
Total	Total	$	3,315	$	3,128	6.0	%		$	9,795		$	9,008		8.7	%	Total	$	3,169	$	3,292		(3.7)		%		$	6,323		$	6,480		(2.4)		%
Ambulatory Care:	Ambulatory Care:																Ambulatory Care:
Salaries, wages and benefits	Salaries, wages and benefits	$	169	$	157	7.6	%		$	512		$	438		16.9	%	Salaries, wages and benefits	$	201	$	169		18.9		%		$	395		$	343		15.2		%
Supplies	Supplies	170		128		32.8	%		496			319			55.5	%	Supplies	205		169			21.3		%		406			326			24.5		%
Other operating expenses	Other operating expenses	97		97		—	%		295			258			14.3	%	Other operating expenses	100		95			5.3		%		205			198			3.5		%
Total	Total	$	436	$	382	14.1	%		$	1,303		$	1,015		28.4	%	Total	$	506	$	433		16.9		%		$	1,006		$	867		16.0		%
Conifer:	Conifer:																Conifer:
Salaries, wages and benefits	Salaries, wages and benefits	$	168	$	167	0.6	%		$	508		$	511		(0.6)	%	Salaries, wages and benefits	$	173	$	170		1.8		%		$	341		$	340		0.3		%
Supplies	Supplies	1		—		N/A			3			2			50.0	%	Supplies	1		1			—		%		2			2			—		%
Other operating expenses	Other operating expenses	60		62		(3.2)	%		171			193			(11.4)	%	Other operating expenses	66		58			13.8		%		129			111			16.2		%
Total	Total	$	229	$	229	—	%		$	682		$	706		(3.4)	%	Total	$	240	$	229		4.8		%		$	472		$	453		4.2		%

Rent/lease expense(1):
Rent/lease expense(1):																	Rent/lease expense(1):
Hospital Operations	Hospital Operations	$	69	$	66	4.5	%		$	210		$	188		11.7	%	Hospital Operations	$	66	$	69		(4.3)		%		$	134		$	141		(5.0)		%
Ambulatory Care	Ambulatory Care	24		24		—	%		75			67			11.9	%	Ambulatory Care	28		24			16.7		%		55			51			7.8		%
Conifer	Conifer	2		3		(33.3)	%		8			9			(11.1)	%	Conifer	3		3			—		%		6			6			—		%
Total	Total	$	95	$	93	2.2	%		$	293		$	264		11.0	%	Total	$	97	$	96		1.0		%		$	195		$	198		(1.5)		%



(1)			Included in other operating expenses.

~~Table of Contents~~

RESULTS OF OPERATIONS BY SEGMENT

Our operations are reported in three segments:

•Hospital Operations, which is comprised of acute care and specialty hospitals, imaging centers, ancillary outpatient facilities, micro‑hospitals ~~imaging centers,~~and physician ~~practices, and other care sites and clinics;~~practices;

•~~Our~~ Ambulatory Care, ~~segment~~which is comprised of USPI’s ~~ambulatory surgery centers~~ASCs and surgical hospitals; and

•Conifer, which provides revenue cycle management and value‑based care services to hospitals, health systems, physician practices, employers and other clients.

Table of Contents

Hospital Operations Segment

The following tables ~~show~~present operating statistics, revenues and expenses of our ~~continuing operations~~ hospitals and related outpatient facilities on a same‑hospital basis, unless otherwise indicated, which includes the results of our same 60 hospitals operated throughout the three and nine months ended September 30, 2021 and 2020 and excludes the five Miami‑area hospitals we sold in August 2021. We present same‑hospital data because we believe it provides investors with useful information regarding the performance of our hospitals and other operations that are comparable for the periods presented. We present certain metrics on a per‑adjusted‑patient‑admission and per‑adjusted‑patient‑day basis to show trends other than volume. We present certain metrics as a percentage of net operating revenues because a significant portion of our operating expenses are variable.indicated:


		Same-Hospital Continuing Operations								Same-Hospital Continuing Operations												Same-Hospital														Same-Hospital
		Three Months Ended September 30,				Increase (Decrease)				Nine Months Ended September 30,						Increase (Decrease)						Three Months Ended June 30,								Increase (Decrease)						Six Months Ended June 30,								Increase (Decrease)
Admissions, Patient Days and Surgeries	Admissions, Patient Days and Surgeries	2021		2020					2021			2020			Admissions, Patient Days and Surgeries					2022			2021					2022								2021
Number of hospitals (at end of period)	Number of hospitals (at end of period)	60		60				—	(1)			60			60				—		(1)	Number of hospitals (at end of period)			60				60					—	(1)				60				60					—	(1)
Total admissions	Total admissions	140,491		136,895		2.6	%			413,942			409,382			1.1	%			Total admissions		128,068				139,331					(8.1)		%				255,850				273,451				(6.4)		%
Adjusted patient admissions(2)	Adjusted patient admissions(2)	248,798		238,372		4.4	%			732,540			709,736			3.2	%			Adjusted patient admissions(2)		239,031				252,469				(5.3)		%				466,964				483,742				(3.5)		%
Paying admissions (excludes charity and uninsured)	Paying admissions (excludes charity and uninsured)	132,614		129,350		2.5	%			391,432			386,552			1.3	%			Paying admissions (excludes charity and uninsured)		121,823				131,813				(7.6)		%				243,620				258,818				(5.9)		%
Charity and uninsured admissions	Charity and uninsured admissions	7,877		7,545		4.4	%			22,510			22,830			(1.4)	%			Charity and uninsured admissions		6,245				7,518				(16.9)		%				12,230				14,633				(16.4)		%
Admissions through emergency department	Admissions through emergency department	106,217		99,966		6.3	%			309,681			295,582			4.8	%			Admissions through emergency department		96,136				102,617				(6.3)		%				193,820				203,464				(4.7)		%
Paying admissions as a percentage of total admissions	Paying admissions as a percentage of total admissions	94.4	%	94.5	%	(0.1)	%	(1)		94.6	%		94.4	%		0.2	%	(1)		Paying admissions as a percentage of total admissions		95.1		%		94.6	%			0.5		%	(1)			95.2		%		94.6		%		0.6		%	(1)
Charity and uninsured admissions as a percentage of total admissions	Charity and uninsured admissions as a percentage of total admissions	5.6	%	5.5	%	0.1	%	(1)		5.4	%		5.6	%		(0.2)	%	(1)		Charity and uninsured admissions as a percentage of total admissions		4.9		%		5.4	%			(0.5)		%	(1)			4.8		%		5.4		%		(0.6)		%	(1)
Emergency department admissions as a percentage of total admissions	Emergency department admissions as a percentage of total admissions	75.6	%	73.0	%	2.6	%	(1)		74.8	%		72.2	%		2.6	%	(1)		Emergency department admissions as a percentage of total admissions		75.1		%		73.6	%			1.5		%	(1)			75.8		%		74.4		%		1.4		%	(1)
Surgeries — inpatient	Surgeries — inpatient	35,535		37,009		(4.0)	%			106,994			108,272			(1.2)	%			Surgeries — inpatient		33,749				37,363				(9.7)		%				66,657				71,459				(6.7)		%
Surgeries — outpatient	Surgeries — outpatient	54,119		51,785		4.5	%			161,982			139,031			16.5	%			Surgeries — outpatient		53,638				57,588				(6.9)		%				104,896				107,863				(2.8)		%
Total surgeries	Total surgeries	89,654		88,794		1.0	%			268,976			247,303			8.8	%			Total surgeries		87,387				94,951				(8.0)		%				171,553				179,322				(4.3)		%
Patient days — total	Patient days — total	748,012		710,369		5.3	%			2,174,982			2,072,369			5.0	%			Patient days — total		658,995				695,445				(5.2)		%				1,364,618				1,426,970				(4.4)		%
Adjusted patient days(2)	Adjusted patient days(2)	1,301,989		1,198,744		8.6	%			3,762,149			3,481,388			8.1	%			Adjusted patient days(2)		1,192,999				1,234,640				(3.4)		%				2,417,823				2,460,160				(1.7)		%
Average length of stay (days)	Average length of stay (days)	5.32		5.19		2.5	%			5.25			5.06			3.8	%			Average length of stay (days)		5.15				4.99				3.2		%				5.33				5.22				2.1		%
Licensed beds (at end of period)	Licensed beds (at end of period)	15,399		15,467		(0.4)	%			15,399			15,467			(0.4)	%			Licensed beds (at end of period)		15,391				15,399				(0.1)		%				15,391				15,399				(0.1)		%
Average licensed beds	Average licensed beds	15,399		15,467		(0.4)	%			15,401			15,451			(0.3)	%			Average licensed beds		15,382				15,402				(0.1)		%				15,389				15,403				(0.1)		%
Utilization of licensed beds(3)	Utilization of licensed beds(3)	52.8	%	49.9	%	2.9	%	(1)		51.7	%		49.0	%		2.7	%	(1)		Utilization of licensed beds(3)		47.1		%		49.6	%			(2.5)		%	(1)			49.0		%		51.2		%		(2.2)		%	(1)



(1)			The change is the difference between the 2022 and 2021 ~~and 2020~~ amounts ~~shown.~~presented.
(2)			Adjusted patient admissions/days represents actual patient admissions/days adjusted to include outpatient services provided by facilities in our Hospital Operations segment by multiplying actual patient admissions/days by the sum of gross inpatient revenues and outpatient revenues and dividing the results by gross inpatient revenues.
(3)			Utilization of licensed beds represents patient days divided by number of days in the period divided by average licensed beds.

~~Table of Contents~~


		Same-Hospital Continuing Operations									Same-Hospital Continuing Operations												Same-Hospital														Same-Hospital
		Three Months Ended September 30,				Increase (Decrease)					Nine Months Ended September 30,						Increase (Decrease)						Three Months Ended June 30,								Increase (Decrease)						Six Months Ended June 30,								Increase (Decrease)
Outpatient Visits	Outpatient Visits	2021		2020						2021			2020			Outpatient Visits					2022			2021					2022								2021
Total visits	Total visits	1,360,953		1,180,516				15.3	%				4,008,056			3,392,446				18.1		%	Total visits			1,281,256				1,424,407					(10.0)	%				2,521,642				2,647,103					(4.7)	%
Paying visits (excludes charity and uninsured)	Paying visits (excludes charity and uninsured)	1,265,603		1,105,627		14.5	%				3,736,175			3,153,510			18.5	%			Paying visits (excludes charity and uninsured)		1,201,750				1,323,061					(9.2)		%				2,367,468				2,470,572				(4.2)		%
Charity and uninsured visits	Charity and uninsured visits	95,350		74,889		27.3	%				271,881			238,936			13.8	%			Charity and uninsured visits		79,506				101,346				(21.5)		%				154,174				176,531				(12.7)		%
Emergency department visits	Emergency department visits	567,260		438,772		29.3	%				1,502,651			1,406,380			6.8	%			Emergency department visits		541,098				511,030				5.9		%				1,041,763				935,391				11.4		%
Surgery visits	Surgery visits	54,119		51,785		4.5	%				161,982			139,031			16.5	%			Surgery visits		53,638				57,588				(6.9)		%				104,896				107,863				(2.8)		%
Paying visits as a percentage of total visits	Paying visits as a percentage of total visits	93.0	%	93.7	%	(0.7)	%	(1)			93.2	%		93.0	%		0.2	%	(1)		Paying visits as a percentage of total visits		93.8		%		92.9	%			0.9		%	(1)			93.9		%		93.3		%		0.6		%	(1)
Charity and uninsured visits as a percentage of total visits	Charity and uninsured visits as a percentage of total visits	7.0	%	6.3	%	0.7	%	(1)			6.8	%		7.0	%		(0.2)	%	(1)		Charity and uninsured visits as a percentage of total visits		6.2		%		7.1	%			(0.9)		%	(1)			6.1		%		6.7		%		(0.6)		%	(1)



(1)			The change is the difference between the 2022 and 2021 ~~and 2020~~ amounts ~~shown.~~presented.

Same-Hospital
Continuing Operations Same-Hospital
Continuing Operations
Three Months Ended
September 30, Increase
(Decrease) Nine Months Ended
September 30, Increase
(Decrease)
Revenues 2021 2020 2021 2020
Total segment net operating revenues(1)
$ 3,799 $ 3,399 11.8 % $ 11,050 $ 9,615 14.9 %
Selected revenue data – hospitals and related outpatient facilities:
Net patient service revenues(1)(2)
$ 3,599 $ 3,246 10.9 % $ 10,498 $ 9,170 14.5 %
Net patient service revenue per adjusted patient admission(1)(2)
$ 14,466 $ 13,617 6.2 % $ 14,331 $ 12,920 10.9 %
Net patient service revenue per adjusted patient day(1)(2)
$ 2,764 $ 2,708 2.1 % $ 2,790 $ 2,634 5.9 %

Table of Contents


	Same-Hospital						Same-Hospital
	Three Months Ended June 30,				Increase (Decrease)		Six Months Ended June 30,				Increase (Decrease)
Revenues	2022		2021				2022		2021
Total segment net operating revenues(1)	$	3,498	$	3,690	(5.2)	%	$	7,150	$	7,251	(1.4)	%
Selected revenue data – hospitals and related outpatient facilities:
Net patient service revenues(1)(2)	$	3,314	$	3,507	(5.5)	%	$	6,792	$	6,899	(1.6)	%
Net patient service revenue per adjusted patient admission(1)(2)	$	13,864	$	13,891	(0.2)	%	$	14,545	$	14,262	2.0	%
Net patient service revenue per adjusted patient day(1)(2)	$	2,778	$	2,841	(2.2)	%	$	2,809	$	2,804	0.2	%



(1)			Revenues are net of implicit price concessions.
(2)			Adjusted patient admissions/days represents actual patient admissions/days adjusted to include outpatient services provided by facilities in our Hospital Operations segment by multiplying actual patient admissions/days by the sum of gross inpatient revenues and outpatient revenues and dividing the results by gross inpatient revenues.


		Same-Hospital Continuing Operations									Same-Hospital Continuing Operations															Same-Hospital														Same-Hospital
		Three Months Ended September 30,				Increase (Decrease)					Nine Months Ended September 30,								Increase (Decrease)							Three Months Ended June 30,									Increase (Decrease)(1)					Six Months Ended June 30,										Increase (Decrease)(1)
Total Segment Selected Operating Expenses	Total Segment Selected Operating Expenses	2021		2020						2021			2020				Total Segment Selected Operating Expenses						2022				2021						2022							2021
Salaries, wages and benefits as a percentage of net operating revenues	Salaries, wages and benefits as a percentage of net operating revenues	48.1	%	49.9	%			(1.8)	%	(1)			48.8	%			51.0	%				(2.2)		%	(1)	Salaries, wages and benefits as a percentage of net operating revenues			49.8		%			49.5		%			0.3		%			49.7		%			49.2		%			0.5	%
Supplies as a percentage of net operating revenues	Supplies as a percentage of net operating revenues	16.8	%	18.0	%	(1.2)	%	(1)			17.1	%			17.9	%			(0.8)	%	(1)		Supplies as a percentage of net operating revenues			17.2		%		17.5		%				(0.3)		%			16.6		%			17.2		%			(0.6)		%
Other operating expenses as a percentage of net operating revenues	Other operating expenses as a percentage of net operating revenues	22.4	%	24.1	%	(1.7)	%	(1)			22.7	%			24.8	%			(2.1)	%	(1)		Other operating expenses as a percentage of net operating revenues			23.6		%		22.2		%			1.4		%			22.2		%			22.9		%			(0.7)		%



(1)			The change is the difference between the 2022 and 2021 ~~and 2020~~ amounts ~~shown.~~presented.

Revenues

Same‑hospital net operating revenues ~~increased $400~~decreased $192 million, or ~~11.8%~~5.2%, during the three months ended ~~September~~June 30, ~~2021~~2022 compared to the three months ended ~~September~~June 30, ~~2020, primarily~~2021, due in part to ~~higher~~the adverse impact of the Cybersecurity Incident on our patient volumes, partially offset by high patient acuity ~~favorable payer mix~~ and negotiated commercial rate increases. Our Hospital Operations segment also recognized ~~net~~ grant income totaling $2$92 million and ~~$(57)~~$4 million from federal, state and local grants in the three months ended ~~September~~June 30, ~~2021~~2022 and 2020, respectively, which is not included in net operating revenues. During the 2020 period, we recognized a reduction of grant income to comply with revised grant guidelines HHS published in September 2020. Same‑hospital admissions and outpatient visits increased 2.6% and 15.3%, respectively, in the three months ended September 30, 2021, ~~compared to the same period in 2020.~~

Same‑hospital net operating revenues increased $1.435 billion, or 14.9%, during the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020, primarily due to higher patient volumes, high patient acuity, favorable payer mix and negotiated commercial rate increases. Our Hospital Operations segment also recognized

~~Table of Contents~~

~~grant income from federal, state and local grants totaling $30 million and $417 million in the nine months ended September 30, 2021 and 2020,~~ respectively, which is not included in net operating revenues. Same‑hospital admissions and outpatient visits ~~increased 1.1%~~decreased 8.1% and ~~18.1%~~10.0%, respectively, in the ~~nine~~three months ended ~~September~~June 30, ~~2021~~2022 compared to the same period in ~~2020.~~2021, due in part to the impact of the Cybersecurity Incident in April 2022.

Same‑hospital net operating revenues decreased $101 million, or 1.4%, during the six months ended June 30, 2022 compared to the six months ended June 30, 2021, primarily due to the same factors that impacted the three‑month period. Our Hospital Operations segment also recognized grant income from federal, state and local grants totaling $96 million and $28 million in the six months ended June 30, 2022 and 2021, respectively, which is not included in net operating revenues. Same‑hospital admissions decreased 6.4% in the six months ended June 30, 2022 compared to the same period in 2021. This decrease was due in part to the impacts of the Omicron variant in the first quarter of 2022 and the Cybersecurity Incident in the second quarter of 2022. Same‑hospital outpatient visits decreased by 4.7% during the 2022 period, due in part to the adverse impact of the Cybersecurity Incident.

Table of Contents

The following table ~~shows the~~presents our consolidated net accounts receivable by ~~payer at September 30, 2021 and December 31, 2020:~~payer:


		September 30, 2021		December 31, 2020			June 30, 2022		December 31, 2021
Medicare	Medicare	$	150	$	152	Medicare	$	141	$	155
Medicaid	Medicaid	53		49		Medicaid	54		47
Net cost report settlements receivable and valuation allowances	Net cost report settlements receivable and valuation allowances	44		34		Net cost report settlements receivable and valuation allowances	49		33
Managed care	Managed care	1,607		1,567		Managed care	1,682		1,602
Self-pay uninsured	Self-pay uninsured	22		32		Self-pay uninsured	12		21
Self-pay balance after insurance	Self-pay balance after insurance	72		74		Self-pay balance after insurance	70		70
Estimated future recoveries	Estimated future recoveries	139		156		Estimated future recoveries	141		137
Other payers	Other payers	341		318		Other payers	345		331
Total Hospital Operations	Total Hospital Operations	2,428		2,382		Total Hospital Operations	2,494		2,396
Ambulatory Care	Ambulatory Care	313		307		Ambulatory Care	346		374
Total discontinued operations		1		1

Accounts receivable, net	Accounts receivable, net	$	2,742	$	2,690	Accounts receivable, net	$	2,840	$	2,770

Collection of accounts receivable has been a key area of focus, particularly over the past several years. At ~~September~~June 30, ~~2021,~~2022, our Hospital Operations segment collection rate on self‑pay accounts was approximately ~~25.6%~~28.2%. Our self‑pay collection rate includes payments made by patients, including co‑pays, co‑insurance amounts and deductibles paid by patients with insurance. Based on our accounts receivable from uninsured patients and co‑pays, co‑insurance amounts and deductibles owed to us by patients with insurance at ~~September~~June 30, ~~2021,~~2022, a 10% decrease or increase in our self‑pay collection rate, or approximately 3%, which we believe could be a reasonably likely change, would result in an unfavorable or favorable adjustment to patient accounts receivable of approximately $9$10 million. There are various factors that can impact collection trends, such as changes in the economy, which in turn have an impact on unemployment rates and the number of uninsured and underinsured patients, the volume of patients through our emergency departments, the increased burden of co‑pays and deductibles to be made by patients with insurance, and business practices related to collection efforts. These factors, many of which have been affected by the COVID‑19 pandemic, continuously change and can have an impact on collection trends and our estimation process.

~~Payment pressure from managed care payers~~We also ~~affects the collectability of our accounts receivable. We~~ typically experience ongoing managed care payment delays and disputes; however, we continue to work with these payers to obtain adequate and timely reimbursement for our services. Our estimated Hospital Operations segment collection rate from managed care payers was approximately ~~96.7%~~96.1% at ~~September~~June 30, ~~2021.~~2022.

We manage our implicit price concessions using hospital‑specific goals and benchmarks such as ~~(1)~~(i) total cash collections, ~~(2)~~(ii) point‑of‑service cash collections, ~~(3)~~(iii) AR Days and ~~(4)~~(iv) accounts receivable by aging category. The following tables present the approximate aging by payer of our net accounts receivable from the continuing operations of our Hospital Operations segment of ~~$2.384~~$2.445 billion and ~~$2.348~~$2.363 billion at ~~September~~June 30, ~~2021~~2022 and December 31, ~~2020,~~2021, respectively, excluding cost report settlements receivable and valuation allowances of ~~$44~~$49 million and ~~$34~~$33 million, respectively, at ~~September~~June 30, ~~2021~~2022 and December 31, ~~2020:~~2021:

September 30, 2021
Medicare Medicaid Managed
Care Indemnity,
Self-Pay
and Other Total
0-60 days 92 % 48 % 57 % 23 % 51 %
61-120 days 4 % 24 % 16 % 14 % 15 %
121-180 days 2 % 11 % 9 % 9 % 9 %
Over 180 days 2 % 17 % 18 % 54 % 25 %
Total 100 % 100 % 100 % 100 % 100 %

~~Table of Contents~~

December 31, 2020
Medicare Medicaid Managed
Care Indemnity,
Self-Pay
and Other Total
0-60 days 91 % 33 % 58 % 24 % 52 %
61-120 days 5 % 31 % 15 % 13 % 14 %
121-180 days 2 % 14 % 8 % 8 % 8 %
Over 180 days 2 % 22 % 19 % 55 % 26 %
Total 100 % 100 % 100 % 100 % 100 %



	Medicare		Medicaid		Managed Care		Indemnity, Self-Pay and Other		Total
At June 30, 2022:
0-60 days	91	%	38	%	53	%	21	%	47	%
61-120 days	5	%	27	%	16	%	14	%	16	%
121-180 days	2	%	15	%	10	%	9	%	10	%
Over 180 days	2	%	20	%	21	%	56	%	27	%
Total	100	%	100	%	100	%	100	%	100	%

At December 31, 2021:
0-60 days	93	%	35	%	57	%	22	%	52	%
61-120 days	4	%	31	%	18	%	14	%	16	%
121-180 days	1	%	14	%	10	%	9	%	9	%
Over 180 days	2	%	20	%	15	%	55	%	23	%
Total	100	%	100	%	100	%	100	%	100	%

Conifer continues to implement revenue cycle initiatives to improve our cash flow. These initiatives are focused on standardizing and improving patient access processes, including pre‑registration, registration, verification of eligibility and benefits, liability identification and collections at point‑of‑service, and financial counseling. These initiatives are intended to reduce denials, improve service levels to patients and increase the quality of accounts that end up in accounts receivable.

Table of Contents

Although we continue to focus on improving our methodology for evaluating the collectability of our accounts receivable, we may incur future charges if there are unfavorable changes in the trends affecting the net realizable value of our accounts receivable.

At ~~September~~June 30, ~~2021,~~2022, we had a cumulative total of patient account assignments to Conifer of ~~$1.952~~$1.870 billion related to our continuing operations. These accounts have already been written off and are not included in our receivables; however, an estimate of future recoveries from all the accounts assigned to Conifer is determined based on our historical experience and recorded in accounts receivable.

Patient advocates from Conifer’s ~~Medicaid~~ Eligibility ~~Program~~and Enrollment Services program (“~~MEP”~~EES”) screen patients in the hospital to determine whether those patients meet eligibility requirements for financial assistance programs. They also expedite the process of applying for these government programs. Receivables from patients who are potentially eligible for Medicaid are classified as Medicaid pending, under the ~~MEP,~~EES, net of appropriate implicit price concessions. Based on recent trends, approximately 97% of all accounts in the ~~MEP~~EES are ultimately approved for benefits under a government program, such as Medicaid.

The following table ~~shows~~presents the approximate amount of accounts receivable in the ~~MEP~~EES still awaiting determination of eligibility under a government program at ~~September~~June 30, ~~2021~~2022 and December 31, ~~2020~~2021 by aging category:


		September 30, 2021		December 31, 2020			June 30, 2022		December 31, 2021
0-60 days	0-60 days	$	76	$	91	0-60 days	$	71	$	87
61-120 days	61-120 days	12		24		61-120 days	19		17
121-180 days	121-180 days	5		6		121-180 days	4		4
Over 180 days	Over 180 days	6		6		Over 180 days	10		7
Total	Total	$	99	$	127	Total	$	104	$	115

Salaries, Wages and Benefits

Same‑hospital salaries, wages and benefits ~~increased $130~~decreased $87 million, or ~~7.7%~~4.8%, in the three months ended ~~September~~June 30, ~~2021~~2022 compared to the same period in ~~2020.~~2021. This ~~change~~decrease was primarily attributable to reduced patient volumes and our continued focus on cost‑efficiency measures. Lower incentive compensation and employee benefits costs also contributed to the decrease in 2022. These factors were partially offset by increased ~~contract labor costs, increased overtime expense,~~premium pay and annual merit increases for certain of our ~~employees and a greater number of employed physicians. This increase was partially mitigated by our continued focus on cost‑reduction measures and corporate efficiencies.~~employees. Same‑hospital salaries, wages and benefits as a percentage of net operating revenues ~~decreased~~increased by ~~180~~30 basis points to ~~48.1%~~49.8% in the three months ended ~~September~~June 30, ~~2021~~2022 compared to the three months ended ~~September~~June 30, ~~2020, primarily~~2021, due in part to the ~~growth~~adverse impact of the Cybersecurity Incident on our ~~net operating~~patient revenues ~~and our focus on strategic cost reduction measures and corporate efficiencies.~~during the period. Salaries, wages and benefits expense for the three months ended ~~September~~June 30, ~~2021~~2022 and ~~2020~~2021 included stock‑based compensation expense of $9$14 million and $7$12 million, respectively.

Same‑hospital salaries, wages and benefits ~~increased $495~~decreased $17 million, or ~~10.1%~~0.5%, in the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 compared to the same period in ~~2020.~~2021. This ~~increase~~decrease was primarily attributable to the same factors that ~~impacted~~caused the ~~three‑month~~decrease in the three-month period, ~~ended September 30, 2021~~partially offset by increased premium pay, increased contract labor costs and ~~higher incentive compensation.~~annual merit increases for certain of our employees. Same‑hospital salaries, wages and benefits as a percentage of net operating revenues ~~decreased~~increased by ~~220~~50 basis points to ~~48.8%~~49.7% in the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 compared to the ~~nine~~six months ended ~~September~~June 30, ~~2020, primarily~~2021, due in part to the ~~same factors that impacted~~adverse impact of the ~~three‑month period ended September 30, 2021.~~Cybersecurity Incident on our patient revenues during the period. Salaries, wages and benefits expense for the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 and ~~2020~~2021 included stock‑based compensation expense of ~~$31~~$26 million and $22 million, respectively.

~~Table of Contents~~

Supplies

Same‑hospital supplies expense ~~increased $25~~decreased $41 million, or ~~4.1%~~6.4%, in the three months ended ~~September~~June 30, ~~2021~~2022 compared to the same period in ~~2020.~~2021. The ~~increase~~decrease was primarily due to ~~higher~~lower patient volumes and our cost-efficiency measures, including those described below, partially offset by the increased cost of certain supplies as a result of the COVID‑19 pandemic and growth in our higher‑acuity, supply‑intensive surgical services. Same‑hospital supplies expense as a percentage of net operating revenues decreased by ~~120~~30 basis points to ~~16.8%~~17.2% in the three months ended ~~September~~June 30, ~~2021~~2022 compared to the three months ended ~~September~~June 30, ~~2020,~~2021, primarily due to ~~the growth of~~ our ~~net operating revenues and our~~continued focus on ~~strategic cost reduction~~cost-efficiency measures.

Same‑hospital supplies expense increased $163 million, or 9.5%, in the nine months ended September 30, 2021 compared to the same period in 2020. The increase was primarily due to the same factors that impacted the three‑month period ended September 30, 2021. Same‑hospital supplies expense as a percentage of net operating revenues decreased by 80 basis points to 17.1% in the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020 primarily due to the same factors that impacted the three‑month period ended September 30, 2021.

We strive to control supplies expense through product standardization, consistent contract terms and end‑to‑end contract management, improved utilization, bulk purchases, focused spending with a smaller number of vendors and operational improvements.

Same‑hospital supplies expense decreased $63 million, or 5.1%, in the six months ended June 30, 2022 compared to the same period in 2021. The ~~items~~decrease was primarily due to the same factors that impacted the three‑month period ended June 30, 2022. Same‑hospital supplies expense as a percentage of ~~current cost‑reduction~~net operating revenues decreased by 60 basis points to 16.6%

Table of Contents

in the six months ended June 30, 2022 compared to the six months ended June 30, 2021, primarily due to our continued focus ~~include PPE, cardiac stents and pacemakers, orthopedics, implants, and high‑cost pharmaceuticals.~~on cost-efficiency measures.

Other Operating Expenses, Net

Same‑hospital other operating expenses increased by ~~$32~~$5 million, or ~~3.9%~~0.6%, in the three months ended ~~September~~June 30, ~~2021~~2022 compared to the same period in ~~2020.~~ 2021. Same‑hospital other operating expenses as a percentage of net operating revenues increased by 140 basis points to 23.6% for the three months ended June 30, 2022 compared to 22.2% for the three months ended June 30, 2021, primarily due to the decrease in our patient volumes and the proportionally higher level of fixed costs (e.g., rent expense) in other operating expenses.

Same‑hospital other operating expenses decreased by $77 million, or 4.6%, in the six months ended June 30, 2022 compared to the same period in 2021. The changes in other operating expenses included:

•net gains from the sale of long-lived assets of $71 million; and

•decreased malpractice expense of $18 million.

Same‑hospital other operating expenses as a percentage of net operating revenues decreased by ~~170~~70 basis points to ~~22.4%~~22.2% in the six months ended June 30, 2022 compared to 22.9% for the ~~three~~six months ended ~~September~~June 30, 2021, ~~compared to 24.1% for the three months ended September 30, 2020,~~ primarily due to the ~~growth~~net gains from the sale of ~~our net operating revenues and our focus on strategic cost reduction measures and corporate efficiencies. The changes in other operating expenses included:~~long-lived assets noted above.

•~~increased software costs of $11 million; and~~

•~~increased malpractice expense of $10 million.~~

Same‑hospital other operating expenses increased by $129 million, or 5.4%, in the nine months ended September 30, 2021 compared to the same period in 2020. Same‑hospital other operating expenses as a percentage of net operating revenues decreased by 210 basis points to 22.7% in the nine months ended September 30, 2021 compared to 24.8% for the nine months ended September 30, 2020, primarily due to the same factors that impacted the three‑month period. The changes in other operating expenses included:

•~~increased malpractice expense of $48 million;~~

•~~increased software costs of $42 million;~~

•~~increased rent and lease expense of $22 million;~~

•~~increased collection fees of $18 million;~~

•~~increased repair and maintenance costs of $15 million; and~~

•~~a gain on sale and leaseback of a medical office building of $12 million, which is classified as a reduction of other operating expenses, net.~~

~~Table of Contents~~

Ambulatory Care Segment

Our Ambulatory Care segment is comprised of USPI’s ~~ambulatory surgery centers~~ASCs and surgical hospitals. USPI operates its surgical facilities in partnership with local physicians and, in many of these facilities, a health system partner. We hold an ownership interest in each facility, with each being operated through a separate legal entity in most cases. USPI operates facilities on a day‑to‑day basis through management services contracts. Our sources of earnings from each facility consist of:

•management and administrative services revenues, computed as a percentage of each facility’s net revenues (often net of implicit price concessions); and

•our share of each facility’s net income (loss), which is computed by multiplying the facility’s net income (loss) times the percentage of each facility’s equity interests owned by USPI.

Our role as an owner and day‑to‑day manager provides us with significant influence over the operations of each facility. For many of the facilities our Ambulatory Care segment operates ~~(110~~(165 of ~~342~~434 facilities at ~~September~~June 30, ~~2021)~~2022), this influence does not represent control of the facility, so we account for our investment in the facility under the equity method for an unconsolidated affiliate. USPI controls ~~232~~269 of the facilities our Ambulatory Care segment operates, and we account for these investments as consolidated subsidiaries. Our net earnings from a facility are the same under either method, but the classification of those earnings differs. For consolidated subsidiaries, our financial statements reflect 100% of the revenues and expenses of the subsidiaries, after the elimination of intercompany amounts. The net profit attributable to owners other than USPI is classified within ~~“net~~net income available to noncontrolling interests.”

For unconsolidated affiliates, our statements of operations reflect our earnings in two line items:

•equity in earnings of unconsolidated affiliates—our share of the net income (loss) of each facility, which is based on the facility’s net income (loss) and the percentage of the facility’s outstanding equity interests owned by USPI; and

•management and administrative services revenues, which is included in our net operating revenues—income we earn in exchange for managing the day‑to‑day operations of each facility, usually quantified as a percentage of each facility’s net revenues less implicit price concessions.

Our Ambulatory Care segment operating income is driven by the performance of all facilities USPI operates and by USPI’s ownership interests in those facilities, but our individual revenue and expense line items contain only consolidated businesses, which represent ~~68%~~62% of those facilities. This translates to trends in consolidated operating income that often do not correspond with changes in consolidated revenues and expenses, which is why we disclose certain statistical and financial data on a pro forma systemwide basis that includes both consolidated and unconsolidated (equity method) facilities.

Table of Contents

Results of Operations

The following table summarizes certain statement of operations ~~items for the periods indicated:~~items:


		Three Months Ended September 30,				Increase (Decrease)				Nine Months Ended September 30,								Increase (Decrease)				Three Months Ended June 30,				Increase (Decrease)				Six Months Ended June 30,						Increase (Decrease)
Ambulatory Care Results of Operations		2021		2020				2021				2020
																						2022		2021					Increase (Decrease)			2022			2021				Increase (Decrease)
Net operating revenues	Net operating revenues	$	666	$	565			17.9	%			$	1,976			$	1,423				38.9	%	Net operating revenues	$	771	$	664						$	1,509		$	1,310
Grant income	Grant income	$	1	$	(9)	111.1	%			$	23			$	28			(17.9)	%	Grant income		$	2	$	15	(86.7)		%		$	4		$	22		(81.8)		%
Equity in earnings of unconsolidated affiliates	Equity in earnings of unconsolidated affiliates	$	43	$	41	4.9	%			$	130			$	102			27.5	%	Equity in earnings of unconsolidated affiliates		$	52	$	49	6.1		%		$	94		$	87		8.0		%
Salaries, wages and benefits	Salaries, wages and benefits	$	169	$	157	7.6	%			$	512			$	438			16.9	%	Salaries, wages and benefits		$	201	$	169	18.9		%		$	395		$	343		15.2		%
Supplies	Supplies	$	170	$	128	32.8	%			$	496			$	319			55.5	%	Supplies		$	205	$	169	21.3		%		$	406		$	326		24.5		%
Other operating expenses, net	Other operating expenses, net	$	97	$	97	—	%			$	295			$	258			14.3	%	Other operating expenses, net		$	100	$	95	5.3		%		$	205		$	198		3.5		%

Revenues

~~Our~~ Ambulatory Care net operating revenues increased by ~~$101~~$107 million, or ~~17.9%~~16.1%, during the three months ended ~~September~~June 30, ~~2021~~2022 compared to the same period in ~~2020.~~2021. The change was driven by an increase from acquisitions of ~~$124~~$83 million, as well as an increase in same‑facility net operating revenues of ~~$27~~$32 million due primarily to negotiated commercial rate increases. These increases were partially offset by a decrease of $8 million due primarily to the sale of the Ambulatory Care segment’s urgent care centers to a third party in April 2021. Our Ambulatory Care segment also recognized grant income from federal grants totaling $2 million and $15 million during the three months ended June 30, 2022 and 2021, respectively, which is not included in net operating revenues.

Ambulatory Care net operating revenues increased by $199 million, or 15.2%, during the six months ended June 30, 2022 compared to the same period in 2021. The change was driven by an increase from acquisitions of $174 million, as well as an increase in same‑facility net operating revenues of $84 million due primarily to higher surgical patient volumes ~~and acuity, incremental revenue from new service lines~~ and negotiated commercial rate increases. These increases were partially offset by a decrease of ~~$50~~$59 million due primarily to the aforementioned sale of ~~our urgent care centers and the transfer~~

~~Table of Contents~~

of imaging centers to the Hospital Operations segment. Our Ambulatory Care segment also recognized net grant income from federal grants totaling $1 million and $(9) million during the three months ended September 30, 2021 and 2020, respectively, which is not included in net operating revenues. During the 2020 period, we recognized a reduction of grant income to comply with revised grant guidelines HHS published in September 2020.

Our Ambulatory Care net operating revenues increased by $553 million, or 38.9%, during the nine months ended September 30, 2021 compared to the same period in 2020. The change was driven by an increase from acquisitions of $365 million, as well as an increase in same‑facility net operating revenues of $271 million due primarily to higher surgical patient volumes and acuity, incremental revenue from new service lines and negotiated commercial rate increases. These increases were partially offset by a decrease of $83 million due primarily to the sale of our urgent care centers and the transfer of imaging centers to the Hospital Operations segment. Our Ambulatory Care segment also recognized grant income from federal grants totaling ~~$23~~$4 million and ~~$28~~$22 million during the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 and ~~2020,~~2021, respectively, which is not included in net operating revenues.

Salaries, Wages and Benefits

Salaries, wages and benefits expense increased by ~~$12~~$32 million, or ~~7.6%~~18.9%, during the three months ended ~~September~~June 30, ~~2021~~2022 compared to the same period in ~~2020.~~2021. Salaries, wages and benefits expense was impacted by an increase from acquisitions of ~~$22~~$27 million, as well as an increase in same‑facility salaries, wages and benefits expense of ~~$13~~$10 million due primarily to higher surgical patient volumes. These increases were partially offset by a decrease of $5 million due primarily to the aforementioned sale of urgent care centers. Salaries, wages and benefits expense included $3 million of stock‑based compensation in each of the three‑month periods ended June 30, 2022 and 2021.

Salaries, wages and benefits expense increased by $52 million, or 15.2%, during the six months ended June 30, 2022 compared to the same period in 2021. Salaries, wages and benefits expense was impacted by an increase from acquisitions of $53 million and an increase in same‑facility salaries, wages and benefits expense of $27 million due primarily to higher surgical patient volumes, partially offset by a decrease of ~~$23~~$28 million due ~~primarily~~ to the aforementioned sale of ~~our~~ urgent care centers and the transfer of imaging centers to the Hospital Operations segment. Salaries, wages and benefits expense ~~for three months ended September 30, 2021 and 2020~~ included $6 million of stock‑based compensation expense in each of ~~$3 million~~the six‑month periods ended June 30, 2022 and ~~$4 million, respectively.~~

Salaries, wages and benefits expense increased by $74 million, or 16.9%, during the nine months ended September 30, 2021 compared to the same period in 2020. Salaries, wages and benefits expense was impacted by an increase from acquisitions of $63 million, an increase in same‑facility salaries, wages and benefits expense of $44 million due primarily to higher surgical patient volumes, partially offset by a decrease of $33 million due to the sale of our urgent care centers, the transfer of imaging centers to the Hospital Operations segment and the deconsolidation of a facility. Salaries, wages and benefits expense for nine months ended September 30, 2021 and 2020 included stock‑based compensation expense of $9 million and $14 million, respectively.2021.

Supplies

Supplies expense increased by ~~$42~~$36 million, or ~~32.8%~~21.3%, during the three months ended ~~September~~June 30, ~~2021~~2022 compared to the same period in ~~2020.~~2021. The change was driven by an increase from acquisitions of ~~$39~~$31 million, as well as an increase in same‑facility supplies expense of $5 million due primarily to additional costs driven by the higher level of patient acuity and higher pricing of certain supplies as a result of the COVID‑19 pandemic.

Supplies expense increased by $80 million, or 24.5%, during the six months ended June 30, 2022 compared to the same period in 2021. The change was driven by an increase from acquisitions of $63 million, as well as an increase in same‑facility supplies expense of $20 million due primarily to an increase in surgical cases at our consolidated centers, ~~higher~~additional costs driven by the higher level of patient acuity, and higher pricing of certain supplies as a result of the COVID‑19 pandemic, partially offset by a decrease of $3 million due to the aforementioned sale of urgent care centers and the transfer of imaging centers to the Hospital Operations segment.

Table of Contents

Other Operating Expenses, Net

Other operating expenses increased by $5 million, or 5.3%, during the three months ended June 30, 2022 compared to the same period in 2021. The change was driven by an increase from acquisitions of $8 million, partially offset by a decrease in same‑facility other operating expenses of $1 million and a decrease of $2 million due to the sale of ~~our~~the Ambulatory Care segment’s urgent care centers.

Other operating expenses increased by $7 million, or 3.5%, during the six months ended June 30, 2022 compared to the same period in 2021. The change was driven by an increase from acquisitions of $20 million and an increase in same‑facility other operating expenses of $4 million, partially offset by a decrease of $17 million due to the aforementioned sale of urgent care centers and the transfer of imaging centers to the Hospital Operations segment.

Supplies expense increased by $177 million, or 55.5%, during the nine months ended September 30, 2021 compared to the same period in 2020. The change was driven by an increase from acquisitions of $113 million, as well as an increase in same‑facility supplies expense of $70 million due primarily to an increase in surgical cases at our consolidated centers, higher costs driven by the higher level of patient acuity, and higher pricing of certain supplies as a result of the COVID‑19 pandemic, partially offset by a decrease of $6 million due to the sale of our urgent care centers, the transfer of imaging centers to the Hospital Operations segment and the deconsolidation of a facility.

~~Other Operating Expenses, Net~~

Other operating expenses during the three months ended September 30, 2021 were consistent with the same period in 2020. The expense included an increase from acquisitions of $14 million, offset by a decrease of $14 million due to the sale of our urgent care centers and the transfer of imaging centers to the Hospital Operations segment.

Other operating expenses increased by $37 million, or 14.3%, during the nine months ended September 30, 2021 compared to the same period in 2020. The change was driven by an increase from acquisitions of $40 million, as well as an increase in same‑facility other operating expenses of $21 million, partially offset by a decrease of $24 million due to the sale of our urgent care centers and the transfer of imaging centers to the Hospital Operations segment.

~~Table of Contents~~

Facility Growth

The following table summarizes the year‑over‑year changes in our same‑facility revenue ~~year‑over‑year~~and cases on a pro forma systemwide basis, which includes both consolidated and unconsolidated (equity method) facilities. While we do not record the revenues of unconsolidated facilities, we believe this information is important in understanding the financial performance of our Ambulatory Care segment because these revenues are the basis for calculating our management services revenues and, together with the expenses of our unconsolidated facilities, are the basis for our equity in earnings of unconsolidated affiliates.


Ambulatory Care Facility Growth	Ambulatory Care Facility Growth	Three Months Ended September 30, 2021	Nine Months Ended September 30, 2021	Ambulatory Care Facility Growth	Three Months Ended June 30, 2022		Six Months Ended June 30, 2022
Net revenues	Net revenues	4.2%	17.4%	Net revenues	2.8	%	5.8	%
Cases	Cases	6.8%	20.4%	Cases	(0.9)	%	3.3	%
Net revenue per case	Net revenue per case	(2.5)%	(2.5)%	Net revenue per case	3.7	%	2.5	%

Joint Ventures with Health System Partners

USPI’s business model is to jointly own its facilities with local physicians and, in many of these facilities, a not‑for‑profit health system partner. Accordingly, as of ~~September~~June 30, ~~2021,~~2022, the majority of facilities in our Ambulatory Care segment are operated in this model.

The table below summarizes the amounts we paid to acquire various ownership interests in ambulatory care facilities:


	Six Months Ended June 30,				Increase (Decrease)
Type of Ownership Interests Acquired	2022		2021
Controlling interests	$	66	$	63	$	3
Noncontrolling interests	—		1		(1)
Equity investment in unconsolidated affiliates and consolidated facilities	14		6		8
Total	$	80	$	70	$	10

The table below provides information about the ownership structure of the facilities operated by our Ambulatory Care segment:


Ownership Structure of Ambulatory Care Facilities									Nine Months Ended SeptemberJune 30, ~~2021~~2022
~~Facilities:~~
~~With~~Owned with a health system partner									~~192~~201
~~Without~~Owned without a health system partner									~~150~~233
Total ~~facilities operated~~									~~342~~434

~~Change from December 31, 2020:~~

The table below reflects the change in the number of facilities operated by our Ambulatory Care segment since December 31, 2021:


									Six Months Ended June 30, 2022






Acquisitions									87
De novo									36
Dispositions/Mergers									~~(65)~~(2)
Total ~~decrease~~increase in number of facilities operated									~~(54)~~11

Table of Contents

During the ~~nine~~six months ended ~~September~~June 30, ~~2021,~~2022, we acquired controlling interests in ~~four ambulatory surgery centers~~three ASCs located in ~~Maryland, two in Georgia~~Florida and one in ~~Florida.~~each of Arizona and New Hampshire. We paid cash totaling ~~approximately $63~~$37 million for these ~~acquisitions. Other than the ambulatory surgery center located in Florida, all of the facilities acquired~~acquisitions, which are jointly owned with physicians. ~~The Florida facility is jointly owned with a health system partner and physicians.~~ During the ~~nine months ended September 30, 2021,~~same period in 2022, we ~~transferred all 24 imaging centers held~~acquired a noncontrolling interest in ~~our Ambulatory Care segment to our Hospital Operations segment. We also divested 40 urgent care centers during the nine months ended September 30, 2021.~~one ASC located in each of New Jersey and Texas.

During the nine months ended September 30, 2021, we acquired noncontrolling interests in one ambulatory surgery center in New Mexico. We paid cash totaling approximately $1 million for this acquisition, which is jointly owned with physicians and a hospital partner. Also during the ~~nine~~six months ended ~~September~~June 30, ~~2021,~~2022, we ~~sold a portion~~acquired controlling interests in nine previously unconsolidated ASCs (including seven SCD Centers), two of which are located in each of Florida and Pennsylvania and one in each of Indiana, Maryland, Michigan, Texas and Wisconsin. We paid an aggregate of $29 million to acquire controlling interests in these facilities. Following our ~~ownership in two ambulatory surgery centers in which we previously had~~acquisition of a controlling interest ~~to a health system for approximately $12 million, resulting~~ in the ~~deconsolidation of these facilities.~~Texas ASC, we contributed our ownership interest in it to our subsidiary Texas Health Ventures Group, L.L.C.

We also regularly engage in the purchase of equity interests with respect to our investments in unconsolidated affiliates and consolidated facilities that do not result in a change in control. These transactions are primarily the acquisitions of equity interests in ~~ambulatory surgery centers~~ASCs and the investment of additional cash in facilities that need capital for new acquisitions, new construction or other business growth opportunities. During the ~~nine~~six months ended ~~September~~June 30, ~~2021,~~2022, we invested approximately ~~$13~~$14 million in such transactions.

Conifer Segment

Revenues

Our Conifer segment generated net operating revenues of ~~$314~~$333 million and ~~$325~~$319 million during the three months ended ~~September~~June 30, ~~2021~~2022 and ~~2020,~~2021, respectively, a portion of which was eliminated in consolidation as described in Note 18 to the accompanying Condensed Consolidated Financial Statements. The ~~decline~~increase in Conifer’s net operating revenues ~~of $11~~was $14 million, or 3.4%, was primarily due to the revised terms in the Amended RCM Agreement, partially offset by client volume improvement in the 2021 period compared to the 2020 period, as well as new business expansion. Conifer4.4%. Conifer’s revenues from third‑party ~~customers,~~clients, which revenues are not eliminated in consolidation, increased $9$27 million, or ~~4.8%~~13.8%, for the three months

~~Table of Contents~~

ended ~~September~~June 30, ~~2021~~2022 compared to the same period in ~~2020.~~2021. The increase was primarily attributable to ~~the transition of the five Miami‑area hospitals and certain related operations sold in August 2021 to a third‑party customer~~contractual rate increases and new business expansion.

Our Conifer segment generated net operating revenues of ~~$943~~$657 million and ~~$962~~$629 million during the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 and ~~2020,~~2021, respectively. The ~~decline~~increase in Conifer’s net operating revenues ~~of $19~~was $28 million, or ~~2.0%, was primarily due to the same factors that impacted the three‑month period.~~4.5%. Conifer revenues from third‑party ~~customers,~~clients, which revenues are not eliminated in consolidation, increased $4$48 million, or ~~0.7%~~12.5%, for the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 compared to the same period in ~~2020.~~2021. The increase was primarily driven by contractual rate increases and new business expansion, as well as the transition of the five Miami‑area hospitals sold in August 2021 to a third‑party ~~customer and new business expansion, partially offset by expected client attrition.~~

The Amended RCM Agreement updates certain terms and conditions related to the revenue cycle management services Conifer provides to Tenet hospitals. Conifer’s contract with Tenet represented 38.4% of the net operating revenues Conifer recognized in the nine months ended September 30, 2021.client.

Salaries, Wages and Benefits

Salaries, wages and benefits expense for Conifer increased $1$3 million, or ~~0.6%~~1.8%, in the three months ended ~~September~~June 30, ~~2021~~2022 compared to the same period in ~~2020,~~2021, and ~~decreased $3~~increased $1 million, or ~~0.6%~~0.3%, in the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 compared to the same period in ~~2020.~~2021. The increase in both periods was primarily due to new business expansion, planned staffing increases and annual merit increases for certain of our employees. Salaries, wages and benefits expense included stock‑based compensation expense of $1 million ~~and zero~~ in each of the three‑month periods ended ~~September~~June 30, ~~2021~~2022 and ~~2020, respectively, and $3 million~~2021, and $2 million in each of the ~~nine‑~~six‑month periods ended ~~September~~June 30, ~~2021~~2022 and ~~2020, respectively.~~2021.

Other Operating Expenses, Net

Other operating expenses for Conifer ~~decreased $2~~increased $8 million, or ~~3.2%~~13.8%, in the three months ended ~~September~~June 30, ~~2021~~2022 compared to the same period in ~~2020.~~2021. Other operating expenses for Conifer ~~decreased $22~~increased $18 million, or ~~11.4%~~16.2%, in the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 compared to the same period in ~~2020.~~2021. The increase in each period was primarily due to higher vendor fees and recruiting expenses in 2022.

Table of Contents

Consolidated

Impairment and Restructuring Charges, and Acquisition-Related Costs

~~During the three months ended September 30, 2021, we recorded~~The following table presents information about our impairment and restructuring charges, and acquisition‑related ~~costs of $15 million, consisting of $14 million of~~costs:


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Consolidated:
Impairment charges	$	5	$	1	$	6	$	1
Restructuring charges	49		18		61		34
Acquisition-related costs	3		1		6		5
Total impairment and restructuring charges, and acquisition-related costs	$	57	$	20	$	73	$	40

By segment:
Hospital Operations	$	42	$	10	$	54	$	20
Ambulatory Care	5		4		8		8
Conifer	10		6		11		12
Total impairment and restructuring charges, and acquisition-related costs	$	57	$	20	$	73	$	40

During the three and six months ended June 30, 2022, restructuring ~~charges and $1 million of acquisition-related costs. Restructuring~~ charges consisted of $3$16 million and $21 million, respectively, of employee severance costs, $4$3 million and $5 million, respectively, related to the transition of various administrative functions to our GBC, $21 million and $22 million, respectively, related to contract and lease termination fees, and $9 million and $13 million, respectively, of other restructuring costs. Acquisition‑related costs consisted entirely of transaction costs during both periods.

During the three and six months ended June 30, 2021, restructuring charges consisted of $6 million and $10 million, respectively, of employee severance costs, $6 million and $12 million, respectively, related to the transition of various administrative functions to our GBC, and $7$6 million and $12 million, respectively, of other restructuring costs. Acquisition‑related costs consisted ~~of $1 million~~entirely of transaction ~~costs. Our impairment and restructuring charges and acquisition‑related~~ costs for the three months ended September 30, 2021 were comprised of $11 million from our Hospital Operations segment, $1 million from our Ambulatory Care segment and $3 million from our Conifer segment.

During the three months ended September 30, 2020, we recorded impairment and restructuring charges and acquisition‑related costs of $57 million, consisting of $52 million of restructuring charges, $3 million of impairment charges and $2 million acquisition‑related costs. Restructuring charges consisted of $16 million of employee severance costs, $15 million related to the transition of various administrative functions to our GBC, $14 million of contract and lease termination fees, and $7 million of other restructuring costs. Acquisition‑related costs consisted of $2 million of transaction costs. Our impairment and restructuring charges and acquisition‑related costs for the three months ended September 30, 2020 were comprised of $44 million from our Hospital Operations segment, $2 million from our Ambulatory Care segment and $11 million from our Conifer segment.

During the nine months ended September 30, 2021, we recorded impairment and restructuring charges and acquisition‑related costs of $55 million, consisting of $48 million of restructuring charges, $1 million of impairment charges and $6 million of acquisition-related costs. Restructuring charges consisted of $13 million of employee severance costs, $16 million related to the transition of various administrative functions to our GBC and $19 million of other restructuring costs. Acquisition‑related costs consisted of $6 million of transaction costs. Our impairment and restructuring charges and acquisition‑related costs for the nine months ended September 30, 2021 were comprised of $31 million from our Hospital Operations segment, $9 million from our Ambulatory Care segment and $15 million from our Conifer segment.

~~Table of Contents~~

$40 million related to the transition of various administrative functions to our GBC, $23 million of charges due to the termination of USPI’s previous management equity plan, $15 million of contract and lease termination fees, and $24 million of other restructuring costs. Acquisition‑related costs consisted of $3 million of transaction costs. Our impairment and restructuring charges and acquisition‑related costs for the nine months ended September 30, 2020 were comprised of $94 million from our Hospital Operations segment, $33 million from our Ambulatory Care segment and $39 million from our Conifer segment.during both periods.

Litigation and Investigation Costs

Litigation and investigation costs ~~for~~during the three months ended ~~September~~June 30, 2022 and 2021 ~~and 2020~~ were ~~$29~~$18 million and $9$22 million, ~~respectively. Litigation~~respectively, and ~~investigation costs for~~$38 million and $35 million during the ~~nine~~six months ended ~~September~~June 30, 2022 and 2021, ~~and 2020 were $64 million and $13 million,~~ respectively. ~~In all periods, these amounts are primarily related to costs associated with significant legal proceedings and governmental investigations.~~

~~Net Gains on Sales, Consolidation and Deconsolidation of Facilities~~

During the three months ended September 30, 2021, we recorded net gains on sales, consolidation and deconsolidation of facilities of approximately $412 million, primarily comprised of a gain of $409 million related to the sale of five Miami‑area hospitals and certain related operations in August 2021.

During the three months ended September 30, 2020, we recorded net gains on sales, consolidation and deconsolidation of facilities of approximately $1 million, primarily related to consolidation changes of certain USPI businesses due to ownership changes.

During the nine months ended September 30, 2021, we recorded net gains on sales, consolidation and deconsolidation of facilities of approximately $427 million, primarily comprised of a gain of $409 million related to the sale of five Miami‑area hospitals in August 2021, a gain of $14 million related to the sale of the majority of our urgent care centers in April 2021 and net gains of $4 million related to other activity.

During the nine months ended September 30, 2020, we recorded net gains on sales, consolidation and deconsolidation of facilities of approximately $4 million, primarily comprised of gains of $12 million related to consolidation changes of certain USPI businesses due to ownership changes, partially offset by a loss of $5 million related to post‑closing adjustments on the 2019 sale of three of our hospitals in the Chicago area and a loss of $3 million related to post‑closing adjustments on the 2018 sale of MacNeal Hospital.

Interest Expense

Interest expense for the three and six months ended ~~September~~June 30, ~~2021~~2022 was ~~$227~~$222 million and $449 million, respectively, compared to ~~$263~~$235 million and $475 million for the same ~~period~~periods in ~~2020. Interest expense for the nine months ended September 30, 2021 was $702 million compared to $761 million for the same period in 2020.~~2021.

Loss from Early Extinguishment of Debt

~~Loss~~During the three and six months ended June 30, 2022, we incurred aggregate losses from early extinguishment of debt ~~was $20~~of $66 million and ~~$74~~$109 million, ~~for the three and nine months ended September 30, 2021,~~ respectively. ~~The loss in the three months ended September 30, 2021~~These losses related to the redemption of our 2024 Senior Secured First Lien Notes in advance of their maturity date. The loss in the nine‑month period included the loss from the redemption of our 2024 Senior Secured First Lien Notes, as well as losses incurred from the redemption of our 5.125%7.500% senior secured ~~second~~first lien ~~notes due 2025 (the “2025 Senior Secured Second Lien Notes”) in June 2021 and the retirement of our 7.000% senior unsecured~~ notes due 2025 (“2025 Senior ~~Unsecured~~Secured First Lien Notes”) in ~~March 2021, both~~February 2022, open market purchases of our 2023 Senior Unsecured Notes during the six months ended June 30, 2022 and the redemption in full of the 2023 Senior Unsecured Notes in June 2022, in all cases in advance of ~~their respective~~the notes’ maturity ~~dates. See Note 6 to the accompanying Condensed Consolidated Financial Statements for additional information.~~date.

Loss from early extinguishment of debt was ~~$312~~$31 million and ~~$316~~$54 million for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, respectively. ~~The loss in the three‑month period~~These losses related to ~~the redemption~~our retirement of ~~$2.665~~approximately $1.888 billion aggregate principal amount ~~then outstanding~~of certain of our ~~8.125%~~ senior unsecured and senior secured first lien notes ~~due 2022 (“2022 Senior Notes”)~~ in advance of their maturity ~~date in~~dates during the ~~three~~six months ended ~~September~~June 30, ~~2020. The loss in~~2021.

In all of the ~~nine months ended September 30, 2020 included~~2022 and 2021 periods, the ~~loss~~losses from early extinguishment of debt primarily related to the ~~redemption~~difference between the purchase prices and the par value of ~~our 2022 Senior Notes,~~the notes, as well as ~~a loss~~the write‑off of $8 million related to the purchase of $135 million aggregate principal amount of the then outstanding 2022 Senior Notes in June 2020, partially offset by $4 million of gains on the extinguishment of mortgage notes.associated unamortized issuance costs.

Table of Contents

Income Tax Expense


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Tax expense at statutory federal rate of 21%	$	56	$	67	$	135	$	123
State income taxes, net of federal income tax benefit	11		14		25		26
Tax benefit attributable to noncontrolling interests	(28)		(28)		(57)		(53)
Nondeductible goodwill	1		7		1		7



Stock-based compensation tax benefit	(1)		(2)		(3)		(3)
Changes in valuation allowance	45		—		77		—

Other items	2		3		7		6
Income tax expense	$	86	$	61	$	185	$	106

Net Income Available to Noncontrolling Interests

Net income available to noncontrolling interests was ~~$129~~$141 million for the three months ended ~~September~~June 30, ~~2021~~2022 compared to ~~$90~~$138 million for the three months ended ~~September~~June 30, ~~2020.~~2021. Net income available to noncontrolling interests for the ~~2021~~2022 period was comprised of $9$114 million related to our Ambulatory Care segment, $8 million related to our Hospital Operations ~~segment, $101 million related to our Ambulatory Care~~ segment, and $19 million related to our Conifer segment. Of the portion related to our Ambulatory Care segment, $5 million related to the minority ~~interests~~interest Baylor held in ~~USPI.~~USPI until June 30, 2022.

Net income available to noncontrolling interests was ~~$392~~$281 million for the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 compared to ~~$237~~$263 million for the ~~nine~~six months ended ~~September~~June 30, ~~2020.~~2021. Net income available to noncontrolling interests for the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 was comprised of ~~$34~~$213 million related to our Ambulatory Care segment, $33 million related to our Hospital Operations segment ~~$306 million related to our Ambulatory Care segment~~ and ~~$52~~$35 million related to our Conifer segment. Of the portion related to our Ambulatory Care segment, ~~$14~~$9 million related to the minority ~~interests~~interest Baylor held in ~~USPI.~~USPI until June 30, 2022.

ADDITIONAL SUPPLEMENTAL NON-GAAP DISCLOSURES

The financial information provided throughout this report, including our Condensed Consolidated Financial Statements and the notes thereto, has been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). However, we use certain non‑GAAP financial measures defined below in communications with investors, analysts, rating agencies, banks and others to assist such parties in understanding the impact of various items on our financial statements, some of which are recurring or involve cash payments. We use this information in our analysis of the performance of our business, excluding items we do not consider relevant to the performance of our continuing operations. In addition, we use these measures to define certain performance targets under our compensation programs.

“Adjusted EBITDA” is a non‑GAAP measure we define as net income available (loss attributable) to Tenet Healthcare Corporation common shareholders before (1) the cumulative effect of changes in accounting principle, (2) net loss attributable (income available) to noncontrolling interests, (3) income (loss) from discontinued operations, net of tax, (4) income tax benefit (expense), (5) gain (loss) from early extinguishment of debt, (6) other non‑operating income (expense), net, (7) interest expense, (8) litigation and investigation (costs) benefit, net of insurance recoveries, (9) net gains (losses) on sales, consolidation and deconsolidation of facilities, (10) impairment and restructuring charges and acquisition‑related costs, (11) depreciation and amortization, and (12) income (loss) from divested and closed businesses (i.e., health plan businesses). Litigation and investigation costs do not include ordinary course of business malpractice and other litigation and related expense.

We believe the foregoing non‑GAAP measure is useful to investors and analysts because it presents additional information about our financial performance. Investors, analysts, company management and our board of directors utilize this

Table of Contents

non‑GAAP measure, in addition to GAAP measures, to track our financial and operating performance and compare that

~~Table of Contents~~

performance to peer companies, which utilize similar non‑GAAP measures in their presentations. The human resources committee of our board of directors also uses certain non‑GAAP measures to evaluate management’s performance for the purpose of determining incentive compensation. We believe that Adjusted EBITDA is a useful measure, in part, because certain investors and analysts use both historical and projected Adjusted EBITDA, in addition to GAAP and other non‑GAAP measures, as factors in determining the estimated fair value of shares of our common stock. Company management also regularly reviews the Adjusted EBITDA performance for each operating segment. We do not use Adjusted EBITDA to measure liquidity, but instead to measure operating performance. The non‑GAAP Adjusted EBITDA measure we utilize may not be comparable to similarly titled measures reported by other companies. Because this measure excludes many items that are included in our financial statements, it does not provide a complete measure of our operating performance. Accordingly, investors are encouraged to use GAAP measures when evaluating our financial performance.

The following table ~~shows~~presents the reconciliation of Adjusted EBITDA to net income available to Tenet Healthcare Corporation common shareholders (the most comparable GAAP term) for the three and ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 and ~~2020:~~2021:


		Three Months Ended September 30,						Nine Months Ended September 30,							Three Months Ended June 30,						Six Months Ended June 30,
		2021			2020			2021			2020				2022			2021			2022			2021
Net income available (loss attributable) to Tenet Healthcare Corporation common shareholders		$	449		$	(196)		$	665		$	(15)
Net income available to Tenet Healthcare Corporation common shareholders														Net income available to Tenet Healthcare Corporation common shareholders	$	38		$	119		$	178		$	216
Less: Net income available to noncontrolling interests	Less: Net income available to noncontrolling interests	(129)			(90)			(392)			(237)			Less: Net income available to noncontrolling interests	(141)			(138)			(281)			(263)
Income from discontinued operations, net of tax		1			1			—			—
Income (loss) from continuing operations		577			(107)			1,057			222
Income tax benefit (expense)		(197)			197			(303)			227
Income (loss) from discontinued operations, net of tax														Income (loss) from discontinued operations, net of tax	—			(1)			1			(1)
Income from continuing operations														Income from continuing operations	179			258			458			480
Income tax expense														Income tax expense	(86)			(61)			(185)			(106)
Loss from early extinguishment of debt	Loss from early extinguishment of debt	(20)			(312)			(74)			(316)			Loss from early extinguishment of debt	(66)			(31)			(109)			(54)
Other non-operating income, net		7			—			16			3
Other non-operating income (expense), net														Other non-operating income (expense), net	—			(1)			—			9
Interest expense	Interest expense	(227)			(263)			(702)			(761)			Interest expense	(222)			(235)			(449)			(475)
Operating income	Operating income	1,014			271			2,120			1,069			Operating income	553			586			1,201			1,106
Litigation and investigation costs	Litigation and investigation costs	(29)			(9)			(64)			(13)			Litigation and investigation costs	(18)			(22)			(38)			(35)
Net gains on sales, consolidation and deconsolidation of facilities	Net gains on sales, consolidation and deconsolidation of facilities	412			1			427			4			Net gains on sales, consolidation and deconsolidation of facilities	1			15			—			15
Impairment and restructuring charges, and acquisition-related costs	Impairment and restructuring charges, and acquisition-related costs	(15)			(57)			(55)			(166)			Impairment and restructuring charges, and acquisition-related costs	(57)			(20)			(73)			(40)
Depreciation and amortization	Depreciation and amortization	(209)			(215)			(654)			(624)			Depreciation and amortization	(216)			(221)			(419)			(445)

Adjusted EBITDA	Adjusted EBITDA	$	855		$	551		$	2,466		$	1,868		Adjusted EBITDA	$	843		$	834		$	1,731		$	1,611

Net operating revenues	Net operating revenues	$	4,894		$	4,557		$	14,629		$	12,725		Net operating revenues	$	4,638		$	4,954		$	9,383		$	9,735

Net income available (loss attributable) to Tenet Healthcare Corporation common shareholders as a % of net operating revenues		9.2		%	(4.3)		%	4.5		%	(0.1)		%
Net income available to Tenet Healthcare Corporation common shareholders as a % of net operating revenues														Net income available to Tenet Healthcare Corporation common shareholders as a % of net operating revenues	0.8		%	2.4		%	1.9		%	2.2		%

Adjusted EBITDA as % of net operating revenues (Adjusted EBITDA margin)	Adjusted EBITDA as % of net operating revenues (Adjusted EBITDA margin)	17.5		%	12.1		%	16.9		%	14.7		%	Adjusted EBITDA as % of net operating revenues (Adjusted EBITDA margin)	18.2		%	16.8		%	18.4		%	16.5		%

LIQUIDITY AND CAPITAL RESOURCES

CASH REQUIREMENTS

There have been no material changes to our obligations to make future cash payments under ~~contracts,~~scheduled contractual obligations, such as debt and lease agreements, and under contingent commitments, such as standby letters of credit and minimum revenue guarantees, as disclosed in our Annual Report, except for the matters set forth below under “Other Contractual Obligations” and the additional lease obligations and the long‑term debt transactions disclosed in Notes 1 and 6, respectively, to our accompanying Condensed Consolidated Financial Statements.

Long-Term Debt

At ~~September~~June 30, ~~2021,~~2022, using the last 12 months of Adjusted EBITDA, our ratio of total long‑term debt, net of cash and cash equivalent balances, to Adjusted EBITDA was ~~3.16x,~~3.81x, or ~~3.47x~~3.92x if adjusted to include outstanding obligations arising from cash advances received from Medicare pursuant to COVID‑19 ~~stimulus~~relief legislation. We anticipate this ratio will fluctuate from quarter to quarter based on earnings performance and other factors, including the use of our ~~revolving credit facility~~Credit Agreement as a source of liquidity and acquisitions that involve the assumption of long‑term debt. We seek to manage this ratio and increase the efficiency of our balance sheet by following our business plan and managing our cost structure, including through possible asset divestitures, and

Table of Contents

through other changes in our capital structure. As part of our long‑term objective to manage our capital structure, we ~~may seek~~continue to evaluate opportunities to retire, purchase, redeem orand refinance ~~some of our~~ outstanding debt ~~or issue equity or convertible securities, in each case~~ subject to prevailing market conditions, our liquidity requirements, operating results, contractual

~~Table of Contents~~

restrictions and other factors. In the year ending December 31, 2023 and beyond, we may also consider share repurchases depending on market conditions and other investment opportunities. Our ability to achieve our leverage and capital structure objectives is subject to numerous risks and uncertainties, many of which are described in the Forward‑Looking Statements and Risk Factors sections in Part I of our Annual Report and the Risk Factors section in Part II of our Q1’22 Report.

Interest payments, net of capitalized interest, were $416 million and $486 million in the six months ended June 30, 2022 and 2021, respectively.

Other Contractual Obligations

Baylor Put/Call Agreement—As previously discussed in our Annual Report, our put/call agreement (the “Baylor Put/Call Agreement”) with Baylor contained put and call options with respect to the 5% ownership interest Baylor held in USPI. The Baylor Put/Call Agreement gave Baylor the option to annually put up to one-third of its total shares in USPI (the “Baylor Shares”) over a period of three years beginning in 2021. We had the right to call the difference between the number of shares Baylor put each year and the maximum number of shares it could have put.

In each of 2021 and 2022, we notified Baylor of our intention to exercise our call option to purchase 33.3% of the Baylor Shares for that year (66.6% in total). In June 2022, we entered into an agreement with Baylor (the “Share Purchase Agreement”) to complete the purchase of the Baylor Shares we called in 2021 and 2022 and to accelerate the acquisition of the remaining Baylor Shares eligible to be put/called in 2023. Under the terms of the Share Purchase Agreement, we agreed to pay Baylor $406 million to buy its entire 5% voting ownership interest in USPI. We paid $11 million upon execution of the Share Purchase Agreement and will make 35 additional non-interest bearing monthly payments of approximately $11 million beginning in August 2022. At June 30, 2022, we had liabilities of $124 million recorded in other current liabilities and $253 million in other long-term liabilities in the accompanying Condensed Consolidated Balance Sheet for the purchase of these shares.

Investment in the SCD Centers—USPI continues to make offers in an ongoing process to acquire a portion of the equity interests in certain of the SCD Centers from the physician owners for consideration of up to approximately $250 million. During the six months ended June 30, 2022, we made aggregate payments of $25 million to acquire controlling interests in seven SCD Centers. We cannot reasonably predict how many additional physician owners will accept our offers to acquire a portion of their equity, nor the timing or amount of any remaining payments. We expect to fund these payments using cash on hand.

We have no off-balance sheet arrangements that may have a current or future material effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources, except for $230 million of standby letters of credit outstanding and guarantees at June 30, 2022.

Other Cash Requirements

Our capital expenditures primarily relate to the expansion and renovation of existing facilities (including amounts to comply with applicable laws and regulations), equipment and information systems additions and replacements, introduction of new medical technologies, design and construction of new buildings or hospitals, and various other capital improvements, as well as commitments to make capital expenditures in connection with acquisitions of businesses. Capital expenditures were ~~$354~~$307 million and ~~$374~~$243 million in the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 and ~~2020,~~2021, respectively. We anticipate that our capital expenditures for continuing operations for the year ending December 31, ~~2021~~2022 will total approximately ~~$675~~$725 million to ~~$725~~$775 million, including ~~$93~~$95 million that was accrued as a liability at December 31, ~~2020.~~

~~Interest payments, net of capitalized interest, were $664 million and $757 million in the nine months ended September 30, 2021 and 2020, respectively.~~2021.

Income tax payments, net of tax refunds, were ~~$54~~$140 million in the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 compared to ~~$10~~$34 million in the ~~nine~~six months ended ~~September~~June 30, ~~2020.~~2021.

SOURCES AND USES OF CASH

Our liquidity for the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 was primarily derived from net cash provided by operating activities and cash on ~~hand and borrowings under our revolving credit facility.~~hand. During the ~~nine~~six months ended ~~September~~June 30, ~~2021,~~2022, we also received supplemental funds from federal ~~state~~ and ~~local~~state grants provided under COVID‑19 relief legislation. We had ~~$2.292~~$1.351 billion of cash and cash equivalents on hand at ~~September~~June 30, ~~2021~~2022 to fund our operations and capital expenditures, and our borrowing availability under our credit facility was ~~$1.802~~$1.500 billion based on our borrowing base calculation at ~~September~~June 30, ~~2021.~~2022.

Table of Contents

When operating under normal conditions, our primary source of operating cash is the collection of accounts receivable. As such, our operating cash flow is impacted by levels of cash collections, as well as levels of implicit price concessions, due to shifts in payer mix and other factors. Our Credit Agreement provides additional liquidity to manage fluctuations in operating cash caused by these factors.

Net cash provided by operating activities was ~~$1.211 billion~~$347 million in the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 compared to ~~$2.961 billion~~$779 million in the ~~nine~~six months ended ~~September~~June 30, ~~2020.~~2021. Key factors contributing to the change between the ~~2021~~2022 and ~~2020~~2021 periods include the following:

•~~An increase~~$475 million of Medicare advances recouped in operating income before net losses on sales, consolidation and deconsolidation of facilities; litigation and investigation costs; impairment and restructuring charges and acquisition-related costs; depreciation and amortization; and income recognized from government relief packages of $986 million;the six months ended June 30, 2022 compared to $152 million recouped during the same period in 2021;

•~~$38~~104 million of cash received from ~~federal, state and local~~ grants in the ~~2021 period~~six months ended June 30, 2022 compared to ~~$848~~$36 million received in the ~~2020 period;~~six months ended June 30, 2021;

•Lower interest payments of ~~$93~~$70 million in ~~the 2021~~2022 period;

•~~A $178 million deferral of our payroll tax match in the 2020 period pursuant to COVID‑19 stimulus legislation;~~

•Higher income tax payments of ~~$44~~$106 million in the ~~2021~~2022 period;

•~~A decrease~~Decreased cash receipts of ~~$136~~$56 million related to supplemental Medicaid programs in ~~payments on reserves for restructuring charges, acquisition‑related costs,~~California and ~~litigation costs and settlements;~~Texas; and

•The timing of other working capital items.

~~Net~~We used net cash ~~provided by~~of $200 million and $195 million in investing activities ~~was $802 million for~~during the ~~nine~~six months ended ~~September~~June 30, 2022 and 2021, ~~compared~~respectively. This $5 million additional use of cash between the 2022 and 2021 periods was attributable to ~~net~~an increase in capital expenditures of $64 million and a $22 million increase in cash used for purchases of ~~$406 million for the nine months ended September 30, 2020. The 2021 activity included~~marketable securities. These changes were partially offset by an increase in proceeds from the sale of facilities and other assets of ~~$1.222 billion compared to the 2020 period,~~$85 million, primarily related to the sale of ~~the majority of our urgent care centers in April 2021 and the sale of five Miami‑area hospitals and certain related operations~~

~~Table of Contents~~

~~in August 2021. Additionally, capital expenditures decreased $20 million~~several medical office buildings in the ~~nine months ended September 30, 2021 compared to the same period in 2020. These inflows were partially offset by a decrease in proceeds from sales~~first quarter of ~~marketable securities, long‑term investments and other assets from $44 million in the nine months ended September 30, 2020, to $18 million in the nine months ended September 30, 2021.~~2022.

Net cash used in financing activities was ~~$2.167~~$1.160 billion for the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 compared to ~~net cash provided by financing activities of $483~~$836 million for the ~~nine~~six months ended ~~September~~June 30, ~~2020. The cash~~2021. Financing activity induring the ~~2021 period~~six months ended June 30, 2022 included ~~total~~ payments of ~~$3.183~~$2.744 billion to early retire ~~approximately $2.988~~our long-term debt, including $1.933 billion paid to redeem all $1.872 billion of aggregate principal amount ~~of certain~~outstanding on our 2023 Senior Unsecured Notes and $730 million paid to redeem all $700 million aggregate principal amount outstanding of our ~~senior unsecured and senior secured notes. Additionally,~~2025 Senior Secured First Lien Notes. In addition, distributions to noncontrolling ~~interests~~interest holders increased $98 million, primarily due to the distribution of $61 million for minority interest holders’ portion of the proceeds received from ~~$184 million in~~ the ~~nine months ended September 30, 2020 to $316 million in the nine months ended September 30, 2021. During the nine‑month period~~sale of ~~2021, we also repaid $26 million~~several medical office buildings. These factors were partially offset by proceeds of Medicare advance payments received by our Ambulatory Care segment’s unconsolidated affiliates compared to $150 million of Medicare advances and stimulus grants received by our unconsolidated affiliates in the 2020 period. In the nine months ended September 30, 2021, we also received proceeds$2.000 billion from the issuance of ~~$1.400 billion aggregate principal amount of~~ our ~~2029~~2030 Senior Secured First Lien Notes ~~partially offset by debt issuance costs of $15 million. Net cash provided by financing activities in~~during the ~~nine~~six months ended ~~September~~June 30, 2020 included proceeds from the issuance of $2.500 billion aggregate principal amount of our 6.125% senior notes due 2028, $700 million aggregate principal amount of our 7.500% senior secured first lien notes due 2025 and $600 million aggregate principal amount of our 4.625% senior secured first lien notes due 2028. These inflows were partially offset by $3.099 billion of payments for the redemption of our 2022 Senior Notes and distributions paid to noncontrolling interests of $184 million in the 2020 period.2022.

We record our equity securities and our debt securities classified as available‑for‑sale at fair market value. The majority of our investments are valued based on quoted market prices or other observable inputs. We have no investments that we expect will be negatively affected by the current economic conditions such that they will materially impact our financial condition, results of operations or cash flows.

DEBT INSTRUMENTS, GUARANTEES AND RELATED COVENANTS

Credit Agreement—~~We have a senior secured revolving credit facility that, at September~~At June 30, ~~2021,~~2022, our Credit Agreement provided for revolving loans in an aggregate principal amount of up to ~~$1.900~~$1.500 billion with a $200 million subfacility for standby letters of credit. In March 2022, we amended the revolving credit facility to, among other things, (i) decrease the previous maximum aggregate revolving credit commitments from $1.900 billion to $1.500 billion, subject to borrowing availability, (ii) extend the scheduled maturity date from September 2024 to March 2027, and (iii) replace the London Interbank Offered Rate (LIBOR) with the Term Secured Overnight Financing Rate (“SOFR”) and Daily Simple SOFR (each, as defined in the Credit Agreement) as the reference interest rate. At ~~September~~June 30, ~~2021,~~2022, we had no cash borrowings outstanding under the ~~revolving credit facility,~~Credit Agreement, and we had less than $1 million of standby letters of credit outstanding. Based on our eligible receivables, ~~$1.802~~$1.500 billion was available for borrowing under the ~~revolving credit facility~~Credit Agreement at ~~September~~June 30, ~~2021. At September 30, 2021, we~~2022. We were in compliance with all covenants and conditions in our ~~senior secured revolving credit facility.~~Credit Agreement at June 30, 2022.

On April 24, 2020, we amended our credit agreement (as amended to date, the “Credit Agreement”) to, among other things, (i) increase the aggregate revolving credit commitments from $1.500 billion to $1.900 billion (the “Increased Commitments”), subject to borrowing availability, and (ii) increase the advance rate and raise limits on certain eligible accounts receivable in the calculation

Table of the borrowing base, in each case, for an incremental period of 364 days. In April 2021, we further amended the Credit Agreement to, among other things, extend the availability of the Increased Commitments through April 22, 2022 and reduce the interest rate margins. See Note 6 to the accompanying Condensed Consolidated Financial Statements for additional information about our Credit Agreement and related amendments.Contents

Letter of Credit Facility—~~In March 2020, we amended our~~We have a letter of credit facility (as amended to date, the “LC Facility”) that provides for the issuance, from time to ~~extend the~~time, of standby and documentary letters of credit in an aggregate principal amount of up to $200 million. The scheduled maturity date of the LC Facility ~~from March 7, 2021 to~~is September 12, 2024 and to increase the aggregate principal amount of standby and documentary letters of credit that from time to time may be issued thereunder from $180 million to $200 million. On July 29, 2020, we further amended the2024. The LC Facility is subject to incrementally increase the maximum secured debt covenant from 4.25 to 1.00 on a quarterly basis up to 6.00 to 1.00 for the quarter ended March 31, 2021, at which point the maximum ratio began to step down incrementally on a quarterly basis through the quarter ending December 31, 2021. At September 30, 2021, thean effective maximum secured debt covenant ~~was 5.00~~of 4.25 to 1.00. Obligations under the LC Facility are guaranteed and secured by a first‑priority pledge of the capital stock and other ownership interests of certain of our wholly owned domestic hospital subsidiaries on an equal ranking basis with our senior secured first lien notes. At ~~September~~June 30, ~~2021,~~2022, we were in compliance with all covenants and conditions in the LC ~~Facility. At September 30, 2021,~~Facility, and we had ~~$139~~$127 million of standby letters of credit outstanding ~~under the LC Facility.~~thereunder.

Senior Unsecured Notes and Senior Secured Notes—On ~~September 10, 2021,~~June 15, 2022, we ~~redeemed approximately $1.100 billion of the then outstanding $1.870~~issued $2.000 billion aggregate principal amount of our ~~2024~~2030 Senior Secured First Lien Notes. We will pay interest on the 2030 Senior Secured First Lien Notes semi‑annually in arrears on June 15 and December 15 of each year, commencing on December 15, 2022. As further discussed below, we used a portion of the proceeds from the issuance of the 2030 Senior Secured First Lien Notes, after payment of fees and expenses, to finance the redemption of our 2023 Senior Unsecured Notes.

Through a series of open‑market transactions during the six months ended June 30, 2022, we repurchased $124 million aggregate principal amount outstanding of our 2023 Senior Unsecured Notes using cash on hand. Following the issuance of our 2030 Senior Secured First Lien Notes, we used a portion of the proceeds to redeem the then-remaining $1.748 billion aggregate principal outstanding of the 2023 Senior Unsecured Notes in advance of their maturity date. In total, we paid $1.933 billion during the six months ended June 30, 2022 to retire our 2023 Senior Unsecured Notes in full and recorded aggregate losses from early extinguishment of debt of $71 million, primarily related to the difference between the purchase prices and the par value of the notes, as well as the write‑off of associated unamortized issuance costs.

On February 23, 2022, we redeemed all $700 million aggregate principal amount outstanding of our 2025 Senior Secured First Lien Notes in advance of their maturity date. We paid ~~$1.113 billion~~$730 million from cash on hand to redeem the ~~notes, which was primarily funded with the proceeds from the sale of five Miami‑area hospitals and certain related operations in August 2021.~~notes. In connection with the redemption, we recorded a loss from

~~Table of Contents~~

early extinguishment of debt of ~~$20~~$38 million in the ~~three~~six months ended ~~September~~June 30, ~~2021,~~2022, primarily related to the difference between the purchase price and the par value of the notes, as well as the write‑off ~~of associated unamortized issuance costs.~~

On June 2, 2021, we issued $1.400 billion aggregate principal amount of our 2029 Senior Secured First Lien Notes. We will pay interest on these notes semi‑annually in arrears on June 1 and December 1 of each year, commencing on December 1, 2021. The proceeds from the sale of the 2029 Senior Secured First Lien Notes were used, after payment of fees and expenses, together with cash on hand, to finance the redemption of all $1.410 billion aggregate principal amount then outstanding of our 2025 Senior Secured Second Lien Notes in advance of their maturity date for approximately $1.428 billion. In connection with the redemption, we recorded a loss from early extinguishment of debt of approximately $31 million in the three months ended June 30, 2021, primarily related to the difference between the purchase price and the par value of the 2025 Senior Secured Second Lien Notes, as well as the write‑off of associated unamortized issuance costs.

In March 2021, we retired approximately $478 million aggregate principal amount of our 2025 Senior Unsecured Notes in advance of their maturity date. We paid approximately $495 million from cash on hand to retire the notes. In connection with the retirement, we recorded a loss from early extinguishment of debt of $23 million in the three months ended March 31, 2021, primarily related to the difference between the purchase price and the par value of the notes, as well as the write-off of associated unamortized issuance costs.

For additional information regarding our long-term debt, see Note 6 to the accompanying Condensed Consolidated Financial Statements and Note 8 to the Consolidated Financial Statements included in our Annual Report.

LIQUIDITY

~~Broad economic factors resulting from~~We continue to experience negative impacts of the COVID‑19 pandemic ~~including increased unemployment rates~~on our business in varying degrees. During the six months ended June 30, 2022, we were affected by a significant acceleration in COVID‑19 cases associated with the Omicron variant and ~~reduced consumer spending, are impacting our service mix, revenue mix~~subvariants. Future variants could similarly emerge and ~~patient volumes. Business closings and layoffs~~cause surges in COVID‑19 cases, which may adversely impact the local economies of areas we ~~operate have led to increases in the uninsured and underinsured populations and adversely affect demand for our services, as well as the ability of patients to pay for services as rendered.~~serve. Any increase in the amount of or deterioration in the collectability of patient accounts receivable could adversely affect our cash flows and results of operations. If general economic conditions ~~continue to~~ deteriorate or remain uncertain for an extended period of time, our liquidity and ability to repay our outstanding debt may be impacted.

~~Throughout the COVID‑19 pandemic, we~~We have taken, and we continue to take, various actions to increase our liquidity and mitigate the impact of reductions in our patient volumes and ~~operating revenues.~~changes in our service mix and revenue mix. These actions included the sale and redemption of various senior unsecured notes and senior secured notes, which eliminated any significant debt maturities until ~~June 2023~~July 2024 and will reduce our future annual cash interest expense payments. In ~~April 2021, we further amended our Credit Agreement to extend the availability of the Increased Commitments through April 22, 2022. In~~ addition, we have continued ~~to focus on cost‑reduction~~cost-efficiency measures, ~~and corporate efficiencies~~as well as necessary cost reductions, to substantially offset incremental costs, including temporary staffing and premium pay, as well as higher supply costs for PPE. We have also sought to compensate for the COVID‑19 pandemic’s disruption of our patient volumes and service mix by growing our services for which demand has been more resilient, including our higher‑acuity service ~~lines,~~lines. While the length of time that will be required for our patient volumes and ~~we expect~~mix to return to pre-pandemic levels is unknown, especially demand for ~~these~~lower‑acuity services, we believe demand for our higher‑acuity service lines will continue to ~~grow in the future.~~grow. We believe ~~all of~~ these actions, together with government relief packages, supported our ability to ~~the extent available to us, will help us to continue operating~~provide essential patient services during the initial uncertainty caused by the COVID‑19 ~~pandemic.~~pandemic and continue to do so.

From time to time, we expect to engage in additional capital markets, bank credit and other financing activities depending on our needs and financing alternatives available at that time. We believe our existing debt agreements provide flexibility for future secured or unsecured borrowings.

Our cash on hand fluctuates day‑to‑day throughout the year based on the timing and levels of routine cash receipts and disbursements, including our book overdrafts, and required cash disbursements, such as interest payments and income tax payments, as well as cash disbursements required to respond to the COVID‑19 pandemic. These fluctuations result in material intra-quarter net operating and investing uses of cash that have caused, and in the future may cause, us to use our Credit Agreement as a source of liquidity. We believe that existing cash and cash equivalents on hand, borrowing availability under

Table of Contents

our Credit Agreement and anticipated future cash provided by our operating activities ~~and possible additional government relief packages~~ should be adequate to meet our current cash needs. These sources of liquidity, in combination with any potential future debt incurrence, should also be adequate to finance planned capital expenditures, payments on the current portion of our long-term debt, payments to current and former joint venture partners, including those related to ~~put~~put/call arrangements and ~~call arrangements~~our Share Purchase Agreement with Baylor, and other presently known operating needs.

~~Table of Contents~~

Long-term liquidity for debt service and other purposes will be dependent on the amount of cash provided by operating activities and, subject to favorable market and other conditions, the successful completion of future borrowings and potential refinancings. However, our cash requirements could be materially affected by the use of cash in acquisitions of businesses, repurchases of securities, the exercise of put rights or other exit options by our joint venture partners, and contractual commitments to fund capital expenditures in, or intercompany borrowings to, businesses we own. In addition, liquidity could be adversely affected by a deterioration in our results of operations, including our ability to generate sufficient cash from operations, as well as by the various risks and uncertainties discussed in this section, other sections of this report and in our Annual Report, including any costs associated with legal proceedings and government investigations.

We do not rely on commercial paper or other short-term financing arrangements nor do we enter into repurchase agreements or other short-term financing arrangements not otherwise reported in our balance sheet. In addition, we do not have significant exposure to floating interest rates given that all of our current long-term indebtedness has fixed rates of interest except for borrowings under our Credit Agreement.

~~OFF-BALANCE SHEET ARRANGEMENTS~~

We have no off-balance sheet arrangements that may have a current or future material effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources, except for $278 million of standby letters of credit outstanding and guarantees at September 30, 2021.

CRITICAL ACCOUNTING ESTIMATES

In preparing our Condensed Consolidated Financial Statements in conformity with GAAP, we must use estimates and assumptions that affect the amounts reported in our Condensed Consolidated Financial Statements and accompanying notes. We regularly evaluate the accounting policies and estimates we use. In general, we base the estimates on historical experience and on assumptions that we believe to be reasonable, given the particular circumstances in which we operate. Actual results may vary from those estimates.

We consider our critical accounting estimates to be those that ~~(1)~~(i) involve significant judgments and uncertainties, ~~(2)~~(ii) require estimates that are more difficult for management to determine, and ~~(3)~~(iii) may produce materially different outcomes under different conditions or when using different assumptions.

Our critical accounting estimates have not changed from the description provided in our Annual Report.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The following table presents information about certain of our market-sensitive financial instruments at ~~September~~June 30, ~~2021.~~2022. The fair values were determined based on quoted market prices for the same or similar instruments. The average effective interest rates presented are based on the rate in effect at the end of the reporting ~~date.~~period. The effects of unamortized discounts and issue costs are excluded from the table.


		Maturity Date, Years Ending December 31,																								Maturity Date, Years Ending December 31,
		2021			2022			2023			2024			2025			Thereafter			Total			Fair Value			2022			2023			2024			2025			2026			Thereafter			Total			Fair Value

		(Dollars in Millions)																								(Dollars in Millions)
Fixed rate long-term debt	Fixed rate long-term debt	$	40		$	115		$	1,950		$	1,409		$	722		$	10,040		$	14,276		$	14,879	Fixed rate long-term debt	$	69		$	126		$	1,462		$	53		$	2,129		$	11,376		$	15,215		$	13,720
Average effective interest rates	Average effective interest rates	4.1		%	4.1		%	6.7		%	4.6		%	7.5		%	5.4		%	5.6		%			Average effective interest rates	4.4		%	4.8		%	4.7		%	6.2		%	4.9		%	5.5		%	5.3		%

We have no affiliation with partnerships, trusts or other entities (sometimes referred to as “special-purpose” or “variable-interest” entities) whose purpose is to facilitate off-balance sheet financial transactions or similar arrangements by us. As a result, we have no exposure to the financing, liquidity, market or credit risks associated with such entities. We do not hold or issue derivative instruments for trading purposes and are not a party to any instruments with leverage or prepayment features.

Table of Contents

ITEM 4. CONTROLS AND PROCEDURES

We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined by Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of the end of the period covered by this ~~report with respect to our operations that existed prior to the acquisition of controlling ownership interests in the SCD Centers by USPI’s subsidiaries in December 2020.~~report. The evaluation was performed under the supervision and with the participation of management, including our chief executive officer and chief financial officer. Based upon that evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are effective as of ~~September~~June 30, ~~2021~~2022 to ensure that material information is recorded, processed, summarized and reported by management on a timely basis in order to comply with our disclosure obligations under the Exchange Act and the SEC rules thereunder.

There were no changes in our internal control over financial reporting during the quarter ended ~~September~~June 30, ~~2021~~2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Because we provide healthcare services in a highly regulated industry, we have been and expect to continue to be party to various lawsuits, claims and regulatory investigations from time to time. For information regarding material legal proceedings in which we are involved, see Note 12 to our accompanying Condensed Consolidated Financial Statements, which is incorporated by reference.

ITEM 1A. RISK FACTORS

There have been no material changes to the risk factors ~~disclosed~~discussed in our Annual Report on Form 10-K for the year ended December 31, ~~2020.~~2021 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2022.

ITEM 6. EXHIBITS

Unless otherwise indicated, the following exhibits are filed with this report:



(4)	(a)	Thirty-Ninth Supplemental Indenture, dated as of June 15, 2022, among the Registrant, the guarantors party thereto and The Bank of New York Mellon Trust Company, N.A. relating to 6.125% Senior Secured First Lien Notes due 2030 (Incorporated by reference to Exhibit 4.2 to Registrant’s Current Report on Form 8-K filed June 15, 2022)

(10)	Material Contracts

	(a)	~~Amended~~Exchange and ~~Restated Employment~~Registration Rights Agreement, ~~between the Company and Ronald A. Rittenmeyer, effective~~dated as of ~~September 1, 2021~~June 15, 2022, among the Registrant, the guarantors party thereto and Barclays Capital Inc. as representative of the other initial purchasers of the notes named therein (Incorporated by reference to Exhibit 10.1 to Registrant’s Current Report on Form ~~8-K~~8 ‑K filed September 3, 2021)*June 15, 2022)











	(b)	~~Amended and Restated Employment Agreement between~~Tenet Healthcare 2019 Stock Incentive Plan, as amended by the Company and Saumya Sutaria, effective as of September 1, 2021 (Incorporated by reference to Exhibit 10.2 to Registrant’s Current Report on Form 8-K filed September 3, 2021)First Amendment

(31)	Rule 13a-14(a)/15d-14(a) Certifications

	(a)	Certification of Saumya Sutaria, M.D., Chief Executive Officer

	(b)	Certification of Daniel J. Cancelmi, Executive Vice President and Chief Financial Officer

(32)	Section 1350 Certifications of Saumya Sutaria, M.D., Chief Executive Officer, and Daniel J. Cancelmi, Executive Vice President and Chief Financial Officer

(101 SCH)	Inline XBRL Taxonomy Extension Schema Document

(101 CAL)	Inline XBRL Taxonomy Extension Calculation Linkbase Document

(101 DEF)	Inline XBRL Taxonomy Extension Definition Linkbase Document

(101 LAB)	Inline XBRL Taxonomy Extension Label Linkbase Document

(101 PRE)	Inline XBRL Taxonomy Extension Presentation Linkbase Document

(101 INS)	Inline XBRL Taxonomy Extension Instance Document - the instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document

(104)	Cover page from the ~~Company’s~~Registrant’s Quarterly Report on Form 10-Q for the quarter ended ~~September~~June 30, ~~2021~~2022 formatted in Inline XBRL (included in Exhibit 101)

* Management contract or compensatory plan or arrangement

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


		TENET HEALTHCARE CORPORATION (Registrant)

Date: ~~October~~July 29, ~~2021~~2022	By:	/s/ R. SCOTT RAMSEY
		R. Scott Ramsey
		Senior Vice President, Controller
		(Principal Accounting Officer)


		Page
PART I. FINANCIAL INFORMATION

Item 1.	Financial Statements (Unaudited)

	Condensed Consolidated Financial Statements	1

	Notes to Condensed Consolidated Financial Statements	5

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	27

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	59

Item 4.	Controls and Procedures	60



PART II. OTHER INFORMATION

Item 1.	Legal Proceedings	61

Item 1A.	Risk Factors	61



Item 6.	Exhibits	61


			Three Months Ending		Years Ending								Later Years
					December 31,
	Total		2021		2022		2023		2024		2025
Amortization of intangible assets	$	796	$	53	$	124	$	110	$	98	$	83	$	328


December 31, 2019	$	170	$	—	$	—
September 30, 2020	171		1,270		—
Increase	$	1	$	1,270	$	—


	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)





At December 31, 2020:
Long-lived assets held for sale	$	140	$	—	$	140	$	—
Long-lived assets held and used	483		—		483		—
	$	623	$	—	$	623	$	—